Information
-
Patent Application
-
20040014783
-
Publication Number
20040014783
-
Date Filed
May 13, 200321 years ago
-
Date Published
January 22, 200420 years ago
-
Inventors
-
Original Assignees
-
CPC
-
US Classifications
-
International Classifications
- A61K031/4545
- A61K031/454
- A61K031/55
Abstract
The present invention provides a compound of a formula (I):
1
Description
[0001] The present invention concerns piperidine derivatives having pharmaceutical activity, to processes for preparing such derivatives, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives as active therapeutic agents.
[0002] Pharmaceutically active piperidine derivatives are disclosed in WO99/38514, WO99/04794 and WO00/35877.
[0003] Chemokines are chemotactic cytokines that are released by a wide variety of cells to attract macrophages, T cells, eosinophils, basophils and neutrophils to sites of inflammation and also play a role in the maturation of cells of the immune system. Chemokines play an important role in immune and inflammatory responses in various diseases and disorders, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. These small secreted molecules are a growing superfamily of 8-14 kDa proteins characterised by a conserved four cysteine motif The chemokine superfamily can be divided into two main groups exhibiting characteristic structural motifs, the Cys-X-Cys (C—X—C, or α) and Cys-Cys (C—C, or β) families. These are distinguished on the basis of a single amino acid insertion between the NH-proximal pair of cysteine residues and sequence similarity.
[0004] The C—X—C chemokines include several potent chemoattractants and activators of neutrophils such as interleukin-8 (IL-8) and neutrophil-activating peptide 2 (NAP-2).
[0005] The C—C chemokines include potent chemoattractants of monocytes and lymphocytes but not neutrophils such as human monocyte chemotactic proteins 1-3 (MCP-1, MCP-2 and MCP-3), RANTES (Regulated on Activation, Normal T Expressed and Secreted), eotaxin and the macrophage inflammatory proteins 1α and 1β (MIP-1α and MIP-1β).
[0006] Studies have demonstrated that the actions of the chemokines are mediated by subfamilies of G protein-coupled receptors, among which are the receptors designated CCR1, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10, CXCR1, CXCR2, CXCR3 and CXCR4. These receptors represent good targets for drug development since agents which modulate these receptors would be useful in the treatment of disorders and diseases such as those mentioned above.
[0007] Histamine is a basic amine, 2-(4-imidazolyl)-ethylamine, and is formed from histidine by histidine decarboxylase. It is found in most tissues of the body, but is present in high concentrations in the lung, skin and in the gastrointestinal tract. At the cellular level inflammatory cells such as mast cells and basophils store large amounts of histamine. It is recognised that the degranulation of mast cells and basophils and the subsequent release of histamine is a fundamental mechanism responsible for the clinical manifestation of an allergic process. Histamine produces its actions by an effect on specific histamine G-protein coupled receptors, which are of three main types, H1, H2 and H3. Histamine H1 antagonists comprise the largest class of medications used in the treatment of patients with allergic disorders, especially rhinitis and urticaria. H1 antagonists are useful in controlling the allergic response by for example blocking the action of histamine on post-capillary venule smooth muscle, resulting in decreased vascular permeability, exudation and oedema. The antagonists also produce blockade of the actions of histamine on the H1 receptors on c-type nociceptive nerve fibres, resulting in decreased itching and sneezing.
[0008] Viral infections are known to cause lung inflammation. It has been shown experimentally that the common cold increases mucosal output of eotaxin in the airways. Instillation of eotaxin into the nose can mimic some of the signs and symptoms of a common cold. (See, Greiff L et al Allergy (1999) 54(11) 1204-8 [Experimental common cold increase mucosal output of eotaxin in atopic individuals] and Kawaguchi M et al Int. Arch. Allergy Immunol. (2000) 122 S1 44 [Expression of eotaxin by normal airway epithelial cells after virus A infection].)
[0009] The present invention provides a compound of formula (I):
2
[0010] wherein:
[0011] q, s and t are, independently, 0 or 1;
[0012] n and r are, independently, 0, 1, 2, 3, 4 or 5;
[0013] m and p are, independently, 0, 1 or 2;
[0014] X is CH2, C(O), O, S, S(O), S(O)2 or NR37; provided that when m and p are both 1 then X is not CH2;
[0015] Y is NHR2or OH;
[0016] T is C(O), C(S), S(O)2 or CH2;
[0017] R1 is hydrogen, C1-6 alkyl, aryl or heterocyclyl;
[0018] R2 and R47 are, independently, hydrogen, C1-6 alkyl, aryl(C1-4)alkyl or CO(C1-6 alkyl);
[0019] R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, CR3aR3bR3c, C2-4 alkenyl {optionally substituted by aryl or heterocyclyl}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl, aryl or oxo }, C3-7 cycloalkenyl {optionally substituted by oxo, C1-6 alkyl or aryl}, aryl, heterocyclyl, thioaryl or thioheterocyclyl;
[0020] R3a is hydrogen, C1-6 alkyl, C1-6 alkoxy or C3-7 cycloalkyl; R3b is aryl, heterocyclyl, S(O)2aryl or S(O)2heterocyclyl; and R3c is C1-6 alkyl, C1-4 haloalkyl, hydroxy, heterocyclyl(C1-4 alkyl) or aryl;
[0021] wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl {itself optionally substituted by halogen, OC(O)C1-6 alkyl, S(O)2R48, phenyl (itself optionally substituted by halogen (such as one or two chlorine or fluorine atoms), C1-6 alkyl, S(O)2R38 or C(O)NR39R40), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl), C3-10 cycloalkyl (itself optionally substituted by C1-4 alkyl or oxo) or NR41C(O)OCH2(fluoren-9-yl)}, NR41C(O)OCH2(fluoren-9-yl), C1-6 alkoxy {itself optionally substituted by halogen, C1-6 alkoxy, NHCO2(C1-6 alkyl), CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)}, C1-6 alkylthio, C1-6 haloalkylthio, C3-10 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)dR15, S(O)2NR42R43, NR44S(O)2R45, phenyl {itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy (itself optionally substituted by halogen, OH or pyridinyl), phenyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy)}, heterocyclyl {itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy, C1-6 haloalkoxy, phenyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy)}, phenoxy {itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy, C1-6 haloalkoxy, phenyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy)}, SCN, CN, SO3H (or an alkali metal salt thereof), methylenedioxy or difluoromethylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring to which they are attached, a dihydrophenanthrene moiety;
[0022] d is 0, 1 or 2;
[0023] R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R37, R39, R40, R41, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl, aryl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy);
[0024] R15, R38, R45 and R48 are, independently, C1-6 alkyl (optionally substituted by halogen, hydroxy or C3-10 cycloalkyl), C3-6 alkenyl, aryl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy);
[0025] or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof; provided that:
[0026] when m and p are both 1, n, q and r are all 0, T and X are both S(O)2, and R1 is methoxyphenyl then R3is not propyl; when m, p, q and r are all 1, n is 0, Y is NH2, T is CO and R1X is (CH3)2N then R3is not 3,5-dibromo-4-aminophenyl, 1-methylindol-3-yl or 1-(tert-butoxycarbonyl)indol-3-yl; and when m and p are both 1, n, q and r are all 0, T is CO, X is NH and R1 is 3-(4-fluorobenzyl)benzimidazol-2-yl then R3 is not 4-fluorophenyl.
[0027] Certain compounds of the present invention can exist in different isomeric forms (such as enantiomers, diastereomers, geometric isomers or tautomers). The present invention covers all such isomers and mixtures thereof in all proportions.
[0028] Suitable salts include acid addition salts such as a hydrochloride, dihydrochloride, hydrobromide, phosphate, acetate, diacetate, fumarate, maleate, tartrate, citrate, oxalate, methanesulphonate or p-toluenesulphonate. Another example of an addition salt is sulphate.
[0029] The compounds of the invention may exist as solvates (such as hydrates) and the present invention covers all such solvates.
[0030] Halogen includes fluorine, chlorine, bromine and iodine.
[0031] Alkyl groups and moieties are straight or branched chain and are, for example, methyl, ethyl, n-propyl, iso-propyl or tert-butyl.
[0032] Alkenyl group are, for example, vinyl or allyl.
[0033] Cycloalkyl is mono-, bi or tricyclic and is, for example, cyclopropyl, cyclopentyl, cyclohexyl, norbornyl or camphoryl. The cycloalkyl ring is optionally fused to a benzene ring (for example forming a bicyclo[4,2.0]octa-1,3,5-trienyl or indanyl ring system).
[0034] Cycloalkenyl is especially monocyclic and is, for example, cyclopentenyl or cyclohexenyl.
[0035] Aryl is preferably phenyl or naphthyl.
[0036] Heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl (for example in 6-oxo-1,6-dihydro-pyridinyl), pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example in 1-dioxo-2,3-dihydrobenz[b]thienyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl (for example in 1H-benzthiazol-2-one-yl), 2,3-dihydrobenzthiazolyl (for example in 2,3-dihydrobenzthiazol-2-one-yl), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxalinyl, dihydro-1-benzopyryliumyl (for example in a coumarinyl or a chromonyl), 3,4-dihydro-1H-2,1-benzothiazinyl (for example in 2-dioxo-3,4-dihydro-1H-2,1-benzothiazinyl), a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), a purine (for example in 3,7-dihydro-purin-2,6-dione-8-yl), quinolinyl, isoquinolinyl (for example in 2H-isoquinolin-1-one-yl), a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl or in 1H-[1,8]naphthyridin-4-one-yl), a benzothiazinyl (for example in 4H-benzo[1,4]thiazin-3-one-yl), benzo[d]imidazo[2,1-b]thiazol-2-yl or dibenzothiophenyl (also known as dibenzothienyl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof.
[0037] In one aspect of the invention heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur. Heterocyclyl is, for example, furyl, thienyl, 2,1,3-benzothiadiazole, 2,1,3-benzoxadiazole, quinoxaline, dihydro-1-benzopyrylium (for example a coumarin or a chromone), piperidine, morpholine, pyrrole, indole, 2,3-dihydroindole, quinoline, thiazole, pyrazole, isoxazole, imidazole, pyridine, benzofuryl, benzimidazole, pyrimidine or dibenzothiophene.
[0038] In a further aspect heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, optionally fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Heterocyclyl is, for example, furyl, thienyl (also known as thiophenyl), pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl, pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example 1-dioxo-2,3-dihydrobenz[b]thienyl), benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl, 2,3-dihydrobenzthiazolyl (for example 2,3-dihydrobenzthiazol-2-onyl), 1,2,3-benzothiadiazolyl, 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxalinyl, dihydro-1-benzopyryliumyl (for example a coumarinyl or a chromonyl), 3,4-dihydro-1H-2,1-benzothiazinyl (for example 2-dioxo-3,4-dihydro-1H-2,1-benzothiazinyl), quinolinyl, isoquinolinyl or dibenzothiophenyl (also known as dibenzothienyl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof.
[0039] An N-oxide of a compound of formula (I) is, for example, a 1-oxy-[1,4′]bipiperidinyl-1′-yl compound.
[0040] In another aspect the present invention provides a compound of formula (I′):
3
[0041] wherein: q is 0 or 1; n and r are, independently, 0, 1, 2, 3, 4 or 5; m and p are, independently, 0, 1 or 2; X is CH2, CO, O, S, S(O), S(O)2 or NR37; provided that when m and p are both 1 then X is not CH2; Y is NHR2 or OH; T is CO, CS, SO2 or CH2; R1 is hydrogen, C1-6 alkyl, aryl or heterocyclyl; R2 is hydrogen, C1-6 alkyl, aryl(C1-4)alkyl or CO(C1-6 alkyl); R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, C3-7 cycloalkenyl {optionally substituted by C1-6 alkyl or aryl}, aryl or heterocyclyl; wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo (such as one or two chlorine or fluorine atoms), C1-6 alkyl, SO2R38 or CONR39R40), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl) or NR4C(O)OCH2(fluoren-9-yl)), NR41C(O)OCH2(fluoren-9-yl), C1-6 alkoxy (itself optionally substituted by halogen, CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, nitro, C3-7 cycloalkyl, NR7R8, NR9COR10, CO2R11, CONR12R13, COR14, SOdR15, SO2NR42R43, NR44SO2R45, phenyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2 or C1-6 alkoxy (itself optionally substituted by halo, OH or pyridinyl)), heterocyclyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), phenoxy (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring to which they are attached, a dihydrophenanthrene moiety; d is 0, 1 or 2; R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R37, R39, R40, R41, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); RR15, R38 and R45 are, independently, C1-6 alkyl or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); or a pharmaceutically acceptable salt thereof; or a solvate thereof; provided that: when m and p are both 1, n, q and r are all 0, T and X are both SO2, and R1 is methoxyphenyl then R3is not propyl; when m, p, q and r are all 1, n is 0, Y is NH2, T is CO and R1X is (CH3)2N then R3 is not 3,5-dibromo-4-aminophenyl, 1-methylindol-3-yl or 1-(tert-butoxycarbonyl)indol-3-yl; and when m and p are both 1, n, q and r are all 0, T is CO, X is NH and R1 is 3-(4-fluorobenzyl)benzimidazol-2-yl then R3 is not 4-fluorophenyl.
[0042] In an further aspect the present invention provides a compound of formula (I), wherein: q, s and t are, independently, 0 or 1; n and r are, independently, 0, 1, 2, 3, 4 or 5; m and p are, independently, 0, 1 or 2; X is CH2, C(O), O, S, S(O), S(O)2 or NR37; provided that when m and p are both 1 then X is not CH2; Y is NHR2 or OH; T is C(O), C(S), S(O)2 or CH2; R1 is hydrogen, C1-6 alkyl, aryl or heterocyclyl; R2 and R47 are, independently, hydrogen, C1-6 alkyl, aryl(C1-4)alkyl or CO(C1-4 alkyl); R3is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, C3-7 cycloalkenyl {optionally substituted by oxo, C1-6 alkyl or aryl}, aryl or heterocyclyl; wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, S(O)2R48, phenyl (itself optionally substituted by halo (such as one or two chlorine or fluorine atoms), C1-6 alkyl, S(O)2R38 or C(O)NR39R40), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl), C3-10 cycloalkyl (itself optionally substituted by C-1-4 alkyl or oxo) or NR41C(O)OCH2(fluoren-9-yl)), NR41C(O)OCH2(fluoren-9-yl), C1-6 alkoxy (itself optionally substituted by halogen, C1-6 alkoxy, NHCO2(C1-6 alkyl), CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, C1-6 haloalkylthio, C3-10 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)dR15, S(O)2NR2R43, NR44S(O)2R45, phenyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2 or C1-6 alkoxy (itself optionally substituted by halo, OH or pyridinyl)), heterocyclyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), phenoxy (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring to which they are attached, a dihydrophenanthrene moiety; d is 0, 1 or 2; R4, R5, R6, R7, R8, R9,R10, R11, R12, R13, R14, R37, R39, R40, R41, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); R15, R38, R45 and R48 are, independently, C1-6 alkyl (optionally substituted by halogen, hydroxy or C3-10 cycloalkyl) or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); or a pharmaceutically acceptable salt thereof; or a solvate thereof; provided that: when m and p are both 1, n, q and r are all 0, T and X are both S(O)2, and R1 is methoxyphenyl then R3 is not propyl; when m, p, q and r are all 1, n is 0, Y is NH2, T is CO and R1X is (CH3)2N then R3 is not 3,5-dibromo-4-aminophenyl, 1-methylindol-3-yl or 1-(tert-butoxycarbonyl)indol-3-yl; and when m and p are both 1, n, q and r are all 0, T is CO, X is NH and R1 is 3-(4-fluorobenzyl)benzimidazol-2-yl then R3 is not 4-fluorophenyl.
[0043] In another aspect the variables m and p are such that m+p is 0, 1 or 2 (for example 1 or 2).
[0044] In a further aspect n is 0 or 1.
[0045] In a still further aspect q and r are both 0.
[0046] In another aspect n, q and r are all 0.
[0047] In another aspect m, p and t are all 1.
[0048] In a further aspect s is 0.
[0049] In another aspect s is 1. In a further aspect q is 1. In a still further aspect n+r is equal to more than 1 (for example n+r is equal to 2, 3, 4 or 5).
[0050] In another aspect t+m+p is not equal to 3 (for example t+m+p is equal to 2).
[0051] In a still further aspect X is 0.
[0052] In another aspect R1 is hydrogen, C1-6 alkyl, optionally substituted (as above) aryl or optionally substituted (as above) monocyclic heterocyclyl. In another aspect R1 is phenyl substituted with one or more of fluorine, chlorine, C1-4 alkyl (especially methyl) or C1-4 alkoxy (especially methoxy).
[0053] In yet another aspect R1 is not phenyl substituted by cycloalkyl.
[0054] In a further aspect R1 is phenyl optionally substituted (for example with one, two or three) by halo (especially fluoro or chloro), C1-4 alkyl (especially methyl) or C1-4 alkoxy (especially methoxy). In a still further aspect R1 is phenyl substituted by one, two or three of: fluoro, chloro, methyl or methoxy.
[0055] In another aspect R1 is one of the substituted phenyl groups exemplified in Method F below.
[0056] In a further aspect T is C(O), S(O)2 or CH2. In a still further aspect T is C(O). In another aspect T is S(O)2 or CH2.
[0057] In another aspect R3 is aryl or heterocyclyl either of which is optionally substituted as described above.
[0058] In a further aspect R3 is unsubstituted phenyl, mono-substituted phenyl or mono-substituted heterocyclyl, the substituents being chosen from those described above.
[0059] In a still further aspect R3 is oxo substituted heterocyclyl, said heterocyclyl optionally further substituted with one or more substituents chosen from those described above.
[0060] In another aspect R3 is a bicyclic heterocyclyl optionally substituted as described above. Bicyclic heterocyclyl is an aromatic or non-aromatic 5 or 6 membered ring, fused to one or more other rings, comprising at least one heteroatom selected from the group comprising nitrogen, oxygen and sulphur; or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Bicyclic heterocyclyl is, for example, indolyl, 2,3-dihydroindolyl, benzo[b]furyl (also known as benzfuryl), benz[b]thienyl (also known as benzthienyl or benzthiophenyl), 2,3-dihydrobenz[b]thienyl (for example in 1-dioxo-2,3-dihydrobenz[b]thienyl), indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl (for example in 1H-benzthiazol-2-one-yl), 2,3-dihydrobenzthiazolyl (for example in 2,3-dihydrobenzthiazol-2-one-yl), 1,2,3-benzothiadiazolyl, an imidazopyridinyl (such as imidazo[1,2a]pyridinyl), thieno[3,2-b]pyridin-6-yl 1,2,3-benzoxadiazolyl (also known as benzo[1,2,3]thiadiazolyl), 2,1,3-benzothiadiazolyl, benzofurazan (also known as 2,1,3-benzoxadiazolyl), quinoxalinyl, dihydro-1-benzopyryliumyl (for example in a coumarinyl or a chromonyl), 3,4-dihydro-1H-2,1-benzothiazinyl (for example in 2-dioxo-3,4-dihydro-1H-2,1-benzothiazinyl), a pyrazolopyridine (for example 1H-pyrazolo[3,4-b]pyridinyl), a purine (for example in 3,7-dihydro-purin-2,6-dione-8-yl), quinolinyl, isoquinolinyl (for example in 2H-isoquinolin-1-one-yl), a naphthyridinyl (for example [1,6]naphthyridinyl or [1,8]naphthyridinyl or in 1H-[1,8]naphthyridin-4-one-yl) or a benzothiazinyl (for example in 4H-benzo[1,4]thiazin-3-one-yl); or an N-oxide thereof, or an S-oxide or S-dioxide thereof.
[0061] In yet another aspect R3 is: C1-6 alkyl {optionally substituted by CO2R16 or phthalimide}, C3-7 cycloalkyl {optionally substituted by oxo}, phenyl {optionally substituted by: halogen, OH, SH, C1-6 alkyl (itself optionally substituted by naphthyloxy (itself optionally substituted by halo or alkenyl) or NR17C(O)OCH2(fluoren-9-yl)), C1-6 alkoxy (itself optionally substituted by CO2R18, NR19R20 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, C1-4 haloalkyl, OCF3, nitro, C3-7 cycloalkyl, NR21R22, NR23C(O)R24, CO2R25, C(O)NR26R27, S(O)2R28, phenyl (itself optionally substituted by NO2 or alkoxy (itself optionally substituted by OH or pyridinyl)), phenoxy, SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy, or adjacent substituents may join to form a dihydrophenanthrene moiety}, naphthyl {optionally substituted by NR29R30 or OH}, heterocyclyl {optionally substituted by halo, NO2, oxo, C1-6 alkyl (itself optionally substituted by OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo or alkyl)), alkoxy, CF3, thioalkyl, C(O)R31, CO2R32, NR33C(O)R34, phenoxy, phenyl or nitrogen containing heterocyclyl;
[0062] R16, R17, R18, R19, R20, R21, R22, R23, R24, R25, R26, R27, R29, R30, R31, R32, R33 and R34 are, independently, hydrogen, C1-6 alkyl or phenyl;
[0063] R28 is C1-6 alkyl; or a pharmaceutically acceptable salt thereof.
[0064] In another aspect R3 is phenyl or heterocyclyl, either of which is optionally substituted by: halo, hydroxy, nitro, cyano, amino, C1-4 alkyl (itself optionally substituted by S(O)2(C1-4 alkyl), S(O)2phenyl), C1-4 alkoxy, S(O)kR46 (wherein k is 0, 1 or 2 (preferably 2); and R46 is C1-4 alkyl, C1-4 hydroxyalkyl, C3-7 cycloalkyl(C1-4 alkyl) (such as cyclopropylmethyl) or phenyl), C1-4 haloalkylthio, C(O)NH2, NHS(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl) or S(O)2N(C1-4 alkyl)2.
[0065] In one aspect the variable R3 can be benzo[1,2,3]thiadiazolyl, thiophenyl or phenyl; the phenyl and thiophenyl rings being optionally substituted by: halo, hydroxy, nitro, cyano, amino, C1-4 alkyl (itself optionally substituted by S(O)2(C1-4 alkyl), S(O)2phenyl), C1-4 alkoxy, S(O)kR46 (wherein k is 0, 1 or 2 (preferably 2); and R46 is C1-4 alkyl, C1-4 hydroxyalkyl, C3-7 cycloalkyl(C1-4 alkyl) (such as cyclopropylmethyl) or phenyl), C1-4 haloalkylthio, C(O)NH2, NHS(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl) or S(O)2N(C1-4 alkyl)2.
[0066] In another aspect the variable R3 can be benzo[1 ,2,3]thiadiazolyl or phenyl (optionally substituted by: halo, hydroxy, nitro, cyano, amino, C1-4 alkyl (itself optionally substituted by S(O)2phenyl), C1-4 alkoxy, S(O)kR46 (wherein k is 0, 1 or 2; and R46 is C1-4 alkyl or phenyl) or C1-4 haloalkylthio.
[0067] In a still further aspect the present invention provides a compound of formula (Ia″):
4
[0068] wherein:
[0069] T is C(O), C(S), S(O)2 or CH2;
[0070] n is 0, 1, 2, 3, 4or 5;
[0071] m and p are, independently, 0, 1 or 2 (but are especially both 1);
[0072] R50 is hydrogen, cyano, S(O)2(C1-4 alkyl), S(O)2(C1-4 haloalkyl), halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or phenyl (optionally substituted by one or two halogen atoms or by one C(O)NR12′R13′, NR9′C(O)R10′, S(O)2R15′, S(O)2NR42R43 or NR44S(O)2R45 group);
[0073] R51 and R52 are, independently, hydrogen, halogen, C1-4 alkyl or C1-4 alkoxy;
[0074] R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, aryl or heterocyclyl;
[0075] wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo or C1-6 alkyl), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl) or NR4C(O)OCH2(fluoren-9-yl)), C1-6 alkoxy (itself optionally substituted by halogen, CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, nitro, C3-7 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)2R15, phenyl (itself optionally substituted by NO2 or C1-6 alkoxy (itself optionally substituted by OH or pyridinyl)), phenoxy, SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring a dihydrophenanthrene moiety;
[0076] R4, R5, R6, R7, R8, R9, R9′, R10, R10′, R11, R12, R12′, R13, R13′, R14, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or phenyl;
[0077] R15, R15′ and R45 are, independently, C1-6 alkyl or phenyl;
[0078] or a pharmaceutically acceptable salt thereof.
[0079] In a further aspect R50, R51 and R52 are, independently, hydrogen, halogen, (especially fluoro or chloro), C1-4 alkyl (especially methyl) or C1-4 alkoxy (especially methoxy).
[0080] In a still further aspect the present invention provides a compound of formula (Ia):
5
[0081] wherein:
[0082] T is C(O), C(S), S(O)2 or CH2;
[0083] n is 0, 1, 2, 3, 4 or 5;
[0084] m and p are, independently, 0, 1 or 2 (but are especially both 1);
[0085] R35 is hydrogen, cyano, S(O)2(C1-4 alkyl), S(O)2(C1-4 haloalkyl), halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or phenyl (optionally substituted by one or two halogen atoms or by one C(O)NR12′R13′, NR9′C(O)R10′, S(O)2R15′, S(O)2NR42R43 or NR44S(O)2R45 group);
[0086] R36 is hydrogen, halogen or C1-4 alkyl;
[0087] R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, aryl or heterocyclyl;
[0088] wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo or C1-6 alkyl), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl) or NR4C(O)OCH2(fluoren-9-yl)), C1-6 alkoxy (itself optionally substituted by halogen, CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, nitro, C3-7 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)2R15, phenyl (itself optionally substituted by NO2 or C1-6 alkoxy (itself optionally substituted by OH or pyridinyl)), phenoxy, SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring a dihydrophenanthrene moiety;
[0089] R4, R5, R6, R7, R8, R9, R9′, R10, R10′, R11, R12, R12′, R13, R13′, R14, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or phenyl;
[0090] R15, R15′ and R45 are, independently, C1-6 alkyl or phenyl;
[0091] or a pharmaceutically acceptable salt thereof.
[0092] In another aspect the present invention provides a compound of formula (Ia′):
6
[0093] wherein:
[0094] T is CO, CS, SO2 or CH2;
[0095] n is 0, 1, 2, 3, 4 or 5;
[0096] m and p are, independently, 0, 1 or 2 (but are especially both 1);
[0097] R35 is hydrogen, cyano, SO2(C1-4 alkyl), SO2(C1-4 haloalkyl), halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy or phenyl (optionally substituted by one or two halogen atoms or by one CONR12′R13′, NR9′COR10′, SO2R15′, SO2NR42R43 or NR44SO2R45 group);
[0098] R36 is hydrogen, halogen or C1-4 alkyl;
[0099] R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, aryl or heterocyclyl;
[0100] wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo or C1-6 alkyl), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl) or NR4C(O)OCH2(fluoren-9-yl)), C1-6 alkoxy (itself optionally substituted by halogen, CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, nitro, C3-7 cycloalkyl, NR7R8, NR9COR10, CO2R11, CONR12R13, COR14, SO2R15, phenyl (itself optionally substituted by NO2 or C1-6 alkoxy (itself optionally substituted by OH or pyridinyl)), phenoxy, SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring a dihydrophenanthrene moiety;
[0101] R4, R5, R6, R7, R8, R9, R9′, R10, R10′, R11, R12, R12′, R13, R13′, R14, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or phenyl;
[0102] R15, R15′ and R45 are, independently, C1-6 alkyl or phenyl;
[0103] or a pharmaceutically acceptable salt thereof.
[0104] In a further aspect R3 is heterocyclyl (such as thienyl, isoxazolyl or indolyl, or a naphthyridinyl, an imidazopyridinyl or an isoquinolinyl) optionally substituted by oxo, halogen or C1-6 alkyl.
[0105] In yet another aspect the present invention provides a compound of formula (Ia) wherein:
[0106] T is C(O), C(S), S(O)2 or CH2;
[0107] n is 0, 1, 2, 3, 4 or 5;
[0108] m and p are, independently, 0, 1 or 2;
[0109] R35 is hydrogen, halogen or phenyl (optionally substituted by one or two halogen atoms or by one C(O)NR12′R13′, NR9′C(O)R10′, S(O)2R15′, S(O)2NR42R43 or NR44S(O)2R45 group);
[0110] R36 is hydrogen or halogen;
[0111] R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, aryl or heterocyclyl;
[0112] wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo or C1-6 alkyl), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl) or NR4C(O)OCH2(fluoren-9-yl)), C1-6 alkoxy (itself optionally substituted by halogen, CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, nitro, C3-7 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)2R15, phenyl (itself optionally substituted by NO2 or C1-6 alkoxy (itself optionally substituted by OH or pyridinyl)), phenoxy, SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring a dihydrophenanthrene moiety;
[0113] R4, R5, R6, R7, R8, R9, R9′, R10, R10′, R11, R12, R12′, R13, R13′, R14, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or aryl;
[0114] R15, R15′ and R45 are, independently, C1-6 alkyl or aryl;
[0115] or a pharmaceutically acceptable salt thereof.
[0116] In a further aspect R35 and R36 are, independently, hydrogen, halogen, (especially fluoro or chloro), C1-4 alkyl (especially methyl) or C1-4 alkoxy (especially methoxy). In another aspect R35 and R36 are both chlorine or both fluorine, especially 3,4 disposed on the phenyl ring to which they are attached.
[0117] In a further aspect the present invention provides a compound of formula (Ib):
7
[0118] wherein T, n and R3 are as defined above.
[0119] In a still further aspect the present invention provides a compound of formula (Ic):
8
[0120] wherein T, m, p and R3 are as defined above.
[0121] In another aspect the present invention provides a compound of formula (Id):
9
[0122] wherein R3 is as defined above.
[0123] In yet another aspect the present invention provides a compound of formula (Ie):
10
[0124] wherein R1, t, s and R3 are as defined above.
[0125] In a further aspect the present invention provides a compound of formula (If):
11
[0126] wherein R1, n, t, s and R3 are as defined above.
[0127] In a still further aspect the present invention provides a compound of formula (Ig):
12
[0128] wherein R1, X and R3 are as defined above.
[0129] A compound of formula (I), wherein s is 0, can be prepared by coupling a compound of formula (II):
13
[0130] with a compound of formula (III):
14
[0131] wherein L is a suitable leaving group, and the variables Y and T are optionally protected during the course of the reaction by standard protecting groups known in the art and deprotected in a separate step or during the reaction work-up. For example:
[0132] when T is carbonyl, L can be OH and the coupling can be carried out in the presence of a coupling agent (such as bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, (known as PYBROP™), oxalyl chloride, thionyl chloride or N,N′-carbonyl diimidazole, or another coupling agent known to a person skilled in the art); or,
[0133] when T is sulphonyl, L can be chloro and the coupling can be carrier out in the presence of a suitable base (such as potassium carbonate) in a suitable solvent (such as acetone).
[0134] A compound of formula (I), wherein s is 1, R47 is hydrogen and T isCO, can be prepared by reacting a compound of formula (II), wherein m and p are both 1, with an aromatic isocyanate of formula with an isocyanate O═C═N—(CH2)n-(CH2)r-R3.
[0135] A compound of formula (II) can be prepared by deprotecting a compound of formula (IV):
15
[0136] for example using trifluoroacetic acid in a suitable solvent (such as dichloromethane) or using a source of hydrogen chloride in a suitable solvent (such as dioxane).
[0137] A compound of formula (IV), wherein X is O, can be prepared by reacting a compound of formula (V):
16
[0138] with a compound of formula (VI):
17
[0139] in the presence of NaBH(OAc)3 and acetic acid.
[0140] A compound of formula (IV), wherein X is CO or CH2, can be prepared by oxidising or reducing a compound of formula (VII):
18
[0141] A compound of formula (VII) can be prepared by reacting a compound of formula (VIII):
19
[0142] with a compound of formula (VI) in the presence of NaBH(OAc)3 and acetic acid. A compound of formula (VIII) can be prepared by reduction of a compound of formula (IX):
20
[0143] A compound of formula (I) wherein X is NR37 can be prepared by reacting a compound of formula (X):
21
[0144] with a compound of formula (XI):
22
[0145] in the presence of NaBH(OAc)3 and acetic acid. A compound of formula (X) can be prepared by reacting NHR1R37 with a compound of formula (XII):
23
[0146] in the presence of NaBH(OAc)3 and acetic acid and then deprotecting the piperidine nitrogen {for example using trifluoroacetic acid in a suitable solvent (such as dichloromethane) or using a source of hydrogen chloride in a suitable solvent (such as dioxane)}.
[0147] Alternatively, a compound of formula (I), wherein s, n, q and r are all 0 and T is CO, can be prepared by reacting a compound of formula (XIII):
24
[0148] with an acid: R3CO2H. A compound of formula (XIII) can be prepared by deprotecting a compound of formula (XIV):
25
[0149] wherein L* is BOC or a benzyl group. A compound of formula (XIV) can be prepared by performing a fluoride displacement reaction on FR1 in the presence of compound of formula (XV):
26
[0150] A compound of formula (XV) can be prepared by coupling a compound of formula (XVI) with a compound of formula (XVII):
27
[0151] Alternatively, a compound of formula (I) wherein s, n, q and r are all 0 and T is CO, can be prepared by performing a fluoride displacement reaction on FR1 in the presence of compound of formula (XVIII):
28
[0152] provided that R47 is not hydrogen.
[0153] A compound of formula (XVIII) can be prepared by reacting a compound of formula (XIX):
29
[0154] with an appropriate mixed anhydride (such as an anhydride of formula R3C(O)OC(O)(C1-6 alkyl), wherein alkyl is, for example, methyl, ethyl or iso-butyl). A compound of formula (XIX) can be prepared by deprotecting a compound of formula (XV).
[0155] Alternatively, a compound of formula (I) can be prepared by reductive ammination of a compound of formula (XX):
30
[0156] with an amine of formula (XXI):
31
[0157] under suitable conditions.
[0158] Further compounds of formula (I) can be prepared by adaptation of: the routes described above, methods described in the art or the Examples recited below.
[0159] Compounds of formula (V), (VI), (IX), (XI), (XII), (XVI) and (XVII) can be prepared by using or adapting methods described in the art.
[0160] In another aspect the present invention provides processes for the preparation of compounds of formula (I) (as defined above), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) and (Ig).
[0161] The intermediates of formula (II), (IV), (XIII), (XIV) and (XVII) defined herein are novel and these, and processes for their preparation, are provided as further features of the invention.
[0162] Examples of compounds of formula (Ib) are listed in Table I below.
1TABLE 1
|
|
CompoundTnR3M + H
|
|
1C(O)0C6H5433
2C(O)03,4-Cl2—C6H3501
3C(O)02,4-Cl2—C6H3501
4C(O)04-CH3—C6H4447
5C(O)04-CH3O—C6H4463
6C(O)04-CF3—C6H4501
7C(O)04-Cl-C6H4467
8C(O)04-NO2—C6H4478
9C(O)03,5-Cl2—C6H3501
10C(O)02-F-C6H4451
11C(O)04-cyclohexyl-C6H4515
12C(O)04-(n-butoxy)-C6H4505
13C(O)03-NMe2-C6H4476
14C(O)04-(NHC(O)Me)-C6H4490
15C(O)04-NEt2-C6H4504
16C(O)03-CO2Me-C6H4491
17C(O)02-C(O)NH2—C6H4
18C(O)04-S(O)2Me-C6H4511
19C(O)02-I—C6H4559
20C(O)03-phenoxy-C6H4525
21C(O)02-Me-C6H4447
22C(O)03-Me-C6H4447
23C(O)03-I—C6H4559
24C(O)03-NH2-6-(NHC6H5)—C6H3539
25C(O)03,5-F2—C6H3469
26C(O)03-NO2-4-(tert-Bu)-C6H3534
27C(O)03-NO2-5-(CO2Me)-C6H3536
28C(O)02-Me-5-NO2—C6H3492
29C(O)03,5-(tert-Bu)2-C6H3545
30C(O)02-NO2-5-Me-C6H3492
31C(O)02-Br-5-MeO—C6H3541
32C(O)03-MeO-4-(CO2Me)-C6H3
33C(O)02-(NHC(O)Me)-5-Br—C6H3568
34C(O)02-NO2-5-SCN—C6H3535
35C(O)03-MeO-4-Me-C6H3477
36C(O)04-CN—C6H4458
37C(O)03-CN—C6H4458
38C(O)02-phenoxy-4-Br—C6H3
39C(O)02-NH2-5-I—C6H3574
40C(O)04-F-C6H4451
41S(O)202-CF3O—C6H4553
42S(O)203-NO2-4-Cl—C6H3548
43S(O)20Camphor-10-yl(alternatively named 7,7-543
dimethyl-bicyclo [2.2.1]heptan-2-on-1-yl)
44S(O)20n-Pr435
45S(O)20C6Me5539
46S(O)204-(n-Pr)—C6H4511
47S(O)20Naphth-2-yl519
48S(O)202,6-Cl2—C6H3537
49S(O)202,6-F2—C6H3505
50S(O)204-NO2—C6H4514
51S(O)203,4-Cl2—C6H3537
52S(O)202,5-Cl2—C6H3
53S(O)205-(NMe2)-naphth-1-yl562
54S(O)202,1,3-benzthiadiazol-4-yl527
55S(O)204-Et-C6H4497
56S(O)202,5-Cl2-thien-3-yl543
57S(O)203,4-(MeO)2—C6H3529
58S(O)203-CF3-6-Cl—C6H3571
59S(O)205-Cl-thien-2-yl509
60S(O)204-Cl—C6H4503
61S(O)204-(iso-Pr)—C6H4511
62S(O)202-Cl-4-CF3—C6H3571
63S(O)20Benzofuraz-4-yl(other name 2,1,3-benzoxadiazol-4-yl511
64S(O)203-Me-C6H4483
65S(O)202,4-F2—C6H3505
66S(O)202-Me-5-F-C6H3501
67S(O)204-CF3O—C6H4553
68S(O)20iso-Pr435
70S(O)204-(CO2H)-C6H4513
71S(O)20chromen-2-one-6-yl537
72S(O)203,5-Cl2—C6H3537
73S(O)202,3-Cl2—C6H3537
74S(O)214-NO2—C6H4
75S(O)203-CF3—C6H4537
76S(O)204-(tert-Bu)-C6H4525
77S(O)203-CO2H-4-OH—C6H3529
78S(O)202-NO2—C6H4514
79S(O)202-F-C6H4487
80S(O)203-NO2—C6H4514
83S(O)20Naphth-1-yl519
84S(O)202-MeO-5-Cl—C6H3533
85S(O)203-F-C6H4487
86S(O)203-Cl-4-(NHC(O)Me)-C6H3560
87S(O)21C6H5483
88S(O)202-NO2-4-MeO—C6H3544
89S(O)202-Me-5-NO2—C6H3528
90S(O)203-CO2H—C6H4513
91S(O)202,4,6-Me3-C6H2511
92S(O)20Me
93S(O)203,4-Cl2—C6H3537
94S(O)204-MeO—C6H4
95S(O)204-NHC(O)Me-C6H4526
96S(O)202-CF3—C6H4537
97S(O)20(CH2)2CO2Me479
98S(O)204-Me-C6H4483
99S(O)204-CF3—C6H4537
100S(O)204-CN—C6H4494
101S(O)203-NO2-4-Me-C6H3528
102S(O)201H-2-oxo-quinolin-6-yl
103S(O)202-(NHCOMe)-4-methylthiazol-5-yl547
104S(O)20Thien-2-yl475
105S(O)20Quinolin-8-yl
106S(O)202-OH-3,5-Cl2—C6H2553
107S(O)202-(CO2Me)-C6H4527
108S(O)202,5-(MeO)2—C6H3529
109S(O)20phenyl469
110S(O)202-Me-4-NO2—C6H3528
111S(O)205-(pyridin-2-yl)thien-2-yl552
112S(O)201,3-Me2-5-Cl-pyrazol-4-yl521
113S(O)203,5-Me2-isoxazol-4-yl488
114S(O)202,3,6-Me3-4-MeO—C6H541
115S(O)201-Me-imidazol-4-yl473
116S(O)202-MeO-5-Me-C6H3513
117S(O)205-(isoxazo1-3-yl)thien-2-yl542
118S(O)202-(CO2Me)thien-3-yl533
119S(O)204-(1,1-dimethylprOP-1-yl)-C6H4539
120S(O)201-(N-phthalimido)-ethyl566
121CH204-Me-C6H4433
122CH204-(CO2H)—C6H4463
123CH202-(CO2H)—C6H4463
124CH204-(NHC(O)MC)—C6H4476
125CH203-OH—C6H4435
126CH204-MeO—C6H4449
127CH205-Me-fur-2-yl423
128CH202,5-F2—C6H3455
129CH205-NO2-fur-2-y1
130CH204-NO2—C6H4
131CH204-iso-Pr—C6H4461
132CH20phenyl419
133CH202-(SO3Na+)—C6H4498
134CH204-F-C6H4437
135CH202,6-Cl2—C6H3487
136CH203,4-Cl2—C6H3487
137CH202,4-Cl2—C6H3
138CH204-(OCH2CO2H)—C6H4493
139CH20Pyrid-2-yl420
140CH203-methylthien-2-yl439
141CH203-Cl—C6H4453
142CH205-methylthien-2-yl439
143CH203-OH-4-MeO—C6H3465
144CH203-NO2-4-OH—C6H3480
145CH20Chromon-3-yl
146CH201,3-Me2-5-Cl-pyrazol-4-y1471
147CH203,4-F2—C6H3455
148CH204-Cl-pyrazol-3-yl443
149C(O)14-S(O)2Me-C6H4
150CH202,6-Cl2-pyridin-4-yl
151CH205-(4-NO2—C6H4)-fur-2-yl530
152CH201-(4-methylbenzyl)-pyrazol-5-yl
153CH20Benzfur-2-yl459
154CH202-phenylimidazol-4-yl485
155CH205-ethylthien-2-yl453
156CH202-Cl-quinolin-3-yl504
157CH206-methylpyridin-2-yl434
158CH201-acetylindol-3-yl500
159CH206-formyl-pyridin-2-yl448
160CH20Quinolin-3-yl
161CH205-(CH2OC(O)CH3)-fur-2-yl
|
162CH2032529
|
163CH20Pyridin-4-yl420
164CH203-OH-4-NO2—C6H3480
165CH203,5-F2—C6H3455
166CH203-CF3—C6H3487
167CH202-F-6-Cl—C6H3471
168CH202-(tert-butyl)S-C6H4
169CH204-Et-C6H4447
170CH203-CO2H-4-OH—C6H4479
171CH203-(OCH2CO2H)—C6H4493
172CH202,3-methylenedioxyphenyl463
173CH20Thiazol-2-yl426
174CH205-ethylfur-2-yl437
175CH20Quinolin-2-yl470
176CH20Quinolin-4-yl470
177CH204-CH2CH(CH3)2—C6H4475
178CH203-MeO-4-OH-5-CO2H—C6H2509
179CH204-bromopyrazol-3-yl
180CH202-(OCH2CO2H)-3-MeO—C6H3523
181CH204-(O(CH2)3N(CH3)2)—C6H4520
182CH203-bromothien-2-yl503
183CH203-phenoxythien-2-yl517
184CH205-methylthio-thien-2-yl471
185CH201-methyl-4-bromopyrazol-3-yl501
186CH204-I—C6H4
187CH206,7-Me2-chromon-3-yl
188CH202-(OCH2CO2H)-5-NO2—C6H4538
189CH202-(2,6-dichlorobenzyloxy)phenyl593
190CH201-(4-chlorobenzyl)pyrazol-3-yl533
191CH204-iso-propoxy-C6H4477
192CH201-methylbenzimidazol-2-yl473
193CH203-Me-C6H4433
194CH20Pyridin-3-yl420
195CH202,4-(MeO)2-pyrimidin-5-yl
196CH203-Cl-5-CF3-pyridin-2-yl522
197CH202,4-Me2-C6H3447
198CH201-methylindol-3-yl472
199CH202-methyl-3-(CO2Et)-fur-5-yl
200CH201-Me-4-Cl-pyrazol-3-yl457
201C(O)2phenyl461
202C(O)14-Br—C6H4525
203C(O)14-NH2—C6H4462
204C(O)12-Br—C6H4525
205C(O)I4-F-C6H4465
206C(O)12-CF3—C6H4
207C(O)13-Me-C6H4461
208C(O)12-Me-C6H4461
209C(O)13-Cl-4-OH—C6H3497
210C(O)39,10-dihydrophenanthren-2-yl577
211C(O)12-NO2—C6H4492
212C(O)12-Cl—C6H4481
213C(O)14-Cl—C6H4481
214C(O)12-benzyloxy-C6H4553
215C(O)23,4-(OH)2—C6H3493
216C(O)14-NO2—C6H4492
217C(O)4Phenyl489
218C(O)13,4-(MeO)2—C6H3507
219C(O)14-EtO—C6H4491
220C(O)13-F-4-OH—C6H3481
221C(O)3Phenyl475
222C(O)13,4-methylenedioxyphenyl491
223C(O)34-MeO—C6H4505
224C(O)24-OH—C6H4477
225C(O)14-OH—C6H4463
226C(O)14-phenyl-C6H4523
227C(O)13,4-Cl2—C6H3515
228C(O)23-OH—C6H4477
229C(O)24-Me-C6H4475
230C(O)34-NO2—C6H4520
231C(O)23,4-(MeO)2—C6H3521
232C(O)34-Me-C6H4489
233C(O)2C6F5551
234C(O)3Dibenzothien-4-yl581
235C(O)14-Me-C6H4461
236C(O)24-SH—C6H4
237C(O)14-CF3O—C6H4531
238C(O)14-CH2Br—C6H4
239C(O)33,4-(MeO)2—C6H3535
240C(O)14-MeO—C6H4477
241C(O)14-(NMe2)—C6H4490
242C(O)24-MeO—C6H4491
243C(O)22-MeO—C6H4491
244C(O)13,4,5-(MeO)3—C6H2537
245C(O)23,4-methylenedioxyphenyl505
246C(O)2Dibenzothien-4-yl
247C(O)13-NH2—C6H4462
248C(O)INaphth-1-yl497
249C(O)13-MeO-4-OH—C6H3493
250C(O)1Naphth-2-yl
251C(O)13-(1-allyl-6-bromonaphth-2-yloxy)CH2—C6H4721
252C(O)14-NO2—C6H4
253C(O)13-F-4-MeO—C6H3495
254C(O)43-Me-C6H4503
255C(O)13-OH—C6H4463
256C(O)14-benzyloxy-C6H4553
257C(O)14-(3-NO2—C6H4—C6H4568
258C(O)12,5-(Me)2—C6H3475
259C(O)14-I—C6H4573
260C(O)I4-(4-(1-Me-2-OH-4-(pyridin-3-yl)-butoxy)-702
C6H4)-C6H4
261C(O)13-Br—C6H4525
262C(O)23-(n-Pr)—C6H4503
263C(O)14-(4-NO2—C6H4CH2O)—C6H4598
264C(O)12,5-(OH)2—C6H3
265C(O)12-Me-3-NO2—C6H3506
266C(O)14-(CH2NHCO2CH2(fluoren-9-yl))-C6H4
267C(O)13-OH-4-MeO—C6H4493
268C(O)13-F-C6H4465
269C(O)12-F-C6H4465
270C(O)13,5-(MeO)2—C6H3507
271C(O)13-Cl—C6H4481
272C(O)1Phenyl447
273C(O)13,5-Me2—C6H3475
274C(O)23-MeO—C6H4491
275C(O)12,4-F2—C6H3483
276C(O)12-MeO—C6H4477
277C(O)13,4-F2—C6H3483
278C(O)13,5-F2—C6H3483
279C(O)5phenyl503
280S(O)205-(pyridin-2-yl)-thien-2-yl
281C(O)03-S(O)2Me-C6H4511
282C(O)03-MeO-4-NH2—C6H3
283C(O)03-MeO-4-F—C6H3481
284C(O)0Benzthiazol-6-yl490
285C(O)03-MeO—C6H4477
286C(O)03-C6H5S(O)—C6H4557
287C(O)04-S(O)2Me-C6H4511
288C(O)02,4-Cl2—C6H3501
289C(O)04-NO2—C6H4478
290C(O)03-CN—C6H4458
291C(O)04-MeO—C6H4463
292C(O)04-CN—C6H4458
293C(O)02-S(O)2Me-C6H4511
294C(O)02-Cl-4-S(O)2Me-C6H3545
295C(O)03-(C6H5S(O)2CH2)-4-NO2—C6H3632
296C(O)02-(C6H5S(O)2CH2)—C6H4
297C(O)0Benzo[1,2,3]thiadiazol-5-yl491
298C(O)04-EtS—C6H4493
299C(O)03-CF3S—C6H4533
300C(O)04-CF3S—C6H4533
301C(O)03-CH3C(O)NH—C6H4490
302C(O)03-CH3-4-NH2—C6H3462
303C(O)0Indol-7-yl472
304C(O)03-CH3CH2O-4-CH3O—C6H3507
305C(O)04-(2,5-dihydropyrrol-1-yl)-C6H4500
306C(O)13-Br-pyridin-5-yl526
307C(O)11-methyl-imidazol-4-yl451
308C(O)15-OH-indol-3-yl502
309C(O)1Thiophen-3-yl453
310C(O)03-CH3CH2S(O)2—C6H4525
311C(O)03-CH3(CH2)2S(O)2—C6H4539
312C(O)03-(CH3)2CHCH2S(O)2—C6H4553
313C(O)03,4-(CH3S(O)2)2—C6H3589
314C(O)03-CH3CH2O-4-NH2—C6H3492
315C(O)1Pyridin-4-yl448
316C(O)02-CH3S(O)2CH2—C6H4525
317C(O)02-NH2—C6H4448
318C(O)01-acetyl-indol-3-yl
319C(O)0Indol-3-yl
320C(O)03-NH2(CH2)2O—C6H4
321C(O)03-CH3NHS(O)2—C6H4
322C(O)03-NH2S(O)2—C6H4
323C(O)03-CH3O(CH2)2O—C6H4
324C(O)03-(CH3)3COC(O)NH(CH2)2O—C6H4
325C(O)01,2,3-benzothiadiazol-6-yl
326C(O)03-HOC(O)CH2O—C6H4
327C(O)02-CH3S(O)2-3-CN-thiophen-5-yl542
328C(O)03-CH3S(O)2-4-NH2—C6H3526
329C(O)02-CH3S(O)2-3-NH2C(O)-thiophen-5-yl560
330C(O)03-CF3O—C6H4501
331C(O)02-(CH3)2CHS(O)2-3-NH2-thiophen-4-yl560
332C(O)02-CH3S(O)2-thiophen-5-yl517
333C(O)03-CH3-5-(4-CH3-1,2,3-thiadiazol-5-yl)-isoxazol-4-yl536
334C(O)03-Cl-5-CF3-pyridin-2-yl536
335C(O)14-CF3O—C6H4531
336C(O)01H-benzotriazol-5-yl474
337C(O)04-CH3S(O)2CH2—C6H4525
338C(O)03-CH3S(O)2CH2—C6H4525
339C(O)02-CN—C6H4458
340C(O)0Quinolin-6-yl484
341C(O)0Quinoxalin-6-yl485
342C(O)03-NH2-4-CH3S(O)2-thiophen-2-yl532
|
343C(O)033566
|
344C(O)034
|
345C(O)03-CF3O—C6H4517
346C(O)02,5-(CH3O)2—C6H3493
347C(O)01-(CH3)2CH-benzotnazol-5-yl
|
348C(O)035
|
349C(O)03-HO(CH2)2S(O)2—C6H4
350C(O)02-HO(CH2)2S(O)2—C6H4
351C(O)03-cyclopropylCH2S(O)2—C6H4
352C(O)02-CH3S(O)2NH—C6H4526
353C(O)0(CF3)(MeO)(C6H5)C545
354C(O)0(C6H5)2CH523
355C(O)0(4-Cl—C6H4)(CH3)2C509
356C(O)0(C6H5)(cyclohexyl)CH529
357C(O)0(4-F—C6H4)(CH3)CH479
358C(O)13,4-methylenedioxy-C6H4491
359C(O)0(C6H5)(cyclopentyl)CH515
360C(O)0((CH3)(CH3CH2)CH)(C6H5)CH503
361C(O)01-phenyl-cyclopentyl501
362C(O)01-(4-Cl—C6H4)cyclopentyl535
363C(O)01-phenyl-cyclopropyl473
364C(O)01-phenyl-cyclohexyl515
365C(O)0(C6H5)(cyclohexyl)C(OH)545
366C(O)0((CH3)2CH)(C6H5)CH489
367C(O)1pyrid-3-yl448
368C(O)1pyrid-2-yl448
369C(O)15-Br-pyrid-3-yl526
370C(O)12,4-(MeO)2—C6H3507
371C(O)14-benzyloxy-phenyl553
372C(O)13-benzyloxy-phenyl553
|
373C(O)136549
|
374C(O)02-EtO—C6H4491
|
375C(O)037549
|
376C(0)14-n-butoxyphenyl519
377C(0)1indol-1-yl486
378C(O)12-NO2-phenyl492
379C(O)1thien-2-yl453
380C(O)13-Cl-4-OH-phenyl497
381C(O)12-Br-phenyl525
382C(O)13-Br-phenyl525
383C(O)13,5-F2-phenyl483
384C(O)13-aminophenyl462
385C(O)13,4-(OH)2-phenyl479
386C(O)12,5-(MeO)2-phenyl507
387C(O)I4-Me-phenyl461
388C(O)05-(4-Cl—C6H4)-tetrazol-2-yl549
389C(O)14-MeS(O)2-phenyl525
390C(O)14-F-phenyl465
391C(O)15-Cl-benzo[b]thiophen-3-yl537
392C(O)14-CF3O-phenyl531
393C(O)13-Me-5-Cl-benzo[b]thiophen-2-yl551
394C(O)12-nitrophenyl492
395C(O)14-Cl-5-Me-3-NO2-pyrazol-1-yl530
396C(O)12-CF3-benzimidazol-1-yl555
397C(O)12-EtS-benzimidazol-1-yl547
398C(O)12-Me-4-(thien-2-yl)-thiazol-5-yl550
399C(O)14-Br-3,5-Me2-pyrazol-1-yl543
400C(O)15-Me-3,4-(NO2)2-pyrazol-1-yl541
401C(O)14-(3-methyl-butoxy)-phenyl533
402C(O)12-tert-butylthio-phenyl535
403C(O)14-Cl-3,5-Me2-pyrazol-1-yl499
|
404C(O)138535
|
405C(O)12,4-(NO2)2-imidazol-1-yl527
406C(O)13,5-Me2-pyrazol-1-yl465
407C(O)14-n-hexyl-phenyl531
408C(O)02-NH2-pyrid-5-yl449
409C(O)0Pyrid-2-yl434
410C(O)02-EtS-pyrid-3-yl494
411C(O)02-OH-quinolin-4-yl500
412C(O)02-OH-pyrid-5-yl450
413C(O)02,6-(MeO)2-pyrid-3-yl494
414C(O)02-(imidazol-1-yl)-pyrid-5-yl500
415C(O)02-CO2CH3-pyrid-3-yl492
416C(O)02-Me-pyrid-5-yl448
417C(O)0Quinolin-2-yl484
418C(O)06-Me-pyrid-2-yl448
419C(O)02-OH-6-Me-pyrid-3-yl464
420C(O)08-OH-quinolin-2-yl500
421C(O)13-F-phenyl465
422C(O)0Imidazo[1,2-a]pyrid-2-yl473
423C(O)02-methyl-[1,8]naphthyfldifl-3-yl499
424C(O)0[1,6]naphthyridin-2-yl485
425C(O)02-methyl-[1,6]naphthyridin-3-yl499
426C(O)01-methyl-1H-pyrid-2-one-5-yl464
427C(O)0Quinolin-4-yl484
428C(O)0Quinolin-6-yl484
429C(O)03-(CH3(CH2)2S(O)2)—C6H4539
430C(O)05-((pyrid-2-yl)SCH2)fur-2-y1546
431C(O)02-Me-3-OH-quinolifl-4-yl514
432C(O)0(pyrid-2-yl)CH═CH460
433C(O)0(2-EtS-pyrid-5-yl)CH═CH520
434C(O)01-(5-CF3-pyrid-2-yl)-piperidin-4-yl585
435C(O)02,7-Me2-imidazo1,2-a]Pyrid-3-yl501
436C(O)0(5-CF3-pyrid-2-yl)SO2CH(CH3)594
437C(O)13-(pyrid-2-yl)pyrazol-l-yl514
438C(O)03-NH2-4-CH3O—C6H3478
439C(O)02,5-(CH3O)2—C6H3493
440C(O)03-F-4-CH3—C6H3465
441C(O)03-phenyl-5-CH3-isoxazol-4-yl514
442C(O)01-phenyl-5-CH3-pyrazol-4-yl513
443C(O)03-CF3O—C6H4517
444C(O)02-CH3O-5-Cl—C6H3497
445C(O)02-CH3-3-F—C6H3465
446C(O)02-(2-phenyl-thiazol-4-yl)phenyl592
447C(O)03,4-methylenedioxyphenyl477
448C(O)05-phenyl-oxazol-4-yl500
449C(O)01H-indazol-3-yl473
450C(O)01-CH3-indol-3-yl486
451C(O)01-iso-propyl-benztriazol-5-yl516
|
452C(O)039473
|
453C(O)02-CH3-5-F—C6H3465
454C(O)03-CF3O-4-NH2—C6H3532
455C(O)03-CH3-5-CF3-isoxazol-4-yl506
456C(O)0(1,2,4-triazol-1-yl)C(CH3)2466
457C(O)02-phenyl-thiazol-4-yl516
458C(O)02-CH3-4-CF3-thiazol-5-yl522
|
459C(O)040529
|
460C(O)041558
|
461C(O)03-F-4-CF3—C6H3519
|
462C(O)042501
|
463C(O)02-CH3-benzimidazol-5-yl487
|
464C(O)143534
|
465C(O)03-iso-propoxy-4-CH3O—C6H3521
|
466C(O)044519
|
467C(O)045534
|
468C(O)02-CH3O-5-F—C6H3481
469C(O)03-CH3CH2O—C6H4
470C(O)02-(C6H5S(O)CH2)—C6H4
471C(O)01H-indol-3-yl472
472S(O)212-NO2—C6H4528
473S(O)202-CN—C6H4494
474C(O)03-CH3S(O)2—C6H4511
475C(O)03-S(O)2NHCH3—C6H4526
476C(O)0Benzo[1,2,3]thiadiazol-6-yl491
477C(O)03-CH3O(CH2)2O—C6H4507
478C(O)03,4-(CH3S(O)2)2-C6H3589
479C(O)03-CH3O—C6H4463
480C(O)03-CN—C6H4458
481C(O)04-F—C6H4451
482C(O)03-CH3O-4-F—C6H3481
483C(O)03H-benzothiazol-2-one-6-yl506
484C(O)02-CH3S(O)2-thien-5-yl517
485C(O)03-CH3-4-NH2—C6H3462
486C(O)0Benzothiazol-6-yl490
487C(O)01H-5-CH3S(O)2-indol-2-yl550
488C(O)01H-5-CH3O-indol-2-yl502
489C(O)01H-indol-4-yl472
490C(O)01H-Benzimidazol-5-yl473
491C(O)03,4-methylenedioxyphenyl477
492C(O)01H-5-Cl-indol-2-yl506
493C(O)0lH-5-OH-indol-2-yl488
|
494C(O)046558
|
495C(O)03,4-difluoromethylenedioxyphenyl513
496C(O)02-(pyrazol-1-yl)-pyridin-5-yl500
497C(O)04-CF3-pyridin-3-yl502
|
498C(O)047576
|
499C(O)048459
|
500C(O)03-n-propoxy-pyridin-2-yl492
501C(O)12-(2,4-F2—C6H3)thiazol-4-yl566
502C(O)01H-indol-2-yl472
503C(O)12-phenyl-5-CH3-thiazol-4-yl544
504C(O)02-S(O)2NH2-4-Cl—C6H3546
505C(O)02-CN—C6H4458
506C(O)01H-indol-7-yl472
507C(O)01H-5-F-indol-2-yl490
508C(O)01 H-pyrazol-4-yl423
509C(O)01-CH3-pyrrol-2-yl436
511C(O)03-pyrrol-1-yl)-4-CN-thief-2-yl529
512C(O)03-CH3O-4-NH2—C6H3478
513C(O)C(O)01H-indol-3-yl500
514C(O)04-(pyrrol-1-yl)phenyl498
515C(O)01-CH3-indol-2-yl486
516C(O)11H-indol-3-yl486
517C(O)11H-5-CH3O-indol-3-yl516
518C(O)02-(pyridin-2-yl)-thien-5-yl516
519C(O)01H-5-F-indol-2-yl490
520C(O)13-CH3-benzo[b]thiophen-2-yl517
521C(O)13,5-(CH3)2-4-NO2-pyrazol-1-yl510
522C(O)02-CF3-[1,6]-naphthyridin-3-yl553
523C(O)02-(1-CH3-5-CF3-pyrazol-3-yl)-thiefl-5-yl587
|
524C(O)049638
|
525C(O)13-Cl—C6H4481
526C(O)15-CH3-3-NO2-pyrazol-1-yl496
527C(O)12-CN—C6H4472
528C(O)0Quinoxalin-2-yl485
529C(O)0Pyrazin-2-yl435
|
530C(O)050549
|
531C(O)01-tert-butyl-3-CH3-pyrazol-5-yl493
532C(O)02-SH-pyridin-3-yl466
533C(O)0Quinolin-3-yl484
|
534C(O)051543
|
535C(O)02-ethoxy-phenyl477
536C(O)14-NO2-imidazol-1-yl482
537C(O)04-CH3O-quinolin-2-yl514
538C(O)02-SCH2CH═CH2-pyridin-3-yl506
539C(O)01-iso-propyl-benztriazol-5-yl516
540C(O)0[1,8]-naphthyridin-2-yl485
541C(O)12-CH3-4-phenyl-thiazol-5-yl544
542C(O)01-CH3-indol-2-yl486
543C(O)02-phenoxy-pyridin-5-yl-CH═CH552
544C(O)13,4-Cl2—C6H3515
545C(O)02-S(O)2CH3-3-CN-6-CH3-pyridin-4-yl551
546C(O)03H-Benzothiazol-2-one-6-yl506
547C(O)02-CH3O-pyridin-3-yl464
548C(O)0Isoquinolin-1-yl484
549C(O)14-OH—C6H4463
550C(O)0Quinolin-8-yl484
551C(O)02-CN—C6H4458
552C(O)02-CF3-[1,8]-naphthyridin-3-yl553
553C(O)02-CO2CH3-pyridin-6-yl492
554C(O)0Isoquinolin-3-yl484
555C(O)03-CH2S(O)2CH3—C6H4525
556C(O)02-ethoxy-pyridin-3-yl478
|
557C(O)152516
|
558C(O)02-CH3O-pyridin-5-yl464
559C(O)0Indan-1-one-3-yl487
560C(O)13-NO2-[1,2,4]-triazol-l-yl483
561C(O)01-(CH3)2CH-benzotriazol-5-yl516
562C(O)11H-2-CH3-indol-3-yl500
563C(O)03,5-(CH3)2-isoxazol-4-yl452
564C(O)01,5-(CH3)2-pyrazol-4-yl451
565C(O)0Quinoxalin-6-yl485
566C(O)03-NO2[1,2,4]triazol-1-yl483
567C(O)01H-indol-3-yl-CH═CH498
568C(O)14-(pyridin-2-yl)-pyrimidin-2-yl-S558
569C(O)03-S(O)2NH2—C6H4512
570C(O)11H-5-OH-indol-3-yl502
571C(O)04-CH2S(O)2CH3—C6H4525
|
572C(O)053500
|
573C(O)0Isoxazol-5-yl424
574C(O)11-CH3-4-NO2-pyrazol-5-yl496
|
575C(O)054645
|
576C(O)03-ethoxy-4-amino-phenyl492
577C(O)11,4-(CH3)2-3-CO2H-pyrrol-2-yl508
|
578C(O)055473
|
579C(O)056491
|
580C(O)02-OH-quinolin-4-yl500
582C(O)03-amino-phenyl448
583C(O)03-NHS(O)2CH3—C6H4526
584C(O)03-C(CH3)3OC(O)NH(CH2)2O—C6H4592
585C(O)03-HO2CCH2O—C6H4507
586C(O)03-H2N(CH2)2O—C6H4492
587C(O)02-NHS(0)2CH3—C6H4526
588C(O)02-S(O)2CH2cyclopropyl-C6H4551
589C(O)03-S(O)2N(CH3)2—C6H4540
590C(O)03-NO2-5-S(O)2OH3—C6H3556
591C(O)03-NH2-5-S(O)2OH3—C6H3526
592C(O)01-S(O)2OH3-indol-3-yl
593C(O)03-CN-5-S(O)2CH3—C6H3536
594C(O)01H-5-S(O)2CH3-indol-3-yl550
595C(O)0CH(Phenyl)(CH2piperazin-1-yl)545
|
596C(O)157518
|
597C(O)03-S(O)2NH2-4-Cl—C6H3546
|
598C(O)058474
|
599C(O)059487
|
600C(O)060507
|
601C(O)061487
|
602C(O)02-NO2-5-S(O)2CH3—C6H3
603C(O)02-NH2-5-S(O)2CH3—C6H3
|
[0163] Examples of compounds of formula (Ic) are listed in Table II below.
2TABLE II
|
|
CompoundmpTR3
|
|
111C(O)3-MeO-4-NH2—C6H3
202C(O)3-MeO-4-NH2—C6H3
311S(O)25-(pyridin-2-yl)-thien-2-yl
411C(O)3-MeO-4-NH2—C6H3
511C(O)3H-benzthiazol-2-one-6-yl
|
611C(O)62
|
711C(O)[1,8]naphthyridin-2-yl
|
811C(O)63
|
[0164] Examples of compounds of formula (Id) are listed in Table III below
3TABLE III
|
|
CompoundR3
|
14-F—C6H4
2Phenyl
33,4-F2—C6H3
|
[0165] Examples of compounds of formula (If) are listed in Table IV below.
644TABLE IV
|
|
CompoundR1tsnR3
|
|
12-CH3-4-Cl—C6H31003-CH3S(O)2—C6H4
23-Cl-4-F—C6H31003-CH3S(O)2—C6H4
33-F-4-Cl—C6H31003-CH3S(O)2—C6H4
43-CH3O-4-Cl—C6H31003-CH3S(O)2—C6H4
52-CH3O-4-F—C6H31003-CH3S(O)2—C6H4
64-CH3O—C6H41003-CH3S(O)2—C6H4
74-CH3O—C6H40003-CH3S(O)2—C6H4
84-Cl—C6H40003-CH3S(O)2—C6H4
93,4-Cl2-C6H30003-CH3S(O)2—C6H4
104-CN-C6H40003-CH3S(O)2—C6H4
113,4-F2—C6H30003-CH3S(O)2—C6H4
124-F—C6H40003-CH3S(O)2—C6H4
134-CH3C(O)NH—C6H41003-CH3S(O)2—C6H4
144-CH3—C6H41003-CH3S(O)2—C6H4
153-CH3-4-Cl—C6H31003-CH3S(O)2—C6H4
164-Cl—C6H41003-CH3S(O)2—C6H4
174-F—C6H41003-CH3S(O)2—C6H4
182,4-Cl2—C6H31003-CH3S(O)2—C6H4
192-Cl-4-F—C6H31003-CH3S(O)2—C6H4
202,4-F2—C6H31003-CH3S(O)2—C6H4
212-F-4-Cl—C6H31003-CH3S(O)2—C6H4
222-CH3-4-F—C6H31003-CH3S(O)2—C6H4
232-CH3-4-Cl—C6H31003-CH3O-4-NH2—C6H3
243-F-4-Cl—C6H31003-CH3O-4-NH2—C6H3
252-CH3O-4-Cl—C6H31003-CH3O-4-NH2—C6H3
262-CH3O-4-F—C6H31003-CH3O-4-NH2—C6H3
274-CH3O—C6H41003-CH3O-4-NH2—C6H3
283-Cl-4-F—C6H31003-CH3O-4-NH2—C6H3
294-CH3—C6H41003-CH3O-4-NH2—C6H3
303-CH3-4-Cl—C6H31003-CH3O-4-NH2—C6H3
314-Cl—C6H41003-CH3O-4-NH2—C6H3
324-F—C6H41003-CH3O-4-NH2—C6H3
332,4-Cl2—C6H31003-CH3O-4-NH2—C6H3
342-Cl-4-F—C6H31003-CH3O-4-NH2—C6H3
352,4-F2—C6H31003-CH3O-4-NH2—C6H3
362-F-4-Cl—C6H31003-CH3O-4-NH2—C6H3
372-CH3-4-F—C6H31003-CH3O-4-NH2—C6H3
382-CH3-4-Cl—C6H31001,2,3-benzthiadiazol-5-yl
393-F-4-Cl—C6H31001,2,3-benzthiadiazol-5-yl
402-CH3O-4-Cl—C6H31001,2,3-benzthiadiazol-5-yl
412-CH3O-4-F—C6H31001,2,3-benzthiadiazol-5-yl
424-CH3O—C6H41001,2,3-benzthiadiazol-5-yl
433-Cl-4-F—C6H31001,2,3-benzthiadiazol-5-yl
444-CH3—C6H41001,2,3-benzthiadiazol-5-yl
453-Cl-4-CH3—C6H31001,2,3-benzthiadiazol-5-yl
464-Cl—C6H41001,2,3-benzthiadiazol-5-yl
474-F—C6H41001,2,3-benzthiadiazol-5-yl
482,4-Cl2—C6H31001,2,3-benzthiadiazol-5-yl
492-Cl-4-F—C6H31001,2,3-benzthiadiazol-5-yl
502,4-F2—C6H31001 ,2,3-benzthiadiazol-5-yl
512-F-4-Cl—C6H31001,2,3-benzthiadiazol-5-yl
522-CH3-4-F—C6H31001,2,3-benzthiadiazol-5-yl
533,4-Cl2—C6H31103-CN-C6H4
543,4-Cl2—C6H31103-CH3S(O)2—C6H4
552-CH3-4-Cl—C6H31002-CH3S(O)2—C6H4
563-Cl-4-F—C6H31002-CH3S(O)2—C6H4
573-F-4-Cl—C6H31002-CH3S(O)2—C6H4
583-CH3O-4-Cl—C6H31002-CH3S(O)2—C6H4
592-CH3O-4-F—C6H31002-CH3S(O)2—CJ14
604-CH3O—C6H41002-CH3S(O)2—C6H4
614-CH3C(O)NH—C6H41002-CH3S(O)2—C6H4
624-CH3—C6H41002-CH3S(O)2—C6H4
633-CH3-4-Cl—C6H31002-CH3S(O)2—C6H4
644-Cl—C6H41002-CH3S(O)2—C6H4
654-F—C6H41002-CH3S(O)2—C6H4
662,4-Cl2—C6H31002-CH3S(O)2—C6H4
672-Cl-4-F—C6H31002-CH3S(O)2—C6H4
682,4-F2—C6H31002-CH3S(O)2—C6H4
692-F-4-Cl—C6H31002-CH3S(O)2—C6H4
702-CH3-4-F—C6H31002-CH3S(O)2—C4H4
712-CH3-4-Cl—C6H31002-CH3S(O)2-thiophen-5-yl
723-Cl-4-F—C6H31002-CH3S(O)2-thiophen-5-yl
733-F-4-Cl—C6H31002-CH3S(O)2-thiophen-5-yl
743-CH3O-4-Cl—C6H31002-CH3S(O)2-thiophen-5-yl
752-CH3O-4-F—C6H31002-CH3S(O)2-thiophen-5-yl
764-CH3O—C6H41002-CH3S(O)2-thiophen-5-yl
774-CH3C(O)NH—C6H41002-CH3S(O)2-thiophen-5-yl
784-CH3—C6H41002-CH3S(O)2-thiophen-5-yl
793-CH3-4-Cl—C6H31002-CH3S(O)2-thiophen-5-yl
804-Cl—C6H41002-CH3S(O)2-thiophen-5-yl
814-F—C6H41002-CH3S(O)2-thiophen-5-yl
822,4-Cl2—C6H31002-CH3S(O)2-thiophen-5-yl
832-Cl-4-F—C6H31002-CH3S(O)2-thiophen-5-yl
842,4-F2—C6H31002-CH3S(O)2-thiophen-5-yl
852-F-4-Cl—C6H31002-CH3S(O)2-thiophen-5-yl
862-CH3-4-F—C6H31002-CH3S(O)2-thiophen-5-yl
873-Cl-4-CH3—C6H31003-CH3S(O)2—C6H4
883-Cl-4-CH3—C6H31003-CH3O-4-NH2—C6H3
893-CH3-4-Cl—C6H31001,2,3-benzthiadiazol-5-yl
903-Cl-4-CH3—C6H31002-CH3S(O)2—C6H4
913-Cl-4-CH3—C6H31002-CH3S(O)2-thiophen-5-yl
922-CH3-4-Cl—C6H3100Quinolin-6-yl
932-CH3-4-Cl—C6H31003-(CH3O(CH2)2O)—C6H4
942-CH3-4-Cl—C6H31003,4-(CH3S(O)2)2—C6H3
952-CH3-4-Cl—C6H31003-CH3O—C6H4
962-CH3-4-Cl—C6H31003-CN—C6H4
972-CH3-4-Cl—C6H31004-F—C6H4
982-CH3-4-Cl—C6H3100Indol-7-yl
992-CH3-4-Cl—C6H31005-CH3S(O)2-indol-2-yl
1002-CH3-4-Cl—C6H3100Benzimidazol-5-yl
1012-CH3-4-Cl—C6H31003,4-methylenedioxy-C6H3
1022-CH3-4-Cl—C6H31005-F-indol-2-yl
1032-CH3-4-Cl—C6H31005-CF3-thieno[3,2-bpyridin-6-yl
1042-CH3-4-Cl—C6H31002-(pyrazol-1-yl)-pyridin-5-yl
1053-CH3-4-Cl—C6H3100Quinolin-6-yl
1063-CH3-4-Cl—C6H31002-CN—C6H4
1073-CH3-4-Cl—C6H31003-(CH3O(CH2)2O)-C6H4
1083-CH3-4-Cl—C6H31003,4-(CH3S(O)2)2—C6H3
1093-CH3-4-Cl—C6H31003-CH3O—C6H4
1103-CH3-4-Cl—C6H31003-CN—C6H4
1113-CH3-4-Cl—C6H31004-F—C6H4
1123-CH3-4-Cl—C6H31005-CH3S(O)2-thien-2-yl
1133-CH3-4-Cl—C6H3100Indol-7-yl
1143-CH3-4-Cl—C6H31005-CH3S(O)2-indol-2-yl
1153-CH3-4-Cl—C6H31003-EtO-4-NH2—C6H3
1163-CH3-4-Cl—C6H31005-CH3O-indol-2-yl
1173-CH3-4-Cl—C6H31003,4-methylenedioxy-C6H3
1183-CH3-4-Cl—C6H31005-F-indol-2-yl
1193-CH3-4-Cl—C6H31005-CF3-thienol[3,2-b]pyridin-6-yl
1203-CH3-4-Cl—C6H31002-(pyrazol-1-yl)-pyridifl-5-yl
1212-CH3-4-Cl—C6H31002-NH2-4-MeO—C6H3
1222-CH3-4-Cl—C6H3100Pyrazin-2-yl
1232-CH3-4-Cl—C6H31003-phenyl-5-Me-isoxazol-4-yl
1242-CH3-4-Cl—C6H31003-CF3O—C6H4
1252-CH3-4-Cl—C6H31002-MeO-5-Cl—C6H3
1262-CH3-4-Cl—C6H31002-Me-3-F—C6H3
1272-CH3-4-Cl—C6H31002-EtO—C6H4
1282-CH3-4-Cl—C6H31005-phenyl-oxazol-4-yl
1292-CH3-4-Cl—C6H31005-F-1H-indol-2-yl
1302-CH3-4-Cl—C6H31002H-isoquinolin-1-one-4-yl
1312-CH3-4-Cl—C6H31003H-benzothiazol-2-one-6-yl
1322-CH3-4-Cl—C6H3100Bicyclo[4.2.0]octa-1,3,5-trien-7-yl
1332-CH3-4-Cl—C6H31001-iso-propylbenztriazol-5-yl
1342-CH3-4-Cl—C6H31001-phenylcyclopropyl
1352-CH3-4-Cl—C6H31003-NH2S(O)2-4-Cl—C6H3
1362-CH3-4-Cl—C6H31003-CF3O-4-NH2—C6H3
1372-CH3-4-Cl—C6H31003-(pyrrol-1-yl)-4-CN-thien-2-yl
1382-CH3-4-Cl—C6H31002-(CH3O(CH2)20)-5-NH2—C6H3
1392-CH3-4-Cl—C6H31001-(1-CH3-5-CF3-pyrazol-3-yl)-thien-5-yl
1402-CH3-4-Cl—C6H3100(1,2,4-triazol-1-yl)C(CH3)2
1412-CH3-4-Cl—C6H31002-phenyl-thiazol-4-yl
1422-CH3-4-Cl—C6H31002-CH3-4-CF3-thiazol-5-yl
1432-CH3-4-Cl—C6H3100[1,8]-naphthyridin-2-yl
|
1442-CH3-4-Cl—C6H310065
|
1452-CH3-4-Cl—C6H310066
|
1462-CH3-4-Cl—C6H31003-F-4-CF3-C6H3
|
1472-CH3-4-Cl—C6H310067
|
1482-CH3-4-Cl—C6H310068
|
1492-CH3-4-Cl—C6H31002-CH3-benzimidazol-5-yl
|
1502-CH3-4-Cl—C6H310169
|
1512-CH3-4-Cl—C6H310070
|
1522-CH3-4-Cl—C6H31001,5-dimethyl-pyrazol-3-yl
1532-CH3-4-Cl—C6H31002-CH3O-5-F—C6H3
1543-CH3-4-Cl—C6H31003-NH2-4-CH3O—C6H3
1553-CH3-4-Cl—C6H31002,5-(CH3O)2—C6H3
1563-CH3-4-Cl—C6H31003-F-4-CH3—C6H3
1573-CH3-4-Cl—C6H3100Pyrazin-2-yl
1583-CH3-4-Cl—C6H31003-phenyl-5-CH3-isoxazol-4-yl
1593-CH3-4-Cl—C6H31001-phenyl-5-CH3-pyrazol-4-yl
1603-CH3-4-Cl—C6H31003-CF3O—C6H4
1613-CH3-4-Cl—C6H31002-CH3O-5-Cl—C6H3
1623-CH3-4-Cl—C6H31002-CH3-3-F—C6H3
1633-CH3-4-Cl—C6H31002-CH3CH2O—C6H4
1643-CH3-4-Cl—C6H31002-(2-phenyl-thiazol-4-yl)-Phenyl
|
1653-CH3-4-Cl—C6H310071
|
1663-CH3-4-Cl—C6H31003,4-methylenedioxyphenyl
1673-CH3-4-Cl—C6H31005-phenyl-oxazol-4-yl
1683-CH3-4-Cl—C6H3100Quinoxalin-2-yl
1693-CH3-4-Cl—C6H31001H-Pyrazol-4-yl
1703-CH3-4-Cl—C6H31001-CH3-indol-3-yl
|
1713-CH3-4-Cl—C6H310072
|
1723-CH3-4-Cl—C6H31001-iso-propyl-benztriazol-5-yl
1733-CH3-4-Cl—C6H31003-n-propoxy-pyridin-2-yl
1743-CH3-4-Cl—C6H31002-CH3-5-F—C6H3
1753-CH3-4-Cl—C6H3101(2-S(O)2NHCH3—C6H4)S
1763-CH3-4-Cl—C6H31003-CH35-CF3-isoxazol-4-yl
1773-CH3-4-Cl—C6H31012-(2,4-F2—C6H3)thiazol-4-yl
1783-CH3-4-Cl—C6H31002-(CH3O(CH2)2O)-5-NH2—C6H3
1793-CH3-4-Cl—C6H31002-phenyl-thiazol-4-yl
|
1803-CH3-4-Cl—C6H310073
|
1813-CH3-4-Cl—C6H310074
|
1823-CH3-4-Cl—C6H31003-F-4-CF3-C6H3
|
1833-CH3-4-Cl—C6H310075
|
1843-CH3-4-Cl—C6H310076
|
1853-CH3-4-Cl—C6H31003-iso-propoxy-C6H4
1863-CH3-4-Cl—C6H31002CH3-benzimidazol-5-yl
|
1873-CH3-4-Cl—C6H310177
|
1883-CH3-4-Cl—C6H31001 -CH3-indol-3-yl
|
1893-CH3-4-Cl—C6H310078
|
1903-CH3-4-Cl—C6H31001-tert-butyl-3-CH3-pyrazol-5-yl
|
1913-CH3-4-Cl—C6H310079
|
1923-CH3-4-Cl—C6H31002-CH3O-5-F—C6H3
1933-CH3-4-Cl—C6H31003-NH2-4-CH3O—C6H3
1943-CH3-4-Cl—C6H31002,5-(CH3O)2—C6H3
1952-CH3-4-Cl—C6H31002-CN—C6H4
1962-CH3-4-Cl—C6H31002-CH3O-4-F—C6H3
1973-CH3-4-Cl—C6H31001-CH3-pyrrol-2-yl
1982-CH3-4-Cl—C6H31003-S(O)2CH3-4-NH2—C6H3
1992-CH3-4-Cl—C6H31001H-5-F-indol-2-yl
2003-CH3-4-Cl—C6H31001H-5-CH3O-indol-3-yl
2012-CH3-4-Cl—C6H31003-F-4-CH3—C6H3
2022-CH3-4-Cl—C6H31001-phenyl-5-CH3-pyrazol-4-yl
2032-CH3-4-Cl—C6H31002-(2-phenyl-thiazol-4-yl)-Phenyl
2043-CH3-4-Cl—C6H31001H-5-F-indol-2-yl
2053-CH3-4-Cl—C6H31003-CF3O-4-NH2—C6H3
2063-CH3-4-Cl—C6H31003-iso-propoxy-4-CH3O—C6H3
2072-CH3-4-Cl—C6H31001H-5-CH3O-indol-2-yl
2082-CH3-4-Cl—C6H31001H-indol-4-yl
2092-CH3-4-Cl—C6H31004-CF3-pyridin-3-yl
|
2102-CH3-4-Cl—C6H310080
|
2112-CH3-4-Cl—C6H31001-CH3-indol-3-yl
2122-CH3-4-Cl—C6H31003-iso-propoxy-4-CH3O—C6H3
2133-CH3-4-Cl—C6H31011H-indol-3-yl
|
2142-CH3-4-Cl—C6H310081
|
2152-CH3-4-Cl—C6H31001-CH3-indol-2-yl
2163-CH3-4-Cl—C6H31003-S(O)2NH2-4-Cl—C6H3
|
2173-CH3-4-Cl—C6H310082
|
2183-CH3-4-Cl—C6H31003-(pyrrol-1-yl)-3-CN-thien-2-yl
2192-CH3-4-Cl—C6H31004-(pyrrol-1-yl)phenyl
2203-CH3-4-Cl—C6H31001H-indazol-3-yl
2212-CH3-4-Cl—C6H31003-CH3O-NH2—C6H3
2222-CH3-4-Cl—C6H31001-CH3-indol-2-yl
|
2233-CH3-4-Cl—C6H310083
|
2242-CH3-4-Cl—C6H31004-S(O)2CH3—C6H4
2253-CH3-4-Cl—C6H31002-(1-CH3-5-CF3-pyrazol-3-yl)-thien-5-yl
2262-CH3-4-Cl—C6H31002-CH3-5-F—C6H3
2272-CH3-4-Cl—C6H31004-CH2S(O)2CH3—C6H4
2282-CH3-4-Cl—C6H3100Quinoxalin-2-yl
2292-CH3-4-Cl—C6H31001H-5-Cl-indol-2-yl
2303-CH3-4-Cl—C6H31003-CH2S(O)2CH3—C6H4
2312-CH3-4-Cl—C6H31012-(2,4-F2—C6H3)thiazol-4-yl
2322-CH3-4-Cl—C6H31003-S(O)2NH2—C6H4
2332-CH3-4-Cl—C6H31011H-indol-3-yl
2343-CH3-4-Cl—C6H31004-S(O)2CH3—C6H4
2353-CH3-4-Cl—C6H31001-CH3-indol-2-yl
2362-CH3-4-Cl—C6H31003-CH3-5-CF3-isoxazol-4-yl
2373-CH3-4-Cl—C6H31001-CH3-indol-2-yl
2384-S(O)2CH3—C61003,4-Cl2—C6H3
2392-CH3-4-Cl—C6H31001-CH3-indol-3-yl
2403-CH3-4-Cl—C6H3100[1,8]-naphthyridin-2-yl
2412-CH3-4-Cl—C6H31003-S(O)2CH3—C6H4
2423-CH3-4-Cl—C6H31003-OH—C6H4
2433-CH3-4-Cl—C6H31003H-Benzthiazol-2-one-6-yl
2442-CH3-4-Cl—C6H31003-n-propoxy-pyridin-2-yl
2452-CH3-4-Cl—C6H31003H-Benzthiazol-2-one-6-yl
2462-CH3-4-Cl—C6H3100Isoxazol-5-yl
2472-CH3-4-Cl—C6H31002,5-(CH3O)2—C6H3
2482-CH3-4-Cl—C6H31001H-pyrazol-4-yl
2493-CH3-4-Cl—C6H3100Benzothiazol-6-yl
2502-CH3-4-Cl—C6H31003,5-(CH3)2-isoxazol-4-yl
2513-CH3-4-Cl—C6H31004-CF3-pyridin-3-yl
2523-CH3-4-Cl—C6H31001H-indol-4-yl
2533-CH3-4-Cl—C6H31001,5-(CH3)2-pyrazol-3-yl
2542-CH3-4-Cl—C6H31001H-indazol-3-yl
2553-CH3-4-Cl—C6H31003-S(O)2NH2—C6H4
2562-CH3-4-Cl—C6H31014-S(O)2CH3—C6H4
2572-CH3-4-Cl—C6H3100Benzthiazol-6-yl
2582-CH3-4-Cl—C6H31001H-5-OH-indol-2-yl
2592-CH3-4-Cl—C6H31003-CH2S(O)2CH3—C6H4
2602-CH3-4-Cl—C6H31003,4-methylenedioxyphenyl
2612-CH3-4-Cl—C6H31001-CH3-pyrrol-2-yl
2622-CH3-4-Cl—C6H31003-CH3-4-NH2—C6H3
2633-CH3-4-Cl—C6H3100Isoxazol-5-yl
2642-CH3-4-Cl—C6H31003-OH—C6H4
2652-CH3-4-Cl—C6H31001H-5-OH-indol-3-yl
|
2663-CH3-4-Cl—C6H310084
|
2672-CH3-4-Cl—C6H310085
|
2682-CH3-4-Cl—C6H310086
|
2693-CH3-4-Cl—C6H310087
|
2703-CH3-4-Cl—C6H310088
|
2712-CH3O-4-Cl—C6H31003-CH3S(O)2—C6H4
2722,6-(CH3)2-4-Cl—C6H21003-CH3S(O)2—C6H4
2732,3-Cl2—C6H31003-CH3S(0)2—C6H4
2742,5-Cl2—C6H31003-CH3S(O)2—C6H4
2752-Cl-4-CH3—C6H31003-CH3S(O)2—C6H4
2762-Cl-5-CH3—C6H31003-CH3S(O)2—C6H4
2772-CH3-4-C(O)CH3—C6H31003-CH3S(O)2—C6H4
2782-(morpholin-4-yl)-1003-CH3S(O)2—C6H4
C6H4
2793-CH3CH2-4-Cl—C6H31003-CH3S(O)2—C6H4
280Naphth-7-yl1003-CH3S(O)2—C6H4
2812-tert-butyl-C6H41003-CH3S(O)2—C6H4
282Indan-5-yl1003-CH3S(O)2—C6H4
2832-cyclohexyl-4-Cl—C6H31003-CH3S(O)2—C6H4
2842-C(O)NH2-4-Cl—C6H31003-CH3S(O)2—C6H4
2852-isoxazol-5-yl-4-Cl—1003-CH3S(O)2—C6H4
C6H3
2862-CH3-5-Cl—C6H31003-CH3S(O)2—C6H4
287phenyl1003-CH3S(O)2—C6H4
2882,4-Cl2-6-CH3—C6H21003-CH3S(O)2—C6H4
2893-Cl-4-CH3—C6H31003-CH3S(O)2—C6H4
2902-CN-4-CH3—C6H31003-CH3S(O)2—C6H4
2912-CN-4-CF3-C6H31003-CH3S(O)2—C6H4
2922-CH3-pyridin-6-yl 1003-CH3S(O)2—C6H4
293Pyrimidin-2-yl1003-CH3S(O)2—C6H4
2942-Cl-4-F—C6H31002-Cl-4-CH3S(O)2—C6H3
2952-CH3-4-Cl—C6H31002-CH3S(O)2—C6H4
2962-CH3-4-Cl—C6H31002-Cl-4-CH3S(O)2—C6H3
2972-CH3-4-Cl—C6H31003-S(O)2NH2-4-Cl—C6H3
|
2982-CH3-4-Cl—C6H310089
|
2992,4-Cl2-3-CH3—C6H21003-S(O)2CH3—C6H4
3002-ethyl-4-F—C6H31003-S(O)2CH3—C6H4
3012-CH3-4-Cl—C6H31001H-5-S(O)2CH3-indol-2-yl
|
3022-CH3-4-Cl—C6H310190
|
3033-CH3-4-Cl—C6H310191
|
3042,4-Cl2-3-CH3—C6H210092
|
3052,4-Cl2-3-CH3—C6H21002-(pyrazol-1-yl)-pyridin-5-yl
3062,4-Cl2-3-CH3—C6H21002-S(O)2CH3-thien-5-yl
3072,4-Cl2-3-CH3—C6H21004-S(O)2CH3—C6H4
3085-CF3-pyridin-2-yl1003-S(O)2CH3—C6H4
3093,4-Cl2—C6H3110phenyl
3103,4-Cl2—C6H31104-OCH3—C6H4
3113,4-Cl2—C6H31104-F—C6H4
3123,4-Cl2—C6H31103-SCH3—C6H4
3133,4-Cl2—C6H3111phenyl
3143,4-Cl2—C6H31114-OCH3—C6H4
3153,4-Cl2—C6H31114-F—C6H4
|
[0166] Examples of compounds of formula (Ig) are listed in Table V below.
5TABLE V
|
|
R1XR3
|
13,4-Cl2—C6H3CH23-S(O)2CH3—C6H4
23,4-Cl2—C6H3NH3-S(O)2CH3—C6H4
33,4-Cl2—C6H3C(O)3-S(O)2CH3—C6H4
43,4-Cl2—C6H3S(O)24-S(O)2CH3—C6H4
53,4-Cl2—C6H3S(O)2C6H5
|
[0167] The compounds of formula (I):
93
[0168] wherein:
[0169] q, s and t are, independently, 0 or 1;
[0170] n and r are, independently, 0, 1, 2, 3, 4 or 5;
[0171] m and p are, independently, 0, 1 or 2;
[0172] X is CH2, C(O), 0, S, S(O), S(O)2 or NR37;
[0173] Y is NHR2 or OH;
[0174] T is C(O), C(S), S(O)2 or CH2;
[0175] R1 is hydrogen, C1-6 alkyl, aryl or heterocyclyl;
[0176] R2 and R47 are, independently, hydrogen, C1-6 alkyl, aryl(C1-4)alkyl or CO(C1-6 alkyl);
[0177] R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, CR3aR3bR3c, C2-4 alkenyl {optionally substituted by aryl or heterocyclyl}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl, aryl or oxo}, C3-7 cycloalkenyl {optionally substituted by oxo, C1-6 alkyl or aryl}, aryl, heterocyclyl, thioaryl or thioheterocyclyl;
[0178] R3a is hydrogen, C1-6 alkyl, C1-6 alkoxy or C3-7 cycloalkyl; R3b is aryl, heterocyclyl, S(O)2aryl or S(O)2heterocyclyl; and R3c is C1-6 alkyl, C1-4 haloalkyl, hydroxy, heterocyclyl(C1-4 alkyl) or aryl;
[0179] wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl {itself optionally substituted by halogen, OC(O)C1-6 alkyl, S(O)2R48, phenyl (itself optionally substituted by halogen (such as one or two chlorine or fluorine atoms), C1-6 alkyl, S(O)2R38 or C(O)NR39R40), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl), C3-10 cycloalkyl (itself optionally substituted by C1-4 alkyl or oxo) or NR41C(O)OCH2(fluoren-9-yl)}, NR41C(O)OCH2(fluoren-9-yl), C1-6 alkoxy {itself optionally substituted by halogen, C1-6 alkoxy, NHCO2(C1-6 alkyl), CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)}, C1-6 alkylthio, C1-6 haloalkylthio, C3-10 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)dR15, S(O)2NR42R43, NR44S(O)2R45, phenyl {itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy (itself optionally substituted by halogen, OH or pyridinyl), phenyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy)}, heterocyclyl {itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy, C1-6 haloalkoxy, phenyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy)}, phenoxy {itself optionally substituted by halogen, C1-4 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy, C1-6 haloalkoxy, phenyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy)}, SCN, CN, SO3H (or an alkali metal salt thereof), methylenedioxy or difluoromethylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring to which they are attached, a dihydrophenanthrene moiety;
[0180] d is 0, 1 or 2;
[0181] R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R37, R39, R40, R41, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl, aryl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy);
[0182] R15, R38, R45 and R48 are, independently, C1-6 alkyl (optionally substituted by halogen, hydroxy or C3-1 cycloalkyl), C3-6 alkenyl, aryl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy) or heterocyclyl (itself optionally substituted by halogen, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy);
[0183] or an N-oxide thereof; or a pharmaceutically acceptable salt thereof; or a solvate thereof; have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CCR3) activity, and may be used in the treatment of autoimmune, inflammatory, proliferative or hyperproliferative diseases, or immunologically-mediated diseases (including rejection of transplanted organs or tissues and Acquired Immunodeficiency Syndrome (AIDS)).
[0184] In one aspect examples of these conditions are:
[0185] (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
[0186] (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
[0187] (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
[0188] (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
[0189] (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
[0190] (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, Sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.
[0191] In another aspect examples of these conditions are:
[0192] (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as cosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung or idiopathic interstitial pneumonia;
[0193] (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
[0194] (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
[0195] (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
[0196] (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
[0197] (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.
[0198] In a further aspect examples of these conditions are:
[0199] (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung or idiopathic interstitial pneumonia;
[0200] (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
[0201] (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
[0202] (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
[0203] (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
[0204] (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle.
[0205] The compounds of formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof, are also H1 antagonists and may be used in the treatment of allergic disorders.
[0206] The compounds of formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof, may also be used to control a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of a common cold or influenza or other associated respiratory virus infection).
[0207] Thus, in a further aspect the present invention provides a compound of formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof, which is both a modulator of chemokine receptor (especially CCR3) activity and an H1 antagonist.
[0208] According to a further feature of the invention there is provided a compound of the formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use in a method of treatment of a warm blooded animal (such as man) by therapy (including prophylaxis).
[0209] According to a further feature of the present invention there is provided a method for modulating chemokine receptor activity (especially CCR3 receptor activity) in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig) or a pharmaceutically acceptable salt thereof or a solvate thereof.
[0210] According to another feature of the present invention there is provided a method for antagonising H1 in a warm blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of the formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof.
[0211] The invention also provides a compound of the formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.
[0212] In another aspect the invention provides the use of a compound of formula (I) (as defined anywhere herein), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity) or antagonising H1 in a warm blooded animal, such as man, or both).
[0213] In a further aspect the present invention provides the use of a compound of the formula (I), wherein: q, s and t are, independently, 0 or 1; n and r are, independently, 0, 1, 2, 3, 4 or 5; m and p are, independently, 0, 1 or 2; X is CH2, C(O), 0, S, S(O), S(O)2 or NR37; Y is NHR2 or OH; T is C(O), C(S), S(O)2 or CH2; R1 is hydrogen, C1-6 alkyl, aryl or heterocyclyl; R2 and R47 are, independently, hydrogen, C1-6 alkyl, aryl(C1-4)alkyl or CO(C1-6 alkyl); R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, C3-7 cycloalkenyl {optionally substituted by oxo, C1-6 alkyl or aryl}, aryl or heterocyclyl; wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by:
[0214] halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, S(O)2R48, phenyl (itself optionally substituted by halo (such as one or two chlorine or fluorine atoms), C1-6 alkyl, S(O)2R38 or C(O)NR39R40), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl), C3-10 cycloalkyl (itself optionally substituted by C1-4 alkyl or oxo) or NR41C(O)OCH2(fluoren-9-yl)), NR41C(O)OCH2(fluoren-9-yl), C1-6 alkoxy (itself optionally substituted by halogen, C1-6 alkoxy, NHCO2(C1-6 alkyl), CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, C1-6 haloalkylthio, C3-10 cycloalkyl, NR7R8, NR9C(O)R10, CO2R11, C(O)NR12R13, C(O)R14, S(O)dR15, S(O)2NR42R43, NR44S(O)2R45, phenyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2 or C1-6 alkoxy (itself optionally substituted by halo, OH or pyridinyl)), heterocyclyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), phenoxy (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring to which they are attached, a dihydrophenanthrene moiety; d is 0, 1 or 2; R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R37, R39, R40, R41, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); R15, R38, R45 and R48 are, independently, C1-6 alkyl (optionally substituted by halogen, hydroxy or C3-10 cycloalkyl) or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); or a pharmaceutically acceptable salt thereof; or a solvate thereof; in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity) or antagonising H1 in a warm blooded animal, such as man, or both).
[0215] In another aspect the present invention provides the use of a compound of the formula (I′):
94
[0216] wherein: q is 0 or 1; n and r are, independently, 0, 1, 2, 3, 4 or 5; m and p are, independently, 0, 1 or 2; X is CH2, CO, O, S, S(O), S(O)2 or NR37; Y is NHR2 or OH; T is CO, CS, SO2 or CH2; R1 is hydrogen, C1-6 alkyl, aryl or heterocyclyl; R2 is hydrogen, C1-6 alkyl, aryl(C1-4)alkyl or CO(C1-6 alkyl); R3 is C1-6 alkyl {optionally substituted by halogen, CO2R4 or phthalimide}, C3-7 cycloalkyl {optionally substituted by C1-4 alkyl or oxo}, C3-7 cycloalkenyl {optionally substituted by C1-6 alkyl or aryl}, aryl or heterocyclyl; wherein, unless stated otherwise, the foregoing aryl and heterocyclyl moieties are optionally substituted by: halogen, OH, SH, NO2, oxo, C1-6 alkyl (itself optionally substituted by halogen, OC(O)C1-6 alkyl, phenyl (itself optionally substituted by halo (such as one or two chlorine or fluorine atoms), C1-6 alkyl, SO2R38 or CONR39R40), naphthyloxy (itself optionally substituted by halo or C2-6 alkenyl) or NR4C(O)OCH2(fluoren-9-yl)), NR41C(O)OCH2(fluoren-9-yl), C1-6 alkoxy (itself optionally substituted by halogen, CO2R4, NR5R6 or phenyl (itself optionally substituted by halogen or NO2)), C1-6 alkylthio, nitro, C3-7 cycloalkyl, NR7R8, NR9COR10, CO2R11, CONR12R13, COR14, SOdR15, SO2NR42R43, NR44SO2R45, phenyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2 or C1-6 alkoxy (itself optionally substituted by halo, OH or pyridinyl)), heterocyclyl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), phenoxy (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy), SCN, CN, SO3H (or an alkali metal salt thereof) or methylenedioxy; when aryl is phenyl adjacent substituents may join to form, together with the phenyl ring to which they are attached, a dihydrophenanthrene moiety; d is 0, 1 or 2; R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R37, R39, R40, R41, R42, R43 and R44 are, independently, hydrogen, C1-6 alkyl or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); R15, R38 and R45 are, independently, C1-6 alkyl or aryl (itself optionally substituted by halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, C1-6 alkoxy or C1-6 haloalkoxy); or a pharmaceutically acceptable salt thereof; or a solvate thereof; in the manufacture of a medicament for use in therapy (for example modulating chemokine receptor activity (especially CCR3 receptor activity) in a warm blooded animal, such as man).
[0217] The invention further provides the use of a compound of formula (I) (as defined anywhere above), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of:
[0218] (1) (the respiratory tract) obstructive diseases of airways including: chronic obstructive pulmonary disease (COPD) (such as irreversible COPD); asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; bronchitis {such as eosinophilic bronchitis}; acute, allergic, atrophic rhinitis or chronic rhinitis including rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis; sarcoidosis; farmer's lung and related diseases; nasal polyposis; fibroid lung, idiopathic interstitial pneumonia, antitussive activity, treatment of chronic cough associated with inflammatory conditions of the airways or iatrogenic induced cough;
[0219] (2) (bone and joints) arthrides including rheumatic, infectious, autoimmune, seronegative spondyloarthropathies (such as ankylosing spondylitis, psoriatic arthritis or Reiter's disease), Behcet's disease, Sjogren's syndrome or systemic sclerosis;
[0220] (3) (skin and eyes) psoriasis, atopic dermatitis, contact dermatitis or other eczmatous dermitides, seborrhoetic dermatitis, Lichen planus, Phemphigus, bullous Phemphigus, Epidermolysis bullosa, urticaria, angiodermas, vasculitides erythemas, cutaneous eosinophilias, uveitis, Alopecia areata or vernal conjunctivitis;
[0221] (4) (gastrointestinal tract) Coeliac disease, proctitis, eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, irritable bowel disease or food-related allergies which have effects remote from the gut (for example migraine, rhinitis or eczema);
[0222] (5) (Allograft rejection) acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea; or chronic graft versus host disease; and/or
[0223] (6) (other tissues or diseases) Alzheimer's disease, multiple sclerosis, atherosclerosis, Acquired Immunodeficiency Syndrome (AIDS), Lupus disorders (such as lupus erythematosus or systemic lupus), erythematosus, Hashimoto's thyroiditis, myasthenia gravis, type I diabetes, nephrotic syndrome, eosinophilia fascitis, hyper IgE syndrome, leprosy (such as lepromatous leprosy), Peridontal disease, sezary syndrome, idiopathic thrombocytopenia pupura or disorders of the menstrual cycle;
[0224] in a warm blooded animal, such as man.
[0225] In a further aspect a compound of formula (I) (as defined anywhere above), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma {such as bronchial, allergic, intrinsic, extrinsic or dust asthma, particularly chronic or inveterate asthma (for example late asthma or airways hyper-responsiveness)}; or rhinitis {including acute, allergic, atrophic or chronic rhinitis, such as rhinitis caseosa, hypertrophic rhinitis, rhinitis purulenta, rhinitis sicca or rhinitis medicamentosa; membranous rhinitis including croupous, fibrinous or pseudomembranous rhinitis or scrofoulous rhinitis; seasonal rhinitis including rhinitis nervosa (hay fever) or vasomotor rhinitis}.
[0226] In a still further aspect a compound of formula (I) (as defined anywhere above), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof, is useful in the treatment of asthma.
[0227] The invention also provides the use of a compound of formula (I) (as defined anywhere above), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a sign and/or symptom of what is commonly referred to as a cold (for example a sign and/or symptom of common cold or influenza or other associated respiratory virus infection).
[0228] The present invention also provides a the use of a compound of formula (I) (as defined anywhere above), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of asthma or rhinitis.
[0229] The present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) or an H1 mediated disease state (such as an allergic disorder) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or solvate thereof.
[0230] The present invention also provides a method of treating a sign and/or symptom of a cold (for example a sign and/or symptom of common cold or influenza or other associated respiratory virus infection) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or solvate thereof.
[0231] In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity or antagonising H1, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
[0232] The present invention further provides a method of treating a chemokine mediated disease state (especially a CCR3 mediated disease state, especially asthma) in a warm blooded animal, such as man, which comprises administering to a mammal in need of such treatment an effective amount of a compound of formula (I), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or solvate thereof.
[0233] In order to use a compound of the invention, or a pharmaceutically acceptable salt thereof or solvate thereof, for the therapeutic treatment of a warm blooded animal, such as man, in particular modulating chemokine receptor (for example CCR3 receptor) activity, said ingredient is normally formulated in accordance with standard pharmaceutical practice as a pharmaceutical composition.
[0234] Therefore in another aspect the present invention provides a pharmaceutical composition which comprises a compound of the formula (I), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically acceptable salt thereof or a solvate thereof (active ingredient), and a pharmaceutically acceptable adjuvant, diluent or carrier. In a further aspect the present invention provides a process for the preparation of said composition which comprises mixing active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99% w (per cent by weight), more preferably from 0.05 to 80% w, still more preferably from 0.10 to 70% w, and even more preferably from 0.10 to 50% w, of active ingredient, all percentages by weight being based on total composition.
[0235] The pharmaceutical compositions of this invention may be administered in standard manner for the disease condition that it is desired to treat, for example by topical (such as to the lung and/or airways or to the skin), oral, rectal or parenteral administration. For these purposes the compounds of this invention may be formulated by means known in the art into the form of, for example, aerosols, dry powder formulations, tablets, capsules, syrups, powders, granules, aqueous or oily solutions or suspensions, (lipid) emulsions, dispersible powders, suppositories, ointments, creams, drops and sterile injectable aqueous or oily solutions or suspensions.
[0236] A suitable pharmaceutical composition of this invention is one suitable for oral administration in unit dosage form, for example a tablet or capsule which contains between 0.1 mg and 1 g of active ingredient.
[0237] In another aspect a pharmaceutical composition of the invention is one suitable for intravenous, subcutaneous or intramuscular injection.
[0238] Each patient may receive, for example, an intravenous, subcutaneous or intramuscular dose of 0.01 mgkg−1 to 100 mgkg−1 of the compound, preferably in the range of 0.1 mgkg−1 to 20 mgkg−1 of this invention, the composition being administered 1 to 4 times per day. The intravenous, subcutaneous and intramuscular dose may be given by means of a bolus injection. Alternatively the intravenous dose may be given by continuous infusion over a period of time. Alternatively each patient will receive a daily oral dose which is approximately equivalent to the daily parenteral dose, the composition being administered 1 to 4 times per day.
[0239] The following illustrate representative pharmaceutical dosage forms containing the compound of formula (I), (I′), (Ia″), (Ia), (Ia′), (Ib), (Ic), (Id), (Ie), (If) or (Ig), or a pharmaceutically-acceptable salt thereof (hereafter Compound X), for therapeutic or prophylactic use in humans:
6|
|
(a)
Tablet Img/tablet
|
Compound X100
Lactose Ph.Eur.179
Croscarmellose sodium12.0
Polyvinylpyrrolidone6
Magnesium stearate3.0
|
[0240]
7
|
|
(b)
|
Tablet II
mg/tablet
|
|
Compound X
50
|
Lactose Ph.Eur.
229
|
Croscarmellose sodium
12.0
|
Polyvinylpyrrolidone
6
|
Magnesium stearate
3.0
|
|
[0241]
8
|
|
(c)
|
Tablet III
mg/tablet
|
|
Compound X
1.0
|
Lactose Ph.Eur.
92
|
Croscarmellose sodium
4.0
|
Polyvinylpyrrolidone
2.0
|
Magnesium stearate
1.0
|
|
[0242]
9
|
|
(d)
|
Capsule
mg/capsule
|
|
Compound X
10
|
Lactose Ph.Eur.
389
|
Croscarmellose sodium
100
|
Magnesium stearate
1.0
|
|
[0243]
10
|
|
(e)
|
Injection I
(50 mg/ml)
|
|
Compound X
5.0% w/v
|
Isotonic aqueous solution
to 100%
|
|
[0244] Buffers, pharmaceutically-acceptable cosolvents such as polyethylene glycol, polypropylene glycol, glycerol or ethanol or complexing agents such as hydroxy-propyl β-cyclodextrin may be used to aid formulation.
[0245] The above formulations may be obtained by conventional procedures well known in the pharmaceutical art. The tablets (a)-(c) may be enteric coated by conventional means, for example to provide a coating of cellulose acetate phthalate.
[0246] The invention will now be illustrated by the following non-limiting examples in which, unless stated otherwise:
[0247] (i) when given, 1H NMR data is quoted and is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 300 MHz or 400 MHz using perdeuterio DMSO-D6 (CD3SOCD3) or CDCl3 as the solvent unless otherwise stated;
[0248] (ii) mass spectra (MS) were run with an electron energy of 70 electron volts in the chemical ionisation (CI) mode using a direct exposure probe; where indicated ionisation was effected by electron impact (EI) or fast atom bombardment (FAB); where values for m/z are given, generally only ions which indicate the parent mass are reported, and unless otherwise stated the mass ion quoted is the positive mass ion-(M+H)+;
[0249] (iii) the title and sub-titled compounds of the examples and methods were named using the AUTONOM program from Beilstein informationssysteme GmbH;
[0250] (iv) unless stated otherwise, reverse phase HPLC was conducted using a Symmetry, NovaPak or Ex-Terra reverse phase silica column; and
[0251] (v) the following abbreviations are used:
11|
|
RPHPLCreverse phase HPLC
RTroom temperature
DEADdiethyl-azodicarboxylate
NMPN-methylpyrrolidone
CDIN,N′-carbonyl diimidazole
MTBEtert-butyl methyl ether
DMFN,N-dimethylformamide
Boc or BOCtert-butoxycarbonyl
HPLChigh pressure liquid chromatography
PYBROP ™bromo-tris-pyrrolidino-phosphonium
hexafluorophosphate
THFtetrahydrofuran
DCMdichloromethane
TFAtrifluoroacetic acid
m.pt.melting point
DMSOdimethylsulfoxide
AcAcetate
aqaqueous
IPAiso-propyl alcohol
equiv.equivalents
|
EXAMPLE 1
[0252] This Example illustrates the preparation of 4-(3,4-dichlorophenoxy)piperidine.
[0253] Step a: tert-Butyl 4-(3,4-dichlorophenoxy)-1-piperidinecarboxylate
[0254] Diethyl azodicarboxylate (41.0 ml) was added to a solution of triphenylphosphine (62.9 g) in tetrahydrofuran (800 ml) at 0° C. After 15 minutes 3,4-dichlorophenol (39.1 g) was added, after a further 15 minutes tert-butyl 4-hydroxy-1-piperidinecarboxylate (48.3 g) in tetrahydrofuran (400 ml) was added dropwise over 30 min. The solution was stirred at room temperature for 16 hours and concentrated to a small volume. Purification by chromatography (ethyl acetate: iso-hexane 95:5) gave the sub-title compound as an oil (61.3 g).
[0255] MS: APCI(+ve): 246 (M-BOC+2H)
[0256] Step b: 4-(3,4-Dichlorophenoxy)piperidine
[0257] The product from Step a was dissolved in dichloromethane (600 ml) and trifluoroacetic acid (300 ml) was added. After 24 hours at room temperature the solution was evaporated and the resultant gum triturated under ether to give the sub-titled product as a solid (36.6 g). The free base was liberated by addition of aqueous NaOH (2M) and extraction with ethyl acetate followed by evaporation of solvent to give the title compound as a gum (25 g).
[0258]
1
H NMR: δ(CDCl3) 1.77 (1H, br s), 2.05-2.26 (4H, m), 3.20-3.49 (4H, m), 4.61 (1H, s), 6.69-7.52 (3H, m).
EXAMPLE 2
[0259] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(3-methanesulfonyl-phenyl)-methanone acetate (acetate salt of Compound 281 in Table I).
[0260] Step a: 4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0261] 4-(3,4-Dichlorophenoxy)piperidine (1.5 g) was dissolved in 1,2-dichloroethane (21 ml). 1-Boc-4-piperidone was added (1.21 g) followed by NaBH(OAc)3 (1.81 g) and acetic acid (0.37 g). After 18 hours at room temperature aqueous NaOH (1M) solution and diethyl ether were added. The product was extracted with diethyl ether, the combined organic extracts dried with MgSO4 and concentrated. Purification by silica chromatography (dichloromethane:methanol 92:8) gave the sub-title product (1.97 g).
[0262] MS: APCl(+ve): 429 (M+H)
[0263] Step b: 4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidine
[0264] The product of Step a was dissolved in dichloromethane (30 ml) and trifluoroacetic acid (15 ml) was added. After 4 hours at room temperature the solution was evaporated and the resultant gum triturated under ether to give the trifluoroacetate salt of the sub-titled product as a solid (1.15 g). The free base was liberated by addition of aqueous NaOH (2M) and extraction with ethyl acetate followed by evaporation of solvent to give the sub-title compound as a solid (0.68 g).
[0265]
1
H NMR: δ(CDCl3) 1.38-1.51 (2H, m), 1.74-2.02 (6H, m), 2.38-2.50 (3H, m), 2.56-2.61 (2H, m), 2.79-2.86 (2H, m), 3.14-3.18 (2H ,m), 4.22-4.28 (1H, m), 6.73-7.32 (3H, m).
[0266] Step c: [4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(3-methanesulfonyl-phenyl)-methanone acetate
[0267] The product of Step b (0.15 g) was dissolved in THF (4 ml), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PYBROP™; 0.235 g), 3-methylsulphonylbenzoic acid (0.091 g) and N,N-di-iso-propylethylamine (0.238 ml) were added. After 18 hours at room temperature ethyl acetate and aqueous NaHCO3 solution were added. The product was extracted with ethyl acetate, the combined organic extracts dried with Na2SO4 and concentrated. Purification by reverse phase HPLC (with a gradient eluent system (45% MeCN/NH4OAcaq (0.1%) to 95% MeCN//NH4OAcaq (0.1%)) gave the title compound (0.095 g).
[0268]
1
H NMR: δ(DMSO-D6) 1.44-1.94 (8H, m), 2.37-2.77 (5H, m), 3.07-3.55 (6H, m), 4.40 (1H, m), 4.50-4.53 (1H, m), 6.96-8.02 (7H, m).
[0269] Melting point: 60-61° C. becomes a gum.
[0270] Melting point of free base: 154° C.
EXAMPLE 3
[0271] This Example illustrates the preparation of (4-amino-3-methoxy-phenyl)-[4-(3,4-dichlorophenoxy)-[1,4′]bipiperidinyl-1′-yl]-methanone acetate (Compound 282 of Table I).
[0272] The compound was prepared by the method of Example 2, Step c using 4-amino-3-methoxybenzoic acid to give the title compound as a solid (0.016 g).
[0273]
1
H NMR: δ(DMSO-D6) 1.32-2.01 (8H, m), 2.28-2.88 (5H, m), 3.32 (4H, br s), 3.77 (3H, s), 4.13 (2H, br s), 4.39-4.44 (1H, m), 6.59-7.50 (6H, m).
[0274] Melting point: 171 ° C. becomes a gum.
EXAMPLE 4
[0275] This Example illustrates the preparation of (4-amino-3-methoxy-phenyl)-{3-[4-(3,4-difluoro-phenoxy)-piperidin-1-yl]-pyrrolidin-1-yl}-methanone (Compound 4 of Table II).
[0276] Step a: tert-Butyl 4-(3,4-difluorophenoxy)-1-piperidinecarboxylate
[0277] This compound was prepared according to the method of Example 1 Step a using 3,4-difluorophenol to afford the compound as an oil (5.4 g).
[0278] MS: ESI(+ve): 213 (M-BOC+H)
[0279] Step b: 4-(3,4-Difluorophenoxy)piperidine
[0280] This compound was prepared according to the method of Example 1 Step b to afford the compound as a pale yellow oil (3 g).
[0281] MS: ESI(+ve): 214 (+H)
[0282] Step c: 3-[4-(3,4-Difluoro-phenoxy)piperidin-1-yl]-Pyrrolidine-1-carboxylic acid tert-butyl ester
[0283] The product of Step b (0.5 g) was dissolved in 1,2-dichloroethane (7 ml). tert-Butyl 3-oxo-1-pyrrolidinecarboxylate (0.43 g) was added followed by NaBH(OAc)3 (0.7 g) and acetic acid (0.08 g). After 24 hours at room temperature aqueous NaOH (1M) solution and diethyl ether were added. The product was extracted with diethyl ether, the combined organic extracts dried with MgSO4 and concentrated. Purification by silica chromatography (100% ethyl acetate) gave the sub-title product (0.79 g).
[0284] MS: ESI(+ve): 383 (M+H)
[0285] Step d: 3,4-Difluorophenyl 1-(3-pyrrolidinyl)-4-piperidinyl ether
[0286] The product of Step c was dissolved in dioxane (10 ml) and HCl (6N) (10 ml) was added and the reaction stirred for 3 hrs. Organic solvent was evaporated and aqueous NaOH (2M) added. The product was extracted with ethyl acetate, the combined organic extracts dried with Na2SO4 and concentrated to give the sub-title product as an oil (0.54 g).
[0287]
1
H NMR: δ(CDCl3) 1.60-2.39 (9H, m), 2.70-3.13 (6H, m), 4.19-4.22 (1H, m), 6.58-7.52 (3H, m).
[0288] Step e: (4-Amino-3-methoxy-phenyl)-{3-[4-(3,4-difluoro-phenoxy)-piperidin-1-yl]-pyrrolidin-1-yl }-methanone
[0289] This compound was prepared by the method of Example 2 Step c using 4-amino-3-methoxybenzoic acid to give the title compound as a solid (0.151 g).
[0290]
1
H NMR: δ(CDCl3) 1.95-2.43 (5H, m), 2.69-2.81 (3H, m), 3.42-3.91 (10H, m), 4.19-4.23 (1H, m), 6.56-7.25 (6H, m).
[0291] Melting point: 138-139° C.
EXAMPLE 5
[0292] This Example illustrates the preparation of (4-amino-3-methoxy-phenyl)-[4-(3,4-difluoro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-methanone (Compound 1 in Table II).
[0293] Step a: 4-(3,4-Difluoro-phenoxy)-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0294] This compound was prepared by the method of Example 2, Step a using 4-(3,4-difluorophenoxy)piperidine to give the sub-title compound as a solid (0.48 g).
[0295] MS: APCl(+ve): 397 (M+H)
[0296] Step b: 4-(3,4-Difluoro-phenoxy)-[1,4′]bipiperidinyl
[0297] This compound was prepared by the method of Example 2, Step b to give the sub-title compound as a solid (0.36 g).
[0298] MS: APCl(+ve): 297 (M+H)
[0299] Step c: (4-Amino-3-methoxy-phenyl)-[4-(3,4-difluoro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-methanone
[0300] This compound was prepared by the method of Example 2, Step c using 4-amino-3-methoxybenzoic acid to give the title compound as a gum (0.133 g).
[0301]
1
H NMR: δ(CDCl3) 1.50-1.60 (2H, m), 1.85-1.93 (4H, m), 2.04-2.08 (2H, m), 2.58-2.62 (2H, m), 2.69-2.75 (1H, m), 2.86-2.90 (4H, m), 3.86 (3H, s), 3.86 (2H, m), 4.25-4.30 (1H, m), 6.50-6.61 (1H, m), 6.65 (1H, dd), 6.70-6.75 (1H. m), 6.85 (1H, dt), 6.94 (1H, s), 7.01-7.09 (1H, m).
EXAMPLE 6
[0302] This Example illustrates the preparation of (4-amino-3-methoxy-phenyl)-[4-(3,4-difluoro-phenoxy)-[1,3′]bipiperidinyl-1′-yl]-methanone (Compound 2 in Table II).
[0303] Step a: 4-(3,4-Difluoro-phenoxy)-[1,3′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0304] This compound was prepared by the method of Example 2, Step a using 3-oxo-piperidine-1-carboxylic acid tert-butyl ester to give the sub-title compound as a solid (0.946 g).
[0305] MS: APCl(+ve): 397 (M+H)
[0306] Step b: 4-(3,4-Difluoro-phenoxy)-[1,3′]bipiperidinyl
[0307] This compound was prepared by the method of Example 2, Step b to give the sub-title compound as a solid (0.706).
[0308] MS: ESI(+ve): 297 (M+H)
[0309] Step c: (4-Amino-3-methoxy-phenyl)-[4-(3,4-difluoro-phenoxy)-[1,3′]bipiperidinyl-1-yl]-methanone
[0310] This compound was prepared by the same method as Example 2, Step c using 4-amino-3-methoxybenzoic acid to give the title compound as a gum (0.070 g).
[0311]
1
H NMR: δ(CDCl3) 1.41-1.67 (4H, m), 1.73-1.80 (2H, m), 1.86-2.00 (2H, m), 2.44 (3H, m), 3.00-3.13 (2H, m), 2.79-2.91 (2H, m), 3.82 (3H, s), 3.97-4.01 (1H, d), 4.14-4.17 (1H, d), 4.32 (1H, sept), 4.89 (2H, s), 6.67 (1H, d), 6.75-6.79 (1H, m), 6.80 (1H, dd), 6.87 (1H, s), 6.98-7.06 (1H, m), 7.27 (1H, q).
EXAMPLE 7
[0312] This Example illustrates the preparation of 4-(3,4-dichloro-phenoxy)-1′-(5-pyridin-2-yl-thiophene-2-sulfonyl)-[1,4′]bipiperidinyl (Compound 280 in Table I).
[0313] The product of Example 2, Step b (0.2 g) was dissolved in acetone (4 ml). Potassium carbonate [0.134 g dissolved in H2O (1.2 ml)] was then added, followed by 5-pyridin-2-yl-thiophene-2-sulfonyl chloride (0.168 g) and the reaction left to stir for 1 hr. Water was then added and the product extracted with ethyl acetate. The combined organic extracts dried with Na2SO4 and concentrated. Purification reverse phase HPLC (with a gradient eluent system (25% MeCN/NH4OAcaq (0.1%) to 95% MeCN//NH4OAcaq (0.1%)) gave the title compound as a solid (0.077 g).
[0314]
1
H NMR: δ(DMSO-D6) 1.45-1.58 (4H, m), 1.79-1.90 (4H, m), 2.28-2.46 (5H, m), 2.66-2.73 (2H, m), 3.67-3.71 (2H, m), 4.35-4.43 (1H, m), 6.93-8.60 (9H, m).
[0315] Melting point: 139-140° C.
EXAMPLE 8
[0316] This Example illustrates the preparation of 4-(3,4-difluoro-phenoxy)-1′-(5-pyridin-2-yl-thiophene-2-sulfonyl)-[1,4′]bipiperidinyl (Compound 3 in Table II).
[0317] This compound was prepared by the method of Example 7 using product of Example 5, step b to give the title compound as a solid (0.095 g).
[0318]
1
H NMR: δ(CDCl3) 1.67-1.80 (4H, m), 1.87-2.01 (1H, t), 2.30 (1H, t), 2.39-2.50 (2H, m), 2.74-2.78 (2H, m), 3.89 (2H, d), 4.16-4.20 (1H, m), 6.56-6.60 (1H, m), 6.67-6.63 (1H, m), 7.03 (1H, q), 7.26 (1H, t), 7.52 (1H, d), 7.53 (1H, d), 7.70 (1H, d), 7.76 (1H, dt), 8.60 (1H, d).
[0319] Melting point: 128-129° C.
EXAMPLE 9
[0320] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(2-methanesulfonyl-phenyl)-methanone (Compound 293 Table I).
[0321] Step 1: Preparation of 4-hydroxy-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0322] To 1-tert-butoxycarbonyl-4-piperidone (200 g, 1.01 mol) in tetrahydrofuran (THF) (1500 ml) was added 4-hydroxypiperidine (78.1 g, 0.77 mol). The resultant slurry was stirred for 30 minutes before cooling the reaction mixture with ice/water, acetic acid (47 ml) is then added (exotherm) which caused precipitation. The slurry was allowed to warm to room temperature before the addition of sodium triacetoxyborohydride (236 g, 1.12 mol) which was washed in with THF (500 ml). The resultant slurry was stirred overnight at room temperature. To the reaction mixture was added water (2000 ml) to give a solution. The solution was then extracted with diethyl ether (3×1800 ml). The aqueous phase was basified with 10% aq NaOH (950 ml) and extracted with dichloromethane (DCM) (3×1500 ml). The combined DCM layers are dried (MgSO4), filtered and the solvent removed to give the sub-titled compound as a yellow viscous oil, (177 g, 81%; MS: (M+H) 285).
[0323] Step 2: Preparation of 4-(3,4-dichlorophenoxy)-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0324] To a solution of potassium tert-butoxide (139.0 g, 1.24 mol) in THF (500 ml) was added a solution of the product of Step 1 (176.2 g, 0.62 mol) in THF (1000 ml). The reaction mixture was stirred 10 minutes before the additon of 3,4 dichlorofluorobenzene (122.8 g, 0.74 mol), this caused a green colouration that subsequently faded. The reaction mixture was then heated at reflux for 90 minutes. The reaction mixture was then cooled to room temperature before the addition of saturated NaHCO3 (1600 ml). The layers were separated and the organic layer stripped to leave an orange semi-solid. The solid was dissolved in DCM (1500 ml) and dried (MgSO4), filtered and the solvent removed. To the resultant solid was added methyl tert-butyl ether (MTBE) (54 ml) and iso-hexane (1000 ml) to give a slurry which was stirred overnight. The slurry was then filtered and washed with isohexane (200 ml) and the solid dried in vacuo at 50° C. to give the sub-titled compound as a pale powder, (211.6 g, 80%; MS: (M+H) 429).
[0325] Step 3: Preparation of 4-(3,4-dichlorophenoxy)-[1,4′]bipiperidine
[0326] The product of Step 2 (10.15 g, 23.6 mmol) was dissolved in dichloromethane (150 ml) and trifluoroacetic acid (40 ml, 519 mmol) added and the resultant solution stirred. After 90 minutes the dichloromethane and trifluoroacetic acid were removed on a rotary evaporator. The resultant oil was partitioned between ethyl acetate (100 ml) and 2M aq NaOH (100 ml). The layers were separated and the organics extracted with 10% aq citric acid (100 ml). The layers were separated and the aqueous basified with 2M aq NaOH and extracted with ethyl acetate (200 ml). The organics were dried (MgSO4), filtered and the solvent removed to give the sub-titled product as a pale oil which solidified on standing (4.62 g, 59%; MS: (M+H) 329).
[0327] Step 4: Preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(2-methanesulfonyl-phenyl)-methanone
[0328] Oxalyl chloride (55 ml, 0.63 mol) was added dropwise over 10 minutes to a stirred suspension of 2-methanesulfonyl-benzoic acid (7.1 g, 0.036) in DCM (550 ml) containing DMF (0.5 ml). The solution was then stirred for 2 hours at room temperature. The solution was then evaporated to give a solid that was redissolved in dichloromethane and again evaporated to give a yellow solid. The solid acid chloride was dissolved in DCM (275 ml) and was added over 10 minutes to a stirred solution of the product of Step 3 (11.0 g, 0.033 mol) and triethylamine (15.4 ml, 0.11 mol) in dichloromethane (125 ml). The resultant solution was stirred at room temperature for 16 hours. The solution was then washed with water (500 ml), 1M aq NaOH (500 ml) and water (2×500 ml). The organic phase was dried (MgSO4), filterered and the solvent removed to give a pale yellow foam. The foam was triturated with diethyl ether to give the title compound (12.96 g, 76%).
[0329] Melting point 141° C.
[0330]
1
H NMR: (400 MHz, CDCl3) δ1.39-1.63 (1H, m), 1.72-2.04 (6H, m), 2.42-2.68 (2H, m), 2.73-2.92 (3H, m), 3.00-3.08 (1H, m), 3.23 (1H, s), 3.28 (2H, s), 3.34-3.40 (1H, m), 3.46-3.52 (1H, m), 4.21-4.30 (1H, m), 4.62-4.68 (1H, m), 4.80-4.86 (1H, m), 6.72-6.76 (1H, m), 6.97-7.00 (1H, m), 7.28-7.32 (1H, m), 7.32-7.37 (1H, m), 7.56-7.61 (1H, m), 7.64-7.70 (1H, m), 8.05-8.10 (1H, m).
EXAMPLE 10
[0331] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(3-methanesulfonyl-phenyl)-methanone (Compound 281 Table I).
[0332] Oxalyl chloride (30 mls, 0.35 mol) was added dropwise over 10 minutes to a stirred suspension of 3-methanesulfonyl-benzoic acid (6 g, 0.03) in DCM (300 ml) containing DMF (0.3 ml). The solution was then stirred for 4 hours at room temperature. The solution was then evaporated under high vacuum to give a solid which was redissolved in dichloromethane and again evaporated to give a yellow solid. The solid acid chloride was dissolved in DCM (100 ml) and was added over 10 minutes to a stirred solution of the product of step 3 of Example 9 (9.3 g, 0.028 mol) and triethylamine (8.4 ml, 0.06 mol) in dichloromethane (100 ml). The resultant solution was stirred at room temperature for 3 hours. The solution was then washed with water (100 ml), 1M aq NaOH (2×100 ml) and water (2×100 ml). The organic phase was dried (MgSO4), filterered and the solvent removed to give a pale yellow foam. The foam was dissolved in methanol (100 ml) and allowed to crystallise. The crystals were filtered, washed with methanol and then dried to give the title compound (12.2 g, 84%).
[0333] Melting point 157° C.
[0334]
1
H NMR: (400 MHz, CDCl3) δ1.40-1.65 (2H, in), 1.75-1.85 (3H, m), 1.93-2.03 (3H, m), 2.42-2.51 (2H, m), 2.58 (1H, tt), 2.74-2.91 (3H, m), 3.00-3.14 (1H, m), 3.07 (3H, s), 3.62-3.76 (1H, m), 4.27 (1H, septet), 4.69-4.80 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.31 (1H, d), 7.64 (1H, t), 7.69 (1H, dt), 7.97-7.98 (1H, m), 8.00 (1H, dt).
[0335] The hydrochloride salt (melting point 159° C.) was prepared by evaporation to dryness of a clear solution of Compound 281 of Table I and HCl in ethanol.
EXAMPLE 11
[0336] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(2-methanesulfonyl-thiophen-5-yl)-methanone (Compound 332 of Table I).
[0337] Oxalyl chloride (32 ml, 0.37 mol) was added dropwise over 10 minutes to a stirred suspension of 5-(methylsulfonyl)-2-thiophenecarboxylic acid (6.64 g, 0.032) in DCM (300 ml) containing DMF (0.3 ml). The solution was then stirred for 2 hours at room temperature. The solution was then removed to give a solid which was redissolved in dichloromethane and the solvent again removed to give a yellow solid. The solid acid chloride was dissolved in DCM (150 ml) and was added over 10 minutes to a stirred solution of the product of step 3 of Example 9 (10 g, 0.03 mol) and triethylamine (9 ml, 0.065 mol) in dichloromethane (300 ml). The resultant solution was stirred at room temperature for 2 hours. The solution was then washed with water (100 ml), 1M aq NaOH (2×100 ml) and water (300 ml). The organic phase was dried (MgSO4), filterered and the solvent removed to give an orange foam. The solid was dissolved in dichloromethane (200 ml) and purified by chromatography using ethyl acetate and then acetone as the eluant. The purified material was precipitated from acetone by the addition of iso-hexane. The crystals were filtered, washed with isohexane and then dried to give the title compound (11.5 g, 74%).
[0338] Melting point: 153-154° C.
[0339]
1
H NMR (399.98 MHz, DMSO-D6) δ1.42-1.48 (2H, in), 1.56-1.62 (2H, m), 1.77-1.84 (2H, m), 1.90-1.96 (2H, m), 2.37-2.43 (2H, m), 2.56-2.63 (2H, m), 2.75-2.80 (2H, m), 2.89-3.14 (2H, m), 3.29-3.32 (1H, m), 3.41 (3H, s), 4.41-4.45 (1H, m), 6.98 (1H, dd), 7.25 (1H, d), 7.49 (2H, q), 7.77 (1H, d).
EXAMPLE 12
[0340] This Example illustrates the preparation of [4-(4-chloro-2-methyl-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(3-methanesulfonyl-phenyl)-methanone (Compound 1 of Table IV)
[0341] A solution of 4-(2-methyl-4-chloro-phenoxy)-piperidine (0.87 mmol) and 1-(3-methanesulfonyl-benzoyl)-piperidin-4-one (0.925 mmol) in NMP (5 ml) and glacial acetic acid (1 mmol) was stirred at room temperature for 1 hour after which sodium triacetoxy borohydride (2 mmol) was added. The resulting mixture was stirred at RT for 24 hours, evaporated on to silica (2 g) and placed on to a Mega Bond elut cartridge (10 g Silica). The product was eluted with DCM/MeOH mixtures and further purified by Reverse Phase preparative chromatography, MeOH/aqueous TFA gradient on a Symmetry column. The free base was isolated by dissolving in EtOAc and washing with sodium bicarbonate solution, drying the organic layer with MgSO4 and evaporation left the product as a white solid (0.047 g; M.pt. 83-84° C).
[0342]
1
H NMR (300 MHz, DMSO-D6) δ1.2-2.8 (bm, 14H), 2.15 (s, 3H), 3.1 (bm, 1H), 3.25 (s, 3H), 3.5 (bm, 1H), 4.4 (bm, 1H), 4.5(bm, 1H), 7.0 (d, 1H), 7.12 (m, 1H), 7.2 (d, 1H), 7.7 (m, 2H), 7.9 (s, 1H), 8.0 (dd, 1H).
EXAMPLE 13
[0343] This Example illustrates the preparation of (4-amino-3-methoxy-phenyl)-[4-(4-chloro-2-methyl-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-methanone ditrifluoroacetate (Compound 23 of Table IV).
[0344] A solution of the 4-(4-chloro-2-methyl-phenoxy)-piperidine (0.87 mmol) and 1-(4-nitro-3-methoxy-benzoyl)-piperidin-4-one (0.925 mmol) in NMP (5 ml) and glacial acetic acid (1 mmol) was stirred at RT for 1 hour after which sodium triacetoxy borohydride (2 mmol) was added. The resulting mixture was stirred at RT for 24 hours, evaporated on to silica (2 g) and placed on to a Mega Bond elut cartridge (10 g Si). The product was eluted with DCM/MeOH mixtures and further purified by SCX, eluting the product with 10% aq NH3 in MeOH. The nitro compound was dissolved in THF (10 ml) and hydrogenated over 10% Pd on C at 3 atmospheres in Peteric apparatus. The mixture was filtered and the filtrate evaporated, the residue was then purified by RPHPLC, using a Symmetry column and eluting with MeOH/aqueous TFA mixtures. The product was isolated as the trifluoroacetate by evaporation of the appropriate HPLC fractions (0.046 g; m.pt. 84-85° C.).
[0345]
1
H NMR (400 MHz, DMSO-D6) δ1.4-2.4 (m, 13H), 2.9 (m, 2H), 3.15 (m, 2H), 3.4 (m, 1H), 3.55 (m, 2H), 3.8 (s, 3H), 4.2 (bs, 2H), 4.55 and 4.8 (2bm, 1H), 6.68 (d, 1H), 6.82 (d, 1H), 6.85 (s, 1H), 7.0-7.22 (m, 2H), 7.25 (s, 1H), 9.5 (bm, 1H).
EXAMPLE 14
[0346] This Example illustrates the preparation of 2-[1′-(3-methanesulfonyl-benzoyl)-[1,4′]bipiperidinyl-4-yloxy]-5-trifluoromethyl-benzonitrile trifluoroacetate (Compound 291 of Table IV).
[0347] The product of Method E (183 mg, 0.5 mmol) was dissolved in DMSO (2 ml) and treated with sodium hydride (22 mg 1 equiv. of 60%) under an inert atmosphere. After stirring the mixture at RT for 1 hour, 2-fluoro-5-trifluoromethyl-benzonitrile (1 equiv.) was added. After stirring at RT for 24 hours, the reaction mixture was acidified (glacial acetic acid) and filtered. The filtrate was purified by RPHPLC. (MeOH/aqueous TFA, Symmetry column) to give the product as the trifluoroacetate salt (0.06 g; m.pt. 110-111° C.).
[0348]
1
H NMR (400 MHz, DMSO-D6) δ1.0-3.8 (m, 20 H), 4.5-5.3 (m, 2H), 7.5 (d, 1H), 7.75 (m, 3H), 8.02 (m, 2H).
EXAMPLE 15
[0349] This Example illustrates the preparation of (3-methanesulfonyl-phenyl)-[4-(6-methyl-pyridin-2-yloxy)-[1,4′]bipiperidinyl-1′-yl]-methanone trifluoroacetate (Compound 292 of Table IV).
[0350] The product of Method E (1 mmol) and potassium tert-butoxide (2 mmol ) were stirred together in dry THF (20 ml) at RT. After 10 mins 2-fluoro-6-methyl-pyridine (1 mmol) was added and the reaction mixture stirred at reflux overnight. The reaction mixture was cooled, diluted with water and extracted into ethyl acetate (3×50 ml). The combined extracts were dried (MgSO4) and evaporated. The residue was purified by RPHPLC. (MeOH/aqueous TFA, Symmetry column) to give the product as the trifluoroacetate salt (0.03 g; m.pt. 61-62° C.).
[0351]
1
H NMR (400 MHz, DMSO-D6) δ1.6-3.8 (m, 15H), 2.4 (s, 3H), 3.3 (s, 3H), 4.5-5.4 (m, 3H), 6.6 (m, 1H), 6.02 (dd, 1H), 7.6 (q, 1H), 7.82 (m, 2H), 7.95 (s, 1H), 8.02 (m, 11H), 9.7 (bs, 1H)
EXAMPLE 16
[0352] This Example illustrates the preparation of N-{3-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carbonyl]-phenyl}-methanesulfonamide (Compound 583 of Table I).
[0353] To (3-amino-phenyl)-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-methanone (0.1 33 g) in pyridine (2 mL) was added methanesulfonyl chloride (0.024 ml) and the reaction left to stir for 5 minutes. The solvent was evaporated, water (0.5 mL) added and the solvent re-evaporated. Purification by RPHPLC (with a gradient eluent system (25% MeCN/NH4OAc aq (0.1%) to 95% MeCN//NH4OAc aq (0.1%)) gave the title compound (0.050 g; m.pt. 94-95° C.).
[0354]
1
H NMR (399.978 MHz, CDCl3) δ1.59-2.09 (8H, m), 2.22 (2H, br s), 2.54-2.60 (1H, m), 2.81 (2H, br s), 3.02 (5H, br s), 3.51-3.75 (1H, br m), 4.25-4.28(1H, m), 4.29 (1H, br s), 6.70-7.52 (8H, m).
EXAMPLE 17
[0355] This Example illustrates the preparation of N-{2-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carbonyl]-phenyl}-methanesulfonamide (Compound 587 of Table I).
[0356] To a solution of (2-amino-phenyl)-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-methanone (0.2 g) in pyridine (2 ml) at 0° C. was added methane sulphonyl chloride (0.039 ml). The mixture was allowed to warm to room temperature and the pyridine removed by evaporation. The residue was azeotroped with water and the product purified by RPHPLC (Symmetry column, eluting 25% to 95% MeCN/0.1% NH4OAc aq at 20 ml/min over 6 minutes) to give the product as a colourless solid (0.09 g).
[0357]
1
H NMR: (399.978 MHz, CDCl3) δ1.49-1.69 (5H, m), 1.77-1.84 (2H, m), 1.87-1.94 (1H, m), 1.95-2.02 (2H, m), 2.43-2.50 (2H, m), 2.59 (1H, tt), 2.78-2.84 (2H, m), 2.87-3.03 (1H, m), 3.08 (3H, s), 3.17 (1H, sextet), 4.27 (1H, septet), 6.75 (1H, dd), 6.99 (1H, d), 7.15 (1H, td), 7.24 (1H, d), 7.31 (1H, d), 7.43 (1H, td), 7.62 (1H, d).
EXAMPLE 18
[0358] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(1-methanesulfonyl-1H-indol-3-yl)-methanone hydrochloride (Compound 592 of Table I).
[0359] To a solution of Compound 471 of Table I (0.17 g) in dimethylformamide (3 ml) at 0° C. under an atmosphere of nitrogen, was added sodium hydride (0.014 g of a 60% suspension in oil). The mixture was stirred for 5 minutes then methanesulphonyl chloride (0.027 ml in 1 ml of dimethylformamide) was added and then mixture allowed to warm to room temperature over 12 hours. The reaction mixture was partitioned between dichloromethane (10 ml) and water (10 ml). The organic layer was separated, dried (MgSO4) and the solvent removed by evaporation. The residue was purified by RPHPLC (Symmetry, 25% to 95% MeCN/0.1% NH4OAc aq over 6 minutes, 20 ml/min, 220 nm) to give a colourless solid (0.062 g; m.pt. 173-175° C.).
[0360]
1
H NMR: (299.944 MHz DMSO-D6) δ1.72-1.87 (2H, m), 2.01-2.34 (5H, m), 2.48-2.55 (1H, m), 2.98-3.13 (2H, m), 3.13-3.27 (2H, m), 3.39-3.47 (2H, m), 3.53-3.62 (2H, m), 3.64 (3H, s), 4.35-4.58 (1H, m), 4.65-4.76 (1H, m), 7.12 (1H, dd), 7.39-7.48 (2H, m), 7.52 (1H, t), 7.61 (1H, t), 7.79 (1H, d), 7.88 (1H, s), 7.95 (1H, d).
EXAMPLE 19
[0361] This Example illustrates the preparation of 1-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-2-phenyl-3-piperazin-1-yl-propan-1-one (Compound 595 of Table I).
[0362] Compound 575 of Table I (0.178 g) was treated with 6N hydrochloric acid (5 ml) and stirred at room temperature for 24 hours. 2N Sodium hydroxide solution was added and the reaction mixture extracted with ethyl acetate. The organic extracts were combined, washed with water, dried (MgSO4) and evaporated to give a white solid. Purification was by reverse phase HPLC (with a gradient eluent system (25% MeCN/NH4OAc aq (0.1%) to 95% MeCN//NH4OAcaq (0.1%)). (Any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with MgSO4 and evaporation of solvent.) The title compound was a white solid (0.087 g).
[0363] 1H NMR (399.98 MHz, DMSO-D6) δ1.20-1.95 (9H, m), 2.10-2.53 (9H, m), 2.59-2.65 (2H, m), 2.70-2.77 (1H, m), 2.89-3.12 (4H, m), 4.02-4.47 (4H, m), 6.89-7.00 (1H, m), 7.16-7.32 (6H, m), 7.44-7.52 (1H, m).
EXAMPLE 20
[0364] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-1-oxy-[1,4′]bipiperidinyl-1′-yl]-(3-methanesulfonyl-phenyl)-methanone.
[0365] The product Example 10 (0.100 g) in dichloromethane (5 ml) was treated with m-chloroperbenzoic acid (0.043 g) and the reaction stirred at room temperature for 0.5 hours. Saturated aqueous sodium hydrogencarbonate was added and the reaction mixture extracted with dichloromethane. The combined organic extracts were washed with water, dried (MgSO4) and evaporated to give a brown foam. Purification by RPHPLC (with a gradient eluent system (25% MeCN/NH4OAc aq (0.1%) to 95% MeCN//NH4OAc aq (0.1%)) gave the title compound as a white solid (0.021 g).
[0366]
1
H NMR (299.946 MHz, DMSO-D6) δ1.70-2.91 (15H, m), 3.24-3.44 (3H, m), 3.55-3.68 (1H, m), 4.55-4.76 (2H, m), 6.99-7.06 (1H, m), 7.29-7.33 (1H, m), 7.53 (1H, dd), 7.71-7.79 (2H, m), 7.93 (1H, s), 7.99-8.05 (1H, m).
EXAMPLE 21
[0367] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-phenyl-methanone (Compound 1 of Table I).
[0368] To a solution of 4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidine (0.1 g, see step b of Example 2) in dichloromethane (5 ml) and triethylamine (0.2 ml) was added benzoyl chloride (0.045 ml) and the reaction mixture was stirred for 2 hours. The mixture was washed with water, dried (MgSO4), filtered and the solvents evaporated to leave a gum. Purification by RPHPLC [with an eluent system (50% MeCN/0.1%NH4OAc aq), any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with MgSO4 and evaporation of solvent] and trituration of the resulting product with diethyl ether gave a solid which was filtered and dried to give the title compound (0.120 g; m.pt. 122° C.).
[0369]
1
H NMR (299.944 MHz CDCl3) δ1.42-1.62 (2H, m), 1.78-1.82 (3H, m), 1.95-2.01 (3H, m), 2.39-2.69 (3H, m), 2.69-3.09 (4H, m), 3.63-3.95 (1H, m), 4.24-4.29 (1H, m), 4.62-4.89 (1H, m), 6.73-6.77 (1H, m), 6.99 (1H, d), 7.26-7.29 (1H, m), 7.39 (5H, s).
EXAMPLE 22
[0370] This Example illustrates the preparation of [4-(3,4-dichloro-benzenesulfonyl)-[1,4′]bipiperidinyl-1′-yl]-(4-methanesulfonyl-phenyl)-methanone (Compound 4 of Table V).
[0371] Step 1: 4-(3,4-dichloro-phenylsulfanyl)-piperidine-1-carboxylic acid tert-butyl ester
[0372] 4-Methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester (11.18 g) and 3,4-dichlorothiophenol (6.15 ml) were stirred together in acetonitrile (200 ml) and potassium carbonate (8.86 g) was added. The mixture was heated at reflux for 18 hours after which water was added and the resulting mixture extracted with dichloromethane. The organic extracts were combined, washed with water, dried (MgSO4) and evaporated to give the sub-title compound (14.58 g).
[0373]
1
H NMR (299.944 MHz, CDCl3) δ1.45 (9H, s), 1.49-1.62 (2H, m), 1.87-1.96 (2H, m), 2.89-2.98 (2H, m), 3.16-3.26 (1H, m), 3.91-4.01 (2H, m), 7.21-7.57 (3H, m).
[0374] Step 2: 4-(3,4-dichloro-benzenesulfonyl)-piperidine-1-carboxylic acid tert-butyl ester
[0375] The product from Step 1 (1 g) and m-chloroperbenzoic acid (1.19 g) were stirred at ambient temperature in dichloromethane (10 ml) for 18 hours. Sodium metabisulphite (1.19 g) in water (5 ml) was added and stirring was continued for 0.5 hours after which the reaction mixture was extracted with dichloromethane. The combined organics were washed with saturated sodium bicarbonate solution, dried (MgSO4) and evaporated to give the sub-title compound (0.34 g).
[0376]
1
H NMR (399.978 MHz, CDCl3) δ1.45 (9H, s), 1.56-1.65 (2H, m), 1.94-2.00 (2H, m), 2.62-2.70 (2H, m), 3.01-3.09 (1H, m), 4.21-4.30 (2H, m), 7.66-7.70 (2H, m), 7.93-7.98 (1H, m).
[0377] Step 3: 4-(3,4-dichloro-benzenesulfonyl)-piperidine
[0378] The product of step 2 was deprotected following the procedure of Example 1 step b. 1H NMR (299.944 MHz, CDCl3) δ1.64-1.71 (2H, m), 1.96-2.05 (2H, m), 2.55-2.64 (2H, m), 2.99-3.10 (1H, m), 3.19-3.27 (2H, m), 7.66-7.71 (2H, m), 7.92-7.98 (11H, m).
[0379] Step 4: 4-(3,4-dichloro-benzenesulfonyl)-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0380] The product of step 3 was used in a reductive amination with 4-oxo-piperidine-1-carboxylic acid tert-butyl ester following the procedure of Example 2 step a.
[0381] Step 5: 4-(3,4-Dichloro-benzenesulfonyl)-[1,4′]bipiperidinyl
[0382] The product of step 4 was deprotected following the procedure of Example 2 step b. 1H NMR (299.946 MHz, DMSO-D6) δ1.22-1.61 (7H, m), 1.77-1.83 (2H, m), 2.09-2.16 (1H, m), 2.25-2.45 (3H, m), 2.87-2.98 (4H, m), 3.35-3.43 (1H, m), 7.81 (1H, dd), 7.96 (1H, d), 8.05 (1H, d)
[0383] Step 6: [4-(3,4-dichloro-benzenesulfonyl)-[1,4′]bipiperidinyl-1′-yl]-(4-methanesulfonyl-phenyl)-methanone
[0384] The product of step 5 was coupled to 4-methanesulfonyl-benzoic acid following the procedure of Example 2 step c.
[0385] 1H NMR (299.946 MHz, DMSO-D6) δ1.34-1.62 (5H, m), 1.70-1.85 (4H, m), 2.13 (3H, t), 2.72-3.04 (4H, m), 3.27 (3H, s), 3.37-3.48 (1H, m), 4.44-4.52 (1H, m), 7.63 (2H, d), 7.81 (1H, dd), 7.95-8.00 (3H, m), 8.06 (1H, d).
[0386] [4-(3,4-Dichloro-benzenesulfonyl)-[1,4′]bipiperidinyl-1′-yl]-phenyl-methanone (Compound 5 of Table V). The product of step 5 was coupled to benzoic acid following the procedure of Example 2 step c. 1H NMR (299.946 MHz, DMSO-D6) δ1.31-1.69 (5H, m), 1.82 (3H, d), 2.15 (2H, d), 2.69-2.75 (1H, m), 2.90-2.97 (4H, m), 3.33-3.43 (1H, m), 3.48-3.63 (1H, m), 4.42-4.53 (1H, m), 7.39 (5H, dt), 7.81 (1H, dd), 7.96 (1H, d), 8.06 (1H, d).
EXAMPLE 23
[0387] This Example illustrates the preparation of 3-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carbonyl]-1-ethyl-7-methyl-1H-[I,8]naphthyridin-4-one (Compound 534 of Table I).
[0388] 4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidine (0.2 g, see step b of Example 2) was dissolved in dichloromethane (5 ml), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PYBROP™; 0.425 g), 1-ethyl-7-methyl-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid (0.155 g) and triethylamine (0.254 ml) were added. After 16 hours at room temperature dichloromethane and aqueous NaHCO3 solution were added. The product was extracted with dichloromethane, the combined organic extracts were washed with water, dried with MgSO4 and concentrated. Purification by RPHPLC (with a gradient eluent system (45% MeCN/NH4OAc aq (0.1%) to 95% MeCN//NH4OAc aq (0.1%)) %)) (any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with Magnesium sulfate and evaporation of solvent) gave the title compound (0.184 g; m.pt. 189-190° C.)
[0389] MS: APCI+(M+H) 543
[0390]
1
H NMR (299.946 MHz, DMSO-D6) δ1.37 (3H, t), 1.47-1.69 (5H, m), 1.78-1.84 (1H, m), 1.89-1.97 (2H, m), 2.36-2.41 (2H, m), 2.49-2.56 (1H, m), 2.66 (3H, s), 2.70-2.79 (3H, m), 2.95-3.04 (1H, m), 3.52-3.59 (1H, m), 4.38-4.57 (4H, m), 6.95-6.99 (1H, m), 7.22-7.24 (1H, m), 7.35-7.40 (1H, m), 7.46-7.51 (1H, m), 8.37 (1H, s), 8.43-8.45 (1H, m).
EXAMPLE 24
[0391] This Example illustrates the preparation of 4-[4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carbonyl]-2H-isoquinolin-1-one (Compound 572 of Table I).
[0392] 4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidine (0.2 g, see step b of Example 2) was dissolved in dichloromethane (5 ml), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PYBROP™; 0.425 g), 1-oxo-1,2-dihydro-isoquinoline4-carboxylic acid (0.126 g) and triethylamine (0.254 ml) were added. After 16 hours at room temperature dichloromethane and aqueous NaHCO3 solution were added. The product was extracted with dichloromethane, the combined organic extracts were washed with water, dried with MgSO4 and concentrated. Purification by RPHPLC (with a gradient eluent system (45% MeCN/NH4OAc aq (0.1%) to 95% MeCN//NH4OAc aq (0.1%))) (any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with Magnesium sulfate and evaporation of solvent) gave the title compound (0.153 g).
[0393] MS: APCI+(M+H) 500
[0394]
1
H NMR (299.944 MHz CDCl3) δ1.37-1.66 (2H, m), 1.73-1.88 (3H, m), 1.93-2.05 (3H, m), 2.41-2.51 (2H, m), 2.52-2.63 (1H, m), 2.75-2.86 (2H, m), 2.86-3.09 (2H, m), 3.71-3.90 (1H, m), 4.23-4.32 (1H, m), 4.77-4.93 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.27-7.32 (3H, m), 7.54-7.67 (1H, m), 7.57 (1H, t), 7.74 (1H, t), 8.46 (1H, d).
EXAMPLE 25
[0395] This Example illustrates the preparation of [4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(6-fluoro-imidazo[1,2-a]pyridin-2-yl)-methanone (Compound 579 of Table I).
[0396] Step a: 6-Fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester
[0397] To a solution of 2-amino-5-fluoropyridine (1.12 g) in diethyl ether (25 ml) was added ethyl bromopyruvate (1.25 ml). the mixture was stirred for 1 hour. The resultant solid was filtered off, suspended in ethanol and heated at reflux for 4 hours. The solvent was removed by evaporation and the residue partitioned between ethyl acetate (100 ml) and aqueous sodium bicarbonate solution (100 ml). The organic layer was separated, dried, (magnesium sulfate) and the solvent removed by evaporation. The residue was purified by flash chromatography (silica) eluting with ethyl acetate: hexane (3:1) to give the sub-title compound as a colourless solid (1.12 g).
[0398] MS: ES+(M+H) 209
[0399]
1
H NMR (399.98 MHz, CDCl3) δ1.44 (3H, t), 4.46 (2H, q), 7.19 (1H, ddd), 7.68 (1H, dd), 8.07-8.09 (1H, m), 8.19 (1H, s).
[0400] Step b: 6-Fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid
[0401] A solution of 6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester (1 g) in 4N HCl was refluxed for 4 hours. The solvent was evaporated to give the sub-title compound as a white solid (0.86 g).
[0402] MS: ES+(M+H) 181
[0403]
1
H NMR (399.98 MHz, DMSO-D6) δ7.81-7.89 (2H,m), 8.71 (1H,s), 9.03 (1H,s).
[0404] Step c: [4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-yl]-(6-fluoro-imidazo[1,2-a]pyridin-2-yl)-methanone
[0405] 4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidine (0.2 g, see step b of Example 2) was dissolved in dichloromethane (5 ml), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (PYBROP™; 0.425 g), 6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid (0.126 g) and triethylamine (0.254 ml) were added. After 16 hours at room temperature dichloromethane and aqueous NaHCO3 solution were added. The product was extracted with dichloromethane, the combined organic extracts were washed with water, dried with MgSO4 and concentrated. Purification by reverse phase HPLC (with a gradient eluent system (45% MeCN/NH4OAc aq (0.1%) to 95% MeCN//NH4OAc aq (0.1%)) (any excess NH4OAc was removed by dissolving the compound in ethyl acetate and washing with aqueous saturated NaHCO3 followed by drying of the organics with magnesium sulfate and evaporation of solvent) gave the title compound (0.104 g).
[0406] MS: APCI+(M+H) 491
[0407]
1
H NMR (399.978 MHz, CDCl3) δ1.61 (1H, qd), 1.75-2.02 (7H, m), 2.42-2.51 (2H, m), 2.59-2.67 (1H, m), 2.75-2.86 (3H, m), 3.12-3.21 (1H, m), 4.23-4.29 (1H, m), 4.76-4.85 (1H, m), 5.23-5.32 (1H, m), 6.75 (1H, dd), 6.99 (1H, d), 7.16 (1H, ddd), 7.30 (1H, d), 7.58 (1H, dd), 8.07 (2H, s).
EXAMPLE 26
[0408] This Example illustrates the preparation of 4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carboxylic acid phenylamide (Compound 309 of Table IV).
[0409] Phenylisocyanate(0.078 ml) was added to a solution of 4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidine (0.2 g, see Example 2 step b) in dichloromethane (5 ml). The mixture was stirred at 23° C. for 16 hours. The resulting precipitate was filtered, washed with dichloromethane (2×5 ml) then crystallised from acetonitrile to afford the title compound as a solid (0.2 g; melting point 215-216° C.).
[0410]
1
H NMR (DMSO-D6) δ1.35 (2H, qd), 1.53-1.62 (2H, m), 1.72-1.78 (2H, m), 1.89-1.96 (2H, m), 2.36-2.42 (2H, m), 2.44-2.52 (1H, m), 2.72-2.78 (4H, m), 4.15 (2H, d), 4.39-4.45 (1H, m), 6.91 (1H, tt), 6.98 (1H, dd), 7.19-7.23 (2H, m), 7.25 (1H, d), 7.43-7.46 (2H, m), 7.49 (1H, d), 8.46 (1H, s).
[0411] 4-(3,4-Dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carbothioic acid phenylamide was prepared using the methodology of Example 26 and employing phenylisothiocyanate, (melting point 162-163° C.). 1H NMR: (DMSO-d6) δ1.39-1.49 (2H, m), 1.53-1.62 (2H, m), 1.79 (2H, d), 1.89-1.96 (2H, m), 2.39 (2H, t), 2.54-2.63 (1H, m), 2.73-2.80 (2H, m), 3.04 (2H, t), 4.39-4.46 (1H, m), 4.72 (2H, d), 6.98 (1H, dd), 7.06-7.10 (1H, m), 7.23-7.30 (5H, m), 7.49 (1H, d), 9.24 (1H, s).
EXAMPLE 27
[0412] This Example illustrates the preparation of 4-(3,4-dichloro-phenoxy)-[1,4′]bipiperidinyl-1′-carboxylic acid (3-methanesulfonyl-phenyl)-amide (Compound 54 of Table IV).
[0413] Hydrogen peroxide (100 μl, 30%) was added to a cooled (0° C.) solution of Compound 312 of Table IV (0.13 g) in trifluoroacetic acid(1ml). The mixture was allowed to reach ambient temperature and stirred for a further 1 hour. The solution was quenched with water(5 ml), basified to pH11 with 2M sodium hydroxide solution and extracted with ethyl acetate. The organic solution was separated, washed with water(2×5 ml), dried (MgSO4), filtered and the filtrate evaporated to leave a gum. The gum was dissolved in acetonitrile and purified by RPHPLC (Nova Pak column) eluting with acetonitrile/0.1% ammonium acetate aq (1:1). The required fractions were evaporated and then lyophilised to give the title compund as a colourless powder (0.03 g).
[0414]
1
H NMR (DMSO-D6) δ1.31-1.42 (2H, m), 1.53-1.62 (2H, m), 1.77 (2H, d), 1.89-1.96 (2H, m), 2.36-2.43 (3H, m), 2.74-2.82 (4H, m), 3.16 (3H, s), 4.18 (2H, d), 4.42 (1H, septet), 6.98 (1H, dd), 7.25 (1H, d), 7.44-7.52 (3H, m), 7.80-7.83 (1H, m), 8.09 (1H, t), 8.90 (1H, s).
[0415] Selected proton NMR data and/or melting point data are provided for certain further compounds in Tables VI and VII below.
12TABLE VI
|
|
Compound
(Table no.)NMR data
|
3 (I)δ(D2O) 1.97-1.69(2H, m), 2.21-2.08(2H, m), 2.51-2.23(4H, m),
3.07-2.96(1H, m), 3.31-3.17(2H, m), 3.45-3.32(2H, m), 3.56-3.45
(1H, m), 3.75-3.56(2H, m), 4.88-4.70(3H, m), 7.07-7.02(1H, m),
7.36-7.30(1H, m), 7.46-7.37(1H, m), 7.55(2H, d), 7.74-7.72(1H, m)
8 (I)δ(CDCl3) 1.67-1.41(2H, m), 1.86-1.76(3H, m), 2.04-1.93(3H, m),
2.51-2.42(3H, m), 2.62-2.56(1H, m), 2.88-2.76(3H, m), 3.06(1H,
t), 3.66(1H, d), 4.28(1H, septet), 4.76(1H, d), 6.75(1H, dd), 6.99(1H,
d), 7.31(1H, d), 7.56(2H, d), 8.28(2H, d)
18 (I)δ(CD3OD) 1.59-1.41(2H, m), 1.83-1.68(2H, m), 2.08-1.93(4H, m),
2.56-2.48(4H, m), 2.68-2.61(1H, m), 2.91-2.80(3H, m), 3.15-3.02
(1H, m), 3.71-3.57(1H, m), 4.23-4.14(1H, m), 4.40(1H, septet), 4.50
(3H, s), 4.75-4.57(1H, m), 6.91(1H, dd), 7.12(1H, d), 7.40(1H, d),
7.66(2H, d), 8.04(2H, d)
36 (I)δ(CD3OD) 1.62-1.42(2H, m), 1.94-1.72(3H, m), 2.11-1.98(3H, m),
2.61-2.52(2H, m), 2.95-2.82(3H, m), 3.15(1H, t), 3.68-3.63(1H,
m), 4.42(1H, septet), 4.71-4.67(2H, m), 6.91(1H, dd), 7.11(1H, d),
7.40(1H, d), 7.60(2H, d), 7.86(2H, d)
37 (I)δ(CD3OD) 2.06-1.76(3H, m), 2.45-2.12(5H, m), 3.05-2.88(1H, m),
3.42-3.25(3H, m), 3.71-3.50(2H, m), 3.93-3.74(1H, m), 4.63(1H,
septet), 4.94-4.82(2H, m), 7.03-6.95(1H, m), 7.24(1H, dd), 7.47-7.42
(1H, m), 7.71-7.66(1H, m), 7.78(1H, td), 7.90-7.86(2H, m)
149 (I)δ(CDCl3) 1.50-1.27(2H, m), 1.90-1.75(5H, m), 2.02-1.92(2H, m),
2.56-2.39(4H, m), 2.63(1H, t), 2.81-2.72(2H, m), 3.09-3.01(3H,
m), 3.82(2H, s), 3.91(1H, d), 4.25(1H, septet), 4.67(1H, d), 6.75(1H,
dd), 6.99(1H, d), 7.31(1H, dd), 7.45(2H, d), 7.90(2H, d)
203 (I)δ(DMSO-D6) 1.61-1.44(2H, m), 2.24-2.01(4H, m), 2.61-2.53(2H,
m), 3.16-2.99(2H, m), 3.60-3.30(5H, m), 3.67(2H, s), 3.77(3H, s),
4.13(1H, d), 4.53(1H, d), 4.69-4.60(1H, m), 7.05(1H, ddd), 7.14(1H,
d), 7.42-7.25(3H, m), 7.55(2H, dd), 10.98-10.78(3H, m)
205 (I)δ((CD3)2CO) 1.26(2H, quintet), 1.76-1.58(4H, m), 1.98-1.90(2H, m),
2.42-2.35(2H, m), 2.58-2.45(2H, m), 2.81-2.71(2H, m), 3.00(1H,
t), 3.70(2H, s), 4.00(1H, d), 4.39(2H, septet), 4.51(1H, d), 6.92(1H,
dd), 7.07-7.01(2H, m), 7.13(1H, d), 7.30-7.25(2H, m), 7.40(1H, d)
220 (I)δ(DMSO-D6) 1.58-1.44(2H, m), 2.28-1.97(5H, m), 2.59-2.53(2H,
m), 3.18-2.93(3H, m), 3.34-3.25(1H, m), 3.51-3.36(2H, m), 3.66-3.56
(2H, m), 4.11(1H, d), 4.53(1H, d), 4.64(1H, septet), 6.92-6.82
(2H, m), 6.99(1H, d), 7.10-7.03(1H, m), 7.36(1H, dd), 7.55(1H, ddd),
10.99-10.87(1H, m)
225 (I)δ((CD3)2CO) 1.71-1.51(2H, m), 2.13-2.08(2H, m), 2.40-2.21(3H,
m), 2.61-2.54(1H, m), 3.05(1H, t), 3.55-3.15(6H, m), 3.69-3.61
(2H, m), 4.16(1H, d), 4.76-4.63(2H, m), 4.91-4.86(1H, m), 6.78-6.76
(2H, m), 7.12-7.02(3H, m), 7.32(1H, dd), 7.51(1H, dd)
244 (I)δ(DMSO-D6) 1.55-1.42(2H, m), 2.25-1.96(6H, m), 2.66-2.54(2H,
m), 3.14-2.96(2H, m), 3.32-3.26(1H, m), 3.51-3.35(2H, m), 3.62
(3H, s), 3.71-3.64(2H, m), 3.74(6H, s), 4.14(1H, d), 4.54(1H, d), 4.66-4.58
(1H, m), 6.53(2H, s), 7.04(1H, dd), 7.35(1H, d), 7.54(1H, tt)
253 (I)δ(CDCl3) 1.47-1.19(2H, m), 2.00-1.76(6H, m), 2.62-2.37(4H, m),
2.80-2.70(2H, m), 2.98(1H, t), 3.65(2H, s), 3.88(3H, s), 3.92-3.89
(1H, m), 4.25(1H, septet), 4.68(1H, d), 6.77-6.72(1H, m), 6.89(1H,
d), 6.94-6.92(2H, m), 7.01-6.96(2H, m), 7.30(1H, dd)
258 (I)δ(DMSO-D6) 1.40-1.26(3H, m), 1.78-1.59(5H, m), 1.98-1.92(1H,
m), 2.17(3H, s), 2.21(3H, s), 2.45-2.37(2H, m), 2.60-2.48(3H, m),
3.01(1H, t), 3.70-3.57(2H, m), 3.89(1H, d), 4.39(1H, septet), 4.55(1H,
d), 7.00(1H, d), 7.13(1H, d), 7.41(1H, d), 7.95-7.89(3H, m)
267 (I)δ(CDCl3) 1.74-1.61(2H, m), 2.21-2.09(3H, m), 2.32-2.25(1H, m),
2.48(1H, t), 2.67-2.53(2H, m), 2.89(1H, t), 3.31-3.05(5H, m), 3.71
(4H, s), 3.82(2H, s), 4.08(1H, d), 4.59-4.53(1H, m), 4.94(1H, d), 6.89
(1H, dd), 6.93(1H, dd), 6.97(1H, d), 7.34(1H, d), 7.40(1H, d), 7.58-7.54
(1H, m),
268 (I)δ(CDCl3) 1.24(1H, dq), 1.41(1H, dq), 1.88-1.72(4H, m), 2.00-1.91
(2H, m), 2.53-2.37(3H, m), 2.59(1H, dt), 2.78-2.70(2H, m), 2.98
(1H, t), 3.73(2H, s), 3.89(1H, d), 4.24(1H, septet), 4.68(1H, d), 6.74
(1H, dd), 7.03-6.91(4H, m), 7.29-7.25(1H, m), 7.30(1H, d)
272 (I)δ(CDCl3) 1.18(1H, dq), 1.40(1H, dq), 1.86-1.68(4H, m), 2.00-1.91
(2H, m), 2.43-2.35(2H, m), 2.48(1H, td), 2.57(1H, dt), 2.77-2.68
(2H, m), 2.95(1H, dt), 3.74(2H, s), 3.91(1H, d), 4.23(1H, septet), 4.69
(1H, d), 6.74(1H, dd), 6.98(1H, d), 7.35-7.23(6H, m)
274 (I)δ(DMSO-D6) 1.74-1.59(5H, m), 1.77(3H, dq), 2.65-2.36(4H, m), 2.86-2.74
(6H, m), 2.95(1H, t), 3.74(3H, s), 3.93(1H, d), 4.40(1H, septet),
4.53(1H, d), 6.73-6.70(1H, m), 6.80-6.78(2H, m), 6.93(1H, dd), 7.18-7.13
(2H, m), 7.41(1H, d)
276 (I)δ((CD3)2CO) 1.63-1.51(2H, m), 2.02-1.98(2H, m), 2.21-2.15(2H,
m), 2.58-2.31(4H, m), 2.96(1H, t), 3.40-3.03(4H, m), 3.60-3.49
(2H, m), 3.72(3H, s), 4.02(1H, d), 4.63-4.55(1H, m), 4.77-4.72(1H,
m), 6.76(1H, t), 6.84(1H, d), 6.96-6.93(1H, m), 7.03(1H, d), 7.11-7.07
(1H, m), 7.16-7.15(1H, m), 7.37-7.31(1H, m)
286 (I)δ(CD3OD) 1.90-1.63(2H, m), 2.49-2.05(6H, m), 3.28-2.87(7H, m),
3.84-3.44(5H, m), 4.69-4.56(1H, m), 4.85-4.78(2H, m), 7.04-6.94
(1H, m), 7.28-7.21(1H, m), 7.45(1H, t), 7.60-7.55(3H, m), 7.64-7.61
(1H, m), 7.66(1H, t), 7.77-7.73(2H, m), 7.85-7.81(2H, m)
291 (I)δ(CD3OD) 1.98-1.71(3H, m), 2.46-2.11(5H, m), 3.18-2.98(1H, m),
3.45-3.26(2H, m), 3.70-3.46(4H, m), 3.86(3H, s), 4.66-4.56(1H,
m), 4.84-4.80(2H, m), 7.04-6.94(3H, m), 7.27-7.20(1H, m), 7.47-7.42
(3H, m)
293 (I)δ(CD3OD) 1.88-1.73(2H, m), 2.22-1.92(5H, m), 2.31(1H, d), 2.87-2.79
(1H, m), 3.06-2.97(1H, m), 3.17(3H, s), 3.57-3.31(5H, m), 4.55-4.44
(1H, m), 4.73-4.65(2H, m), 6.92-6.82(1H, m), 7.12(1H, td),
7.40-7.31(2H, m), 7.63(1H, dt), 7.75-7.68(1H, m), 7.99(1H, dt)
294 (I)δ(CD3OD) 1.98-1.70(2H, m), 2.45-2.08(6H, m), 2.97(1H, t), 3.21
(3H, s), 3.41-3.21(3H, m), 3.72-3.49(3H, m), 4.67-4.56(1H, m),
4.95-4.81(2H, m), 7.03-6.94(1H, m), 7.27-7.20(1H, m), 7.47-7.42
(1H, m), 7.74-7.62(1H, m), 8.02(1H, ddd), 8.13(1H, dd)
295 (I)δ(CD3OD) 2.04-1.74(3H, m), 2.36-2.12(4H, m), 2.48-2.40(1H, m),
3.03-2.87(1H, m), 3.43-3.15(3H, m), 3.80-3.47(3H, m), 4.68-4.58
(1H, m), 4.85-4.80(2H, m), 5.13(2H, s), 7.03-6.96(1H, m), 7.27-7.21
(1H, m), 7.46-7.42(1H, m), 7.63-7.56(3H, m), 7.79-7.69(4H,
m), 8.12(1H, d)
296 (I)δ(CD3OD) 2.46-1.75(8H, m), 2.96(1H, t), 3.32(2H, s), 3.72-3.19
(4H, m), 3.97-3.92(1H, m), 4.69-4.56(1H, m), 4.98-4.79(2H, m),
7.03-6.94(1H, m), 7.24(1H, d), 7.69-7.35(10H, m)
297 (I)δ(CD3OD) 1.66-1.51(2H, m), 1.89-1.69(3H, m), 2.08-1.96(3H, m),
2.71-2.50(3H, m), 3.01-2.81(3H, m), 3.24-3.10(1H, m), 3.84-3.71
(1H, m), 4.46-4.38(1H, m), 4.79-4.67(1H, m), 6.92(1H, dd), 7.14
(1H, d), 7.41(1H, d), 7.81(1H, dd), 8.39(1H, d), 8.71(1H, s)
298 (I)δ(CD3OD) 1.33(3H, t), 1.62-1.41(2H, m), 1.95-1.74(3H, m), 2.11-1.98
(3H, m), 2.73-2.52(3H, m), 2.95-2.79(3H, m), 3.03(2H, q), 3.26-3.09
(1H, m), 3.93-3.78(1H, m), 4.48-4.39(1H, m), 4.78-4.56(1H,
m), 6.91(1H, dd), 7.11(1H, d), 7.42-7.34(5H, m)
299 (I)δ(CD3OD) 1.99-1.72(3H, m), 2.36-2.11(4H, m), 2.44(1H, d), 3.06-2.87
(1H, m), 3.42-3.23(2H, m), 3.71-3.46(4H, m), 3.95-3.77(1H,
m), 4.67-4.55(1H, m), 4.84-4.80(1H, m), 7.03-6.94(1H, m), 7.27-7.20
(1H, m), 7.47-7.43(1H, m), 7.66-7.61(2H, m), 7.87-7.81(2H,
m)
300 (I)δ(CD3OD) 1.96-1.72(3H, m), 2.33-2.09(4H, m), 2.46-2.41(1H, m),
3.02-2.87(1H, m), 3.43-3.22(3H, m), 3.72-3.47(3H, m), 3.93-3.78
(1H, m), 4.66-4.56(1H, m), 4.84-4.80(1H, m), 7.03-6.94(1H, m),
7.28-7.21(1H, m), 7.47-7.43(1H, m), 7.59(2H, d), 7.83(2H, d)
301 (I)(500.076MHz, DMSO-D6) δ 1.33-1.44(m, 2H), 1.55-1.60(m, 2H),
1.66-1.73(m, 1H), 1.78-1.86(m, 1H), 1.91(s, 3H), 1.91-1.96(m, 2H),
2.05(s, 3H), 2.39(t, 2H), 2.55(t, 1H), 2.74-2.79(m, 3H), 2.94-3.04(m,
1H), 3.56-3.66(m, 1H), 4.42(septet, 1H), 4.45-4.52(m, 1H), 6.98(dd,
2H), 7.02(d, 2H), 7.25(d, 1H), 7.35(t, 1H), 7.49(d, 1H), 7.58(d, 1H),
7.66(s, 1H)
302 (I)(500.076MHz, DMSO-D6) δ 1.36(dq, 2H), 1.54-1.60(m, 2H), 1.72-1.75
(m, 2H), 1.91(s, 3H), 1.91-1.95(m, 2H), 2.05(s, 3H), 2.39(t,
2H), 2.74-2.78(m, 2H), 2.80-2.87(m, 1H), 4.05-4.19(m, 2H), 4.42
(septet, 1H), 5.22(s, 2H), 6.58(d, 1H), 6.97-6.99(m, 2H), 7.00(s, 1H),
7.25(d, 1H), 7.49(d, 1H)
303 (I)(500.076MHz, DMSO-D6) δ 1.54-1.63(m, 4H), 1.69-1.82(m, 4H),
1.91-1.96(m, 2H), 1.91(s, 3H), 2.35-2.44(m, 2H), 2.73-3.04(m,
7H), 4.39-4.46(m, 2H), 6.48-6.49(m, 1H), 6.98(d, 1H), 7.02-7.07
(m, 3H), 7.26(s, 1H), 7.34(t, 1H), 7.49(d, 1H), 7.62(d, 1H)
304 (I)(500.076MHz, DMSO-D6) δ 1.33(t, 3H), 1.36-1.43(m, 2H), 1.54-1.60
(m, 2H), 1.70-1.80(m, 2H), 1.91-1.96(m, 2H), 1.91(s, 3H), 2.39
(t, 2H), 2.51-2.55(m, 1H), 2.74-2.79(m, 2H), 3.79(s, 3H), 4.01-4.05
(m, 1H), 4.02(q, 2H), 4.42(septet, 1H), 4.47-4.53(m, 1H), 6.94(s,
2H), 6.97-6.99(m, 2H), 7.25(d, 1H), 7.49(d, 1H)
305 (I)(500.076MHz, DMSO-D6) δ 1.37-1.46(m, 2H), 1.54-1.61(m, 2H),
1.67-1.83(m, 2H), 1.91-1.96(m, 2H), 1.91(s, 3H), 2.40(t, 2H), 2.53-2.58
(m, 1H), 2.74-2.80(m, 2H), 2.99-3.10(m, 1H), 3.63-3.74(m,
1H), 4.42(septet, 1H), 4.46-4.54(m, 1H), 6.29-6.30(m, 1H), 6.98(dd,
1H), 7.25(d, 1H), 7.43-7.44(m, 1H), 7.48(t, 3H), 7.64(d, 2H)
306 (I)(500.076MHz, DMSO-D6) δ 1.22-1.40(m, 2H), 1.54-1.61(m, 2H),
1.75(t, 2H), 1.91-1.96(m, 2H), 2.38(t, 2H), 2.53-2.60(m, 1H), 2.71-2.77
(m, 2H), 3.03(t, 1H), 3.79(s, 2H), 3.98-4.03(m, 1H), 4.36-4.40
(m, 1H), 4.40-4.45(m, 1H), 6.98(dd, 1H), 7.25(d, 1H), 7.50(d, 1H),
8.34(s, 1H), 8.40(s, 1H), 8.57(d, 1H)
307 (I)(500.076MHz, DMSO-D6) δ 1.17-1.31(m, 2H), 1.53-1.59(m, 2H),
1.69(t, 2H), 1.88-1.94(m, 2H), 2.35(t, 2H), 2.45-2.52(m, 1H), 2.68-2.74
(m, 2H), 2.95(t, 1H), 3.50(s, 2H), 3.59(s, 3H), 4.06-4.10(m, 1H),
4.36-4.43(m, 2H), 6.88(s, 1H), 6.97(dd, 1H), 7.25(d, 1H), 7.45(s, 1H),
7.49(d, 1H)
308 (I)(500.076MHz, DMSO-D6) δ 1.03(dq, 1H), 1.18(dq, 1H), 1.49-1.58
(m, 3H), 1.68(d, 1H), 1.83-1.90(m, 2H), 1.91(s, 3H), 2.23-2.30(m,
2H), 2.41-2.49(m, 3H), 2.57-2.67(m, 2H), 2.90(t, 1H), 3.66(q, 2H),
4.01(d, 1H), 4.38(septet, 1H), 4.43(d, 1H), 6.58(dd, 1H), 6.88(d, 1H),
6.96(dd, 1H), 7.07(d, 1H), 7.12(d, 1H), 7.23(d, 1H), 7.49(d, 1H), 8.58
(s, 1H)
309 (I)(500.076MHz, DMSO-D6) δ 1.46-1.56(m, 2H), 1.89-1.98(m, 2H),
2.03-2.18(m, 4H), 2.23(d, 1H), 2.55-2.61(m, 1H), 3.02-3.17(m,
4H), 3.42-3.51(m, 2H), 3.98(s, 2H), 4.16(d, 1H), 4.54(d, 1H), 4.60-4.66
(m, 1H), 6.93-6.97(m, 1H), 7.01-7.09(m, 1H), 7.15(s, 1H), 7.25
(s, 1H), 7.34-7.38(m, 1H), 7.54-7.58(m, 1H)
310 (I)(500.076MHz, DMSO-D6) δ 1.11(t, 3H), 1.39-1.48(m, 2H), 1.55-1.60
(m, 2H), 1.65-1.72(m, 1H), 1.81-1.87(m, 1H), 1.90-1.95(m,
2H), 1.90(s, 3H), 2.39(t, 2H), 2.53-2.59(m, 1H), 2.74-2.83(m, 2H),
3.03-3.10(m, 1H), 3.36(q, 2H), 3.47-3.55(m, 1H), 4.42(septet, 1H),
4.46-4.54(m, 1H), 6.98(dd, 1H), 7.25(d, 1H), 7.49(d, 1H), 7.72-7.78
(m, 2H), 7.86(s, 1H), 7.96(d, 1H)
311 (I)(500.076MHz, DMSO-D6) δ 0.92(t, 3H), 1.40-1.49(m, 2H), 1.55-1.64
(m, 2H), 1.57(sextet, 2H), 1.65-1.73(m, 1H), 1.81-1.88(m, 1H),
1.91(s, 3H), 1.91-1.96(m, 2H), 2.36-2.44(m, 2H), 2.54-2.61(m,
1H), 2.73-2.84(m, 2H), 3.02-3.11(m, 1H), 3.45-3.53(m, 1H), 4.40-4.46
(m, 1H), 4.50-4.54(m, 1H), 6.98(dd, 1H), 7.25(d, 1H), 7.49(d,
1H), 7.72-7.78(m, 2H), 7.86(s, 1H), 7.96(d, 1H)
312 (I)(500.076MHz, DMSO-D6) δ 0.98(d, 6H), 1.39-1.49(m, 2H), 1.54-1.61
(m, 2H), 1.64-1.71(m, 1H), 1.81-1.87(m, 1H), 1.90-1.95(m,
2H), 1.91(s, 3H), 2.02(septet, 1H), 2.39(t, 2H), 2.53-2.59(m, 1H),
2.74-2.79(m, 2H), 3.03-3.11(m, 1H), 3.45-3.52(m, 1H), 4.42
(septet, 1H), 4.47-4.53(m, 1H), 6.98(dd, 1H), 7.25(d, 1H), 7.49(d,
1H), 7.71-7.77(m, 2H), 7.88(s, 1H), 7.98(d, 1H)
313 (I)(500.076MHz, DMSO-D6) δ 1.41-1.53(m, 2H), 1.54-1.62(m, 2H),
1.66-1.74(m, 1H), 1.84-1.89(m, 1H), 1.91-1.96(m, 2H), 1.91(s,
3H), 2.36-2.44(m, 2H), 2.54-2.62(m, 1H), 2.73-2.87(m, 4H), 3.10
(t, 1H), 3.50(s, 3H), 3.52(s, 3H), 3.52-3.58(m, 1H), 4.40-4.46(m,
1H), 4.48-4.54(m, 1H), 6.97-7.00(m, 1H), 7.23-7.29(m, 1H), 7.50
(d, 1H), 8.06(d, 1H), 8.16(s, 1H), 8.29(d, 1H)
314 (I)(500.076MHz, DMSO-D6) δ 1.34(t, 3H), 1.35-1.41(m, 2H), 1.54-1.60
(m, 2H), 1.74(d, 2H), 1.90-1.96(m, 2H), 1.90(s, 3H), 2.39(t, 2H),
2.50-2.55(m, 1H), 2.73-2.79(m, 2H), 2.80-2.89(m, 1H), 4.01(q,
2H), 4.08-4.19(m, 2H), 4.42(septet, 2H), 5.06(s, 2H), 6.62(d, 1H),
6.77(d, 1H), 6.81(s, 2H), 6.98(dd, 1H), 7.25(d, 1H), 7.49(d, 1H)
315 (I)(DMSO-D6) δ 1.53-1.82(m, 2H), 2.02-2.36(m, 5H), 2.60-2.67(m,
1H), 3.07-3.15(m, 2H), 3.31-3.38(m, 1H), 3.43-3.53(m, 2H), 4.12-4.19
(m, 4H), 4.51(d, 1H), 4.68(septet, 1H), 4.85(s, 1H), 7.06(ddd, 1H),
7.37(dd, 1H), 7.56(t, 1H), 7.94(d, 2H), 8.86(d, 2H), 11.47(s, 1H)
316 (I)(DMSO-D6) δ 1.58-2.28(m, 4H), 2.67-2.84(m, 1H), 2.91-3.04(m,
2H), 2.97(s, 2H), 3.06-3.26(m, 2H), 3.24-3.42(m, 1H), 3.44-3.67
(m, 3H), 3.57(s, 3H), 4.55-4.77(m, 2H), 4.83(s, 1H), 7.00-7.09(m, 2H),
7.35-7.58(m, 5H)
317 (I)(DMSO-D6) δ 1.52(dq, 2H), 1.74-1.92(m, 2H), 1.93-2.04(m, 4H),
2.42-2.50(m, 2H), 2.55(tt, 1H), 2.77-2.85(m, 2H), 2.87-2.96(m,
2H), 4.22-4.30(m, 3H), 6.69-6.74(m, 2H), 6.76(d, 1H), 6.99(d, 1H),
7.07(dd, 1H), 7.16(dt, 1H), 7.29(s, 2H), 7.32(s, 1H)
318 (I)(DMSO-D6) δ 1.71(m, 2H), 2.18(m, 3H), 2.70(s, 3H), 3.02(m, 1H),
3.15(m, 2H), 3.32(m, 3H), 3.50(m, 2H), 4.63(m, 1H), 7.05(ddd, 1H),
7.36(m, 4H), 7.56(t, 1H), 7.66(d, 1H), 8.11(s, 1H), 8.37(d, 1H)
319 (I)(DMSO-D6) δ 1.40(m, 2H), 1.57(m, 2H), 1.79(m, 2H), 1.90(m, 2H),
2.40(m, 2H), 2.58(m, 1H), 2.79(m, 2H), 2.87(m, 2H), 4.30(d, 2H),
4.43(m, 1H), 6.97(dd, 1H), 7.13(m, 2H), 7.25(d, 1H), 7.43(d, 1H), 7.49(d,
1H), 7.65(m, 2H)
321 (I)(DMSO-D6) δ 1.67-1.78(m, 2H), 1.95-2.09(m, 3H), 2.18-2.27(m,
2H), 2.44(d, 3H), 2.77-2.88(m, 1H), 3.08-3.19(m, 3H), 3.33-3.52
(m, 5H), 3.59-3.67(m, 1H), 4.60-4.68(m, 1H), 4.84(s, 1H), 7.05
(ddd, 1H), 7.14-7.27(m, 1H), 7.37(dd, 1H), 7.55(t, 1H), 7.61(q, 1H),
7.70-7.71(m, 2H), 7.78-7.80(m, 1H), 7.86-7.89(m, 1H)
322 (I)(DMSO-D6) δ 1.65-1.80(m, 2H), 1.99-2.09(m, 2H), 2.19-2.30(m,
3H), 2.77-2.90(m, 1H), 3.07-3.21(m, 3H), 3.30-3.37(m, 3H), 3.47-3.57
(m, 2H), 3.59-3.71(m, 1H), 4.59-4.69(m, 1H), 4.82-4.86(m,
1H), 7.05(ddd, 1H), 7.37(dd, 1H), 7.49(s, 2H), 7.55(t, 1H), 7.64-7.69
(m, 2H), 7.84-7.86(m, 1H), 7.92(td, 1H)
323 (I)(DMSO-D6) δ 1.64-1.78(m, 2H), 1.99-2.09(m, 2H), 2.17-2.29(m,
3H), 2.70-2.85(m, 1H), 3.04-3.19(m, 3H), 3.28-3.38(m, 3H), 3.31
(s, 3H), 3.46-3.55(m, 2H), 3.66(t, 2H), 4.12(t, 2H), 4.56-4.68(m,
1H), 4.81-4.86(m, 1H), 6.94-6.97(m, 2H), 7.04(dd, 1H), 7.05(ddd,
1H), 7.34-7.39(m, 2H), 7.55(t, 1H)
324 (I)(CDCl3) δ 1.45(s, 9H), 1.48-1.67(m, 4H), 1.75-1.85(m, 2H), 1.90-2.03
(m, 3H), 2.42-2.51(m, 2H), 2.56(m, 1H), 2.71-2.84(m, 3H),
2.91-3.06(m, 1H), 3.54(q, 2H), 3.75-3.88(m, 1H), 4.03(t, 2H), 4.27
(septet, 1H), 4.68-4.82(m, 1H), 4.93-5.01(m, 1H), 6.75(dd, 1H), 6.90-7.00
(m, 3H), 7.25-7.32(m, 3H)
325 (I)(DMSO-D6) δ 1.70-1.84(m, 2H), 2.00-2.09(m, 2H), 2.20-2.29(m,
3H), 2.81-2.91(m, 1H), 3.09-3.21(m, 3H), 3.28-3.38(m, 3H), 3.48-3.57
(m, 2H), 3.61-3.70(m, 1H), 4.61-4.72(m, 1H), 4.82-4.86(m,
1H), 7.05(ddd, 1H), 7.14-7.27(m, 1H), 7.37(dd, 1H), 7.56(t, 1H), 7.76-7.79
(m, 1H), 8.51(s, 1H), 8.80(d, 1H)
326 (I)(DMSO-D6) δ 1.70-1.78(m, 2H), 2.00-2.09(m, 2H), 2.18-2.26(m,
2H), 3.05-3.17(m, 2H), 3.24-3.40(m, 2H), 3.97-4.06(m, 2H), 4.44-4.52
(m, 2H), 4.59-4.70(m, 2H), 4.73(s, 2H), 4.81-4.86(m, 1H), 4.91-4.93
(m, 2H), 6.90-6.93(m, 1H), 6.96-7.04(m, 1H), 7.07-7.11(m,
1H), 7.17-7.20(m, 1H), 7.34-7.43(m, 2H), 7.52-7.55(m, 1H)
327 (I)(CDCl3) δ 1.52-1.63(m, 4H), 1.77-1.86(m, 2H), 1.92-2.03(m, 4H),
2.44-2.50(m, 2H), 2.58-2.67(m, 1H), 2.77-2.83(m, 2H), 3.05(bs,
1H), 3.36(s, 3H), 4.26-4.31(m, 2H), 6.74-6.77(m, 1H), 6.99-7.01
(m, 1H), 7.30-7.33(m, 1H), 7.47(s, 1H)
328 (I)(CDCl3) δ 1.43-1.67(m, 4H), 1.73-1.91(m, 4H), 1.95-2.02(m, 2H),
2.42-2.50(m, 2H), 2.52-2.62(m, 1H), 2.77-2..85(m, 2H), 2.92(bs,
2H), 3.06(s, 3H), 4.23-4.30(m, 1H), 5.26(s, 2H), 6.73-6.79(m, 2H),
6.99-7.00(m, 1H), 7.29-7.32(m, 1H), 7.47-7.50(m, 1H), 7.82-7.82
(m, 1H)
329 (I)(CDCl3) δ 1.50-1.69(m, 4H), 1.77-1.86(m, 2H), 1.92-2.02(m, 4H),
2.45-2.49(m, 2H), 2.59-2.65(m, 1H), 2.79-2.83(m, 2H), 3.02(bs,
1H), 3.39(s, 3H), 4.26-4.30(m, 2H), 5.88(bs, 1H), 6.74-6.77(m, 1H),
6.99-7.00(m, 1H), 7.30-7.32(m, 1H), 7.46(bs, 1H), 7.65(s, 1H)
330 (I)(DMSO-D6) δ 1.73-3.63(m, 17H), 4.57-4.70(m, 1H), 7.01-7.88(m,
7H)
331 (I)(DMSO-D6) δ 1.21(d, 6H), 1.37-2.03(m, 8H), 2.33-3.42(m, 7H),
4.15-4.19(m, 1H), 4.37-4.45(m, 1H), 5.89(s, 2H), 6.96-8.34(m, 4H)
332 (I)(DMSO-D6) δ 1.41-1.94(m, 8H), 2.37-2.78(m, 8H), 3.32(s, 3H),
4.38-4.46(m, 1H), 6.96-7.78(m, 5H)
333 (I)(CDCl3) δ 1.80-1.96(m, 5H), 2.38(s, 4H), 2.41-3.00(m, 12H), 3.57-3.60
(m, 1H), 4.26(s, 1H), 4.73-4.76(m, 1H), 6.73-7.32(m, 3H)
334 (I)(DMSO-D6) δ 1.33-1.93(m, 8H), 2.33-3.27(m, 7H), 4.39-4.45(m,
1H), 4.49-4.53(m, 1H), 6.96-8.98(m, 5H)
335 (I)(CDCl3) δ 1.16-1.30(m, 1H), 1.33-1.48(m, 1H), 1.76-2.75(m,
12H), 2.96-3.05(m, 1H), 3.72(s, 2H), 3.89-3.93(m, 1H), 4.21-4.30
(m, 1H), 4.66-4.71(m, 1H), 6.72-7.32(m, 7H)
336 (I)(DMSO-D6) δ 1.37-2.83(m, 17H), 4.38-4.47(m, 1H), 5.76(s, 1H),
6.96-7.96(m, 6H)
337 (I)(DMSO-D6) δ 1.33-1.99(m, 8H), 2.36-2.60(m, 4H), 2.73-2.82(m,
2H), 2.94(s, 3H), 2.98-3.09(m, 1H), 3.55-3.66(m, 1H), 4.38-4.46
(m, 1H), 4.56(s, 2H), 6.96-7.00(m, 1H), 7.23-7.27(m, 1H), 7.41-7.52
(m, 5H)
338 (I)(DMSO-D6) δ 1.35-1.99(m, 8H), 2.37-2.46(m, 2H), 2.55-2.63(m,
2H), 2.73-2.85(m, 2H), 2.92(s, 3H), 2.97-3.06(m, 1H), 3.55-3.65
(m, 1H), 4.41-4.49(m, 1H), 4.56(s, 2H), 6.96-7.01(m, 1H), 7.25-7.27
(m, 1H), 7.39-7.52(m, 5H)
1 (III)δ(DMSO-D6) 1.57-1.36(2H, m), 2.25-1.87(5H, m), 2.45-2.33(2H,
m), 3.16-2.97(2H, m), 3.37-3.17(4H, m), 3.45-3.40(1H, m), 4.12
(0H, t), 4.53(1H, d), 4.67-4.58(1H, m), 4.84-4.77(1H, m), 5.45(1H,
d), 7.03(1H, ddd), 7.19(2H, t), 7.42-7.33(3H, m), 7.55(1H, m), 10.59-10.38
(1H, m)
2 (III)δ(DMSO-D6) 1.60-1.36(2H, m), 2.27-1.93(5H, m), 2.61-2.57(1H,
m), 2.90-2.73(1H, m), 3.13-2.94(2H, m), 3.41-3.23(3H, m), 4.17-3.85
(2H, m), 4.68-4.47(2H, m), 4.84-4.77(1H, m), 5.43(1H, d), 7.09-6.99
(1H, m), 7.40-7.27(6H, m), 7.55(1H, t), 11.13-10.92(1H, m)
3 (III)δ(DMSO-D6) 1.27-1.07(1H, m), 1.57-1.36(1H, m), 2.24-1.89(5H,
m), 2.66-2.56(1H, m), 2.93-2.79(1H, m), 3.16-3.00(2H, m), 3.51-3.39
(2H, m), 4.18(1H, t), 4.67-4.46(2H, m), 4.84-4.78(1H, m), 5.51-5.43
(1H, m), 6.05(1H, s), 7.04(1H, dd), 7.24-7.17(1H, m), 7.48-7.33
(3H, m), 7.55(1H, dd), 10.41-10.23(1H, m)
|
[0416]
13
TABLE VII
|
|
|
Compound
MP
|
(Table)
MS
(° C.)
1
H NMR
Can be prepared using:
|
|
3 (IV)
495
181-182
(DMSO-D6) δ 1.2-2.8(bm, 14H), 3.1(bm, 1H), 3.35(s, 3H), 3.5(bm,
Example 12
|
(M + H)
1H), 4.4(m, 1H), 4.5(bm, 1H), 6.82(dd, 1H), 7.1(dd, 1H), 7.4(t, 1H),
|
7.7(m, 2H), 7.9(s, 1H), 8.0(dd, 1H)
|
2 (IV)
495
111-112
(DMSO-D6) δ 1.6-2.3(bm, 8H), 3.0-3.6(bm, 8H), 3.3(s, 3H), 4.5-4.8
Example 12 and final product
|
(M + H)
(m, 2H), 6.9-7.1(m, 1H), 7.2-7.4(m, 2H), 7.8(m, 2H), 7.94(d, 1H),
isolated as Hydrochloride by
|
8.03(d, 1H), 10.9(bm, 1H)
treatment with a solution of HCl in
|
dioxan and evaporation.
|
7 (IV)
459
149-150
(DMSO-D6) δ 1.2-3.7(bm, 16H), 3.75(s, 3H), 3.85(bm, 1H), 4.6(bm,
As for 2 (IV) above
|
(M + H)
1H), 5.05(bm, 1H), 6.9(m, 4H), 7.78(m, 2H), 7.92(d, 1H), 8.05(m,
|
1H), 11.0 and 11.8(bm, 1H)
|
8 (IV)
463
126-127
(DMSO-D6) δ 1.2-3.6(bm, 16H), 3.9(bm, 1H), 4.6 bm, 1H), 5.14
As for 2 (IV) above
|
(M + H)
(bm, 1H), 7.0(d, 2H), 7.38(d, 2H), 7.75(m, 2H), 7.9(m, 1H), 8.05(m,
|
1H), 11.3 and 11.95(bm, 1H)
|
9 (IV)
497
78-80
(DMSO-D6) δ 1.2-4.0(bm, 17H), 4.6(bm, 1H), 5.2(bm, 1H), 7.0(dd,
As for 2 (IV) above
|
(M + H)
1H), 7.3(m, 1H), 7.58(d, 1H), 7.78(d, 2H), 7.95(d, 1H), 8.05(m,
|
1H) 11.0 and 11.65(bm, 1H)
|
10 (IV)
454
78-80
(DMSO-D6) δ 1.2-3.6(m, 17H), 4.25(bm, 1H), 4.98(m, 1H), 7.03(d,
Example 12
|
(M + H)
2H), 7.72(m, 4H), 7.9(s, 1H), 8.0(m, 1H)
|
11 (IV)
465
82-83
(DMSO-D6) 1.2-3.4(m, 16H), 3.5(bm, 1H), 4.3(bm, 1H), 4.85(m,
Example 12
|
(M + H)
1H), 6.7(m, 1H), 7.0(m, 1H), 7.3(q, 1H), 7.7(m, 2H), 7.9(s, 1H), 8.0
|
(m, 1H)
|
12 (IV)
447
64-65
(DMSO-D6) δ 1.2-3.3(m, 16H), 3.45(bm, 1H), 4.25(m, 1H), 4.8(m,
Example 12
|
(M + H)
1H), 6.9(m, 2H), 7.1(t, 2H), 7.75(m, 2H), 7.9(s, 1H), 8.0(dd, 1H)
|
13 (IV)
500
110-111
(DMSO-D6) δ 1.2-4.8(bm, 24H), 6.95(dd, 2H), 7.5(m, 2H), 7.8(m,
As for 2 (IV) above
|
(M + H)
2H), 7.95(s, 1H), 8.02(d. 1H), 9.85(d, 1H), 10.7(bm, 1H)
|
14 (IV)
457
140-142
(DMSO-D6) δ 1.2-4.8(m, 24H), 6.86(bm, 2H), 7.02(m, 2H), 7.75
Example 12
|
(M + H)
(bm, 2H), 7.90(s, 1H), 8.03(bm, 1H)
|
15 (IV)
491
94-95
(DMSO-D6) δ 1.2-4.8(bm, 24 H). 6.8(bd, 1H), 7.0(bs, 1H), 7.3(d,
Example 12
|
(M + H)
1H), 7.75(m, 2H), 7.9(s, 1H), 8.0(m, 1H)
|
16 (IV)
477
150-152
(DMSO-D6) δ 1.2-4.6(bm, 21H), 7.0(bm, 2H), 7.3(bm, 2H), 7.75
Example 12.
|
(M + H)
(m, 2H), 7.9(s, 1H), 8.0(m, 1H)
|
17 (IV)
461
219-220
(DMSO-D6) δ 1.2-4.8(bm, 21 H), 6.9-7.3(m, 4H), 7.75(m, 2H), 7.92
As for 2 (IV) above
|
(M + H)
(s, 1 h), 8.02(m, 1H).
|
18 (IV)
511
104-105
(DMSO-D6) δ 1.2-5.0(bm, 21H), 7.3(d, 1H) 7.4(dd, 1H), 7.6(dd,
Example 12 and final product
|
(M + H)
1H), 7.75(m, 2H), 7.95(s, 1H), 8.0(d, 1H), 9.5 and 9.7(bs, 1H)
isolated as trifluoroacetate by
|
evaporation of Reverse Phase HPLC
|
fractions.
|
19 (IV)
495
76-77
(DMSO-D6) δ 1.2-5.0(bm, 21H), 7.2(m, 1H), 7.3(m, 1H), 7.45(m,
As for 18 (IV) above
|
(M + H)
1H), 7.75(m, 2H), 7.95(s, 1H), 8.05(m, 1H), 9.5(bm, 1H)
|
20 (IV)
479
230-232
(DMSO-D6) δ 1.2-3.7(bm, 19H), 4.4-4.7(bm, 2H), 7.02(t, 1H), 7.3
As for 2 (IV) above
|
(M + H)
(m, 2H), 7.75(m, 2H), 7.95(s, 1H), 8.02(d, 1H)
|
21 (IV)
495
69-70
(DMSO-D6) 1.2-4.0(m, 19 H), 4.4-4.8(m, 2H), 7.3(m, 2H), 7.5(m,
As for 18 (IV) above
|
(M + H)
1H), 7.75(m, 2H), 7.98(s, 1H), 8.0(m, 1H), 9.5(bm, 1H)
|
22 (IV)
475
130-132
(CDCl3) δ 1.0-3.6(m, 19H), 3.7(s, 3H), 4.6(m, 2H), 6.6-6.9(m, 3H),
As for 2 (IV) above
|
(M + H)
7.7(m, 2H), 8.0(m, 2H)
|
24 (IV)
462
72-73
(DMSO-D6) 1.6(m, 2H), 1.8(m, 1H), 2.01(m, 4H), 2.3(m, 1H), 2.55
Example 13
|
(M + H)
(m, 2H), 2.9(m, 2H), 3.2(m, 2H), 3.4(m, 1H), 3.58(m, 2H), 3.8(s,
|
3H), 4.3(bs, 2H), 4.6 and 4.8(m, 1H), 6.7(d, 1H), 6.8-7.0(m, 3H), 7.2
|
(m, 1H), 7.5(m, 1H), 9.5(bs, 1H)
|
26 (IV)
458
111-112
(DMSO-D6) δ 1.4-3.6(m, 17H), 3.8(2s, 6H), 4.2-4.5(m, 3H), 6.7(m,
Example 13
|
(M + H)
2H), 6.82(m, 2H), 6.9-7.2(m, 2H)
|
27 (IV)
440
73-75
(DMSO-D6) δ 1.6-1.9(m, 3H), 2.0-2.3(m, 5H), 2.4-2.6(m, 2H), 2.9
Example 13
|
(M + H)
(m, 2H), 3.18(m, 2H), 3.4(m, 1H), 3.5(m, 2H), 3.7(s, 3H), 3.8(s,
|
3H), 4.2(bs, 2H), 4.4 and 4.6 (2m, 1H), 6.7(d, 1H), 6.9(m, 5H), 7.0
|
(d, 1H), 9.7(bm, 1H)
|
28 (IV)
462
81-83
(DMSO-D6) δ 1.6(m, 2H), 1.8(m, 1H), 2.05(m, 4H), 2.3(m, 1H), 2.5
Example 13
|
(M + H)
(m, 1H), 2.9(m, 2H), 3.2(m, 2H), 3.3(m, 2H), 3.4(m, 1H), 3.55(m,
|
2H), 3.8(s, 3H), 4.3(bs, 2H), 4.6 and 4.8(m, 1H), 6.62(d, 1H), 6.81
|
(d, 1H), 6.9(s, 1H), 7.05(m, 1H), 7.35(m, 2H), 9.76(bm, 1H)
|
29 (IV)
424
97-99
(DMSO-D6) δ 1.4-2.6(m, 14H), 2.9(m, 2H), 3.2(m, 2H), 3.4(m, 1H),
Example 13
|
(M + H)
3.55(m, 2H), 3.8(s, 3H), 4.3(bs, 2H), 4.5 and 4.7(m, 1H), 6.65(d,
|
1H), 6.9(m, 4H), 7.1(m, 1H), 9.5(bs, 1H)
|
30 (IV)
458
78-79
(DMSO-D6) δ 1.5-2.6(m, 13H), 2.3(s, 3H), 2.9(m, 2H), 3.2(m, 2H),
Example 13
|
(M + H)
3.4(m, 1H), 3.55(m, 2H), 4.3(bs, 2H), 4.55 and 4.75(m, 1H), 6.67
|
(d, 1H), 6.85(m, 3H), 7.0(dd, 1H), 7.32(t, 1H), 9.5(bs, 1H)
|
31 (IV)
444
100-101
(DMSO-D6) δ 1.6(m, 2H), 1.8(m, 1H), 2.0(m, 4H), 2.3(m, 1H), 2.5
Example 13
|
(M + H)
(m, 2H), 2.9(m, 2H), 3.18(m, 2H), 3.4(m, 1H), 3.5(m, 2H), 3.8(s,
|
3H), 4.2(bs, 2H), 4.6 and 4.8(m, 1H), 6.62(d, 1H), 6.8(m, 2H), 7.0
|
(m, 2H), 7.36(m, 2H), 9.7(bs, 1H)
|
32 (IV)
428
74-75
(DMSO-D6) 1.6(m, 2H), 1.8(m, 1H), 2.0(m, 4H), 2.3(m, 1H), 2.5
Example 13
|
(M + H)
(m, 2H), 2.9(m, 2H), 3.2(m, 2H), 3.4(m, 1H), 3.5(m, 2H), 3.8(s,
|
3H), 4.2(bs, 2H), 4.5 and 4.7(m, 1H), 6.7(d, 1H), 6.85(d, 1H), 6.9(s,
|
1H), 7.02(m, 1H), 7.04(m, 1H), 7.18(m, 2H), 9.6(m, 1H)
|
33 (IV)
478
117-119
(DMSO-D6) δ 1.6-3.6(m, 17H), 3.8(s, 3H), 4.25(bs, 2H), 4.6 and 4.9
Example 13
|
(M + H)
(m, 1H), 6.6(d, 1H), 6.8(m, 2H), 7.3(m, 1H), 7.4(m, 1H), 7.6(m,
|
1H), 9.5(bs, 1H)
|
34 (IV)
462
109-110
(DMSO-D6) δ 1.6-3.6(m, 17H), 3.8(s, 3H), 4.25(bs, 2H), 4.55 and
Example 13
|
(M + H)
4.85(m, 1H), 6.6(d, 1H), 6.8(m, 2H), 7.2(m, 1H), 7.3(m, 1H), 7.45
|
(m, 1H), 9.5(bs, 1H)
|
37 (IV)
442
89-90
(DMSO-D6) δ 1.6-3.6(m, 20H), 3.8(s, 3H), 4.25(bs, 2H), 4.45 and
Example 13
|
(M + H)
4.75(m, 1H), 6.6(d, 1H), 6.8(m, 2H), 7.0(m, 3H), 9.6(bs, 1H)
|
38 (IV)
471
143-145
(DMSO-D6) δ 1.6-3.6(m, 19H), 4.2-4.8(m, 2H), 7.0(m, 1H), 7.2(d,
As for 18 (IV) above
|
(M + H)
1H), 7.22(s, 1H), 7.8(d, 1H), 8.5(d, 1H), 8.8(s, 1H)
|
39 (IV)
475
141-142
(DMSO-D6) δ 1.6-3.6(m, 16H), 4.2-4.8(m, 2H), 6.9(m, 1H), 7.2(m,
As for 18 (IV) above
|
(M + H)
1H), 7.5(m, 1H), 7.8(d, 1H), 8.5(d, 1H), 8.8(d, 1H)
|
41 (IV)
471
160-162
(DMSO-D6) δ 1.6-3.6(m, 16H), 3.8(s, 3H), 4.2-4.8(m, 2H), 6.7(m,
As for 18 (IV) above
|
(M + H)
1H), 6.9-7.2(m, 2H), 7.8(d, 1H), 8.5(d, 1H), 8.8(d, 1H)
|
42 (IV)
453
116-118
(DMSO-D6) δ 1.6-3.6(m, 16H), 3.7(s, 3H), 4.2-4.8(m, 2H), 6.8-7.1
As for 18 (IV) above
|
(M + H)
(m, 3H), 7.82(d, 1H), 8.52(d, 1H), 8.8(d, 1H), 9.6(bs, 1H)
|
43 (IV)
475
109-110
(DMSO-D6) δ 1.6-3.6(m, 16H), 4.2-4.8(m, 2H), 7.07(m, 1H), 7.35
As for 18 (IV) above
|
(M + H)
(m, 2H), 7.82(d, 1H), 8.52(d, 1H), 8.8(d, 1H), 9.6(bs, 1H)
|
44 (IV)
437
136-137
(DMSO-D6) δ 1.6-3.2(m, 15H), 3.3(s, 3H), 3.6(m, 1H), 4.22(m,
Example 12
|
(M + H)
1H), 4.5(m, 1H), 6.8(d, 2H), 7.10(d, 2H), 7.82(d, 1H), 8.52(d, 1H),
|
8.8(d, 1H)
|
89 (IV)
471
100-102
(DMSO-D6) δ 1.0-4.2(m, 21H), 6.0(m, 1H), 6.18(m, 1H), 6.42(m,
As for 18 (IV) above
|
(M + H)
1H), 7.02(d, 1H), 7.6(d, 1H), 7.85(d, 1H)
|
47 (IV)
441
133-136
(DMSO-D6) δ 1.6-4.8(m, 18H), 6.9-7.2(m, 4H), 7.82(d, 1H), 8.52(d,
As for 18 (IV) above
|
(M + H)
1H), 8.8(d, 1H)
|
48 (IV)
491
105-106
(DMSO-D6) δ 1.6-4.8(m, 18H), 6.3(d, 1H), 6.4(d, 1H), 6.58(s, 1H),
As for 18 (IV) above
|
(M + H)
6.9(d, 1H), 7.52(d, 1H), 7.8(d, 1H)
|
49 (IV)
475
123-125
(DMSO-D6) δ 1.6-4.8(m, 18H), 7.2(m, 1H), 7.3(m, 1H), 7.45(m,
As for 18 (IV) above
|
(M + H)
1H), 7.82(d, 1H), 8.52(d, 1H), 8.8(d, 1H)
|
50 (IV)
459
93-94
(DMSO-D6) δ 1.6-4.8(m, 18H), 7.05(m, 1H), 7.3(m, 2H), 7.82(d,
As for 18 (IV) above
|
(M + H)
1H), 8.52(d, 1H), 8.8(d, 1H), 9.7(bm, 1H)
|
271 (IV)
507
102-103
(DMSO-D6) δ 1.6-3.8(m, 16H), 3.3(s, 3H), 3.8(d, 3H), 4.4-4.7(m,
Example 12
|
(M + H)
2H), 6.95(m, 1H), 7.1(m, 2H), 7.78(m, 2H), 7.95(s, 1H), 8.03(d,
|
1H)
|
272 (IV)
505
97-98
(DMSO-D6) δ 1.6-4.8(m, 27H), 7.1(s, 2H), 7.6(m, 2H), 7.95(s, 1H),
As for 18 (IV) above
|
(M + H)
8.03(d, 1H)
|
273 (IV)
511
110-112
(DMSO-D6) δ 1.4-3.8(m, 16H), 3.3(s, 3H), 4.4-5.0(m, 2H), 7.22(m,
As for 18 (IV) above
|
(M + H)
2H), 7.3(m, 1H), 7.75(m, 2H), 7.95(s, 1H), 8.02(d, 1H)
|
274 (IV)
511
114-115
(DMSO-D6) δ 1.4-3.8(m, 16H), 3.3(s, 3H), 4.4-5.0(m, 2H), 7.02(m,
Example 12
|
(M + H)
1H), 7.4(m, 2H), 7.75(m, 2H), 7.95(s, 1H), 8.02(d, 1H)
|
275 (IV)
491
88-89
(DMSO-D6) δ 1.4-3.8(m, 16H), 2.25(s, 3H), 3.3(s, 3H), 4.2-4.8(m,
Example 12
|
(M + H)
2H), 7.02(m, 2H), 7.22(m, 1H), 7.75(m, 2H), 7.95(s, 1H), 8.02(d,
|
1H)
|
276 (IV)
491
182-183
(DMSO-D6) δ 1.4-3.8(m, 16H), 2.25(s, 3H), 3.3(s, 3H), 4.4-4.6(m,
Example 12
|
(M + H)
2H), 6.74(d, 1H), 7.02(s, 1H), 7.22(d, 1H), 7.75(m, 2H), 7.90(s,
|
1H), 8.0(d, 1H)
|
277 (IV)
499
162-164
(DMSO-D6) δ 1.6-3.8(m, 19H), 2.25(s, 3H), 3.3(s, 3H), 4.5-5.0(m,
As for 2 (IV) above
|
(M + H)
2H), 7.14(t, 1H), 7.8(m, 4H), 7.95(m, 1H), 8.02(d, 1H), 10.9(bm,
|
1H)
|
278 (IV)
528
120-122
(DMSO-D6) δ 1.5-5.0(m, 29H), 6.9-7.2(m, 4H), 7.75(m, 2H), 7.95
As for 2 (IV) above
|
(M + H)
(s, 1H), 8.02(d, 1H), 10.2(bs, 1H), 11.0-11.3(bm, 1H)
|
279 (IV)
505
97-99
(DMSO-D6) δ 1.18(t, 3H), 1.6-3.7(m, 17H), 2.62(q, 2H), 3.3(s, 3H),
Example 12
|
(M + H)
4.4-4.8(m, 1H), 6.8-7.1(m, 2H), 7.3(m, 1H), 7.75(m, 2H), 7.95(s,
|
1H), 8.02(m, 1H), 9.4(bs, 1H)
|
280 (IV)
494
138-140
(DMSO-D6) δ 1.8(m, 2H), 2.1-4.4(m, 14H), 3.3(s, 3H), 4.62(bm,
As for 2 (IV) above
|
(M + H)
1H), 4.9 and 5.1(m, 1H), 7.65(m, 1H), 7.8(m, 2H), 7.85(m, 2H), 7.95
|
(d, 1H), 8.01(d, 1H), 8.3(t, 1H), 9.0(t, 1H), 9.15(t, 1H), 10.35(bs,
|
1H), 11.5(bs, 1H)
|
281 (IV)
499
98-99
(DMSO-D6) δ 1.2(s, 9H), 1.3-3.6(m, 20H), 4.5(m, 1H), 6.8(t, 1H),
Example 12
|
(M + H)
6.9(d, 1H), 7.1(t, 1H), 7.2(d, 1H), 7.7(m, 2H), 7.9(s, 1H), 8.0(d,
|
1H)
|
282 (IV)
483
79-80
(DMSO-D6) δ 1.2-3.6(m, 22H), 3.3(s, 3H), 4.22 and 4.5(m, 2H),
Example 12
|
(M + H)
6.67(d, 1H), 6.8(s, 1H), 7.08(d, 1H), 7.75(m, 2H), 7.9(s, 1H), 8.0(d,
|
1H)
|
283 (IV)
559
113-115
(DMSO-D6) δ 1-1.48(m, 29H), 3.3(s, 3H), 7.0(m, 1H), 7.18(m, 2H),
Example 12
|
(M + H)
7.75(m, 2H), 7.9(s, 1H), 8.0(m, 1H)
|
284 (IV)
520
111-112
(DMSO-D6) δ 1.6-4.0(m, 19H), 4.6 and 4.9(m, 2H), 7.2(m, 1H), 7.4-7.8
As for 18 (IV) above
|
(M + H)
(m, 6H), 7.95(s, 1H), 8.02(d, 1H), 9.5(bm, 1H)
|
285 (IV)
544
111-112
(DMSO-D6) δ 1.6-3.2(m, 15H), 3.3(s, 3H), 3.5(m, 1H), 4.5 and 4.6
Example 12
|
(M + H)
(m, 2H), 6.9(d, 1H), 7.35(d, 1H), 7.5(dd, 1H), 7.75(m, 2H), 7.81(d,
|
1H), 7.9(s, 1H), 8.0(dd, 1H), 8.68(d, 1H)
|
286 (IV)
491
115-117
(DMSO-D6) δ 1.6-3.2(m, 16H), 3.3(s, 3H), 3.35-3.6(m, 3H), 4.4-4.9
Example 12
|
(M + H)
(m, 2H), 6.9(m, 1H), 7.0-7.2(m, 2H), 7.75(m, 2H), 7.92(s, 1H),
|
8.02(m, 1H)
|
287 (IV)
443
142-144
(DMSO-D6) δ 1.6-3.4(m, 14H), 3.3(s, 3H), 3.4-3.7(m, 2H), 4.6-4.8
Example 12
|
(M + H)
(m, 2H), 7.0(m, 3H), 7.3(m, 2H), 7.75(m, 2H), 7.92(s, 1H), 8.04(dd,
|
1H)
|
288 (IV)
525
84-86
(DMSO-D6) δ 1.6-3.4(m, 22H), 4.2-4.7(m, 2H), 7.38(d, 1H), 7.5(d,
As for 18 (IV) above
|
(M + H)
1H), 7.75(m, 2H), 7.95(s, 1H), 8.02(m, 1H)
|
289 (IV)
491
149-151
(DMSO-D6) δ 1.3-2.0(m, 8H), 2.22(s, 3H), 2.3-2.6(m, 4H), 2.8(m,
Example 12
|
(M + H)
2H), 3.1(m, 1H), 3.3(s, 3H), 3.5(m, 1H), 4.3-4.6(m, 2H), 6.84(dd,
|
1H), 7.0(d, 1H), 7.2(m, 1H), 7.75(m, 2H), 7.9(s, 1H), 8.0(dd, 1H)
|
290 (IV)
502
93-95
(DMSO-D6) δ 1.6-4.0(m, 16H), 3.3(s, 3H), 4.4-5.1(m, 2H), 7.4(t,
As for 18 (IV) above
|
(M + H)
1H), 7.8(m, 3H), 7.9-8.1(m, 3H), 9.5-10.0(bm, 1H)
|
293 (IV)
445
66-68
(DMSO-D6) δ 1.6-3.0(m, 7H), 2.8(m, 1H), 3.2(m, 3H), 3.3(s, 3H),
Example 15
|
(M + H)
3.4-3.7(m, 4H), 4.62(m, 1H), 5.1-5.4(m, 2H), 7.2(m, 1H), 7.8(m,
|
2H), 7.95(m, 1H), 8.02(d, 1H), 8.6(m, 2H), 9.5(bs, 1H)
|
339 (I)
(M + H)
foam
(DMSO-D6) δ 1.42-1.70(m, 5H), 1.84-1.94(m, 3H), 2.35-2.42
Example 2 step c
|
458
(m, 2H), 2.54-2.62(m, 1H), 2.73-2.87(m, 3H), 3.02-3.10(m, 1H),
|
3.30-3.36(m, 1H), 4.39-4.44(m, 1H), 4.53-4.57(m, 1H), 6.95-6.99
|
(m, 1H), 7.24-7.25(m, 1H), 7.47-7.50(m, 1H), 7.56-7.67(m,
|
2H), 7.77-7.82(m, 1H), 7.94-7.96(m, 1H)
|
340 (I)
(M + H)
156-157
(DMSO-D6) δ 1.40-1.99(m, 8H), 2.35-2.46(m, 2H), 2.54-2.62
Example 2 step c
|
484
(m, 1H), 2.73-2.85(m, 3H), 3.02-3.13(m, 1H), 3.60-3.72(m, 1H),
|
4.39-4.47(m, 1H), 4.51-4.64(m, 1H), 6.96-7.00(m, 1H), 7.25-7.26
|
(m, 1H), 7.50(d, 1H), 7.59-7.63(m, 1H), 7.74-7.78(m, 1H),
|
8.06-8.09(m, 2H), 8.45-8.48(m, 1H), 8.96-8.98(m, 1H)
|
341 (I)
(M + H)
127-129
(DMSO-D6) δ 1.44-1.99(m, 8H), 2.40-2.48(m, 2H), 2.58-2.67
Example 2 step c using Quinoxaline-
|
485
(m, 1H), 2.75-2.90(m, 3H), 3.04-3.16(m, 1H), 3.56-3.69(m, 1H),
6-carboxylic acid (obtained from
|
4.40-4.49(m, 1H), 4.53-4.63(m, 1H), 6.96-7.00(m, 1H), 7.26-7.27
hydrolysis of the commercially
|
(m, 1H), 7.48-7.51(m, 1H), 7.85-7.88(m, 1H), 8.09-8.11(m,
available Quinoxaline-6-carboxylic
|
1H), 8.16-8.19(m, 1H), 9.01(s, 2H)
acid methyl ester)
|
342 (I)
(M + H)
foam
(DMSO-D6) δ 1.36-1.44(2H, m), 1.55-1.61(2H, m), 1.76-1.82
Example 2 step using 3-Amino-4-
|
532
(2H, m), 1.89-1.96(2H, m), 2.34-2.41(3H, m), 2.72-2.80(2H, m),
methanesulfonyl-thiophene-2-
|
2.95(2H, t), 3.21(3H, s), 4.15-4.22(2H, m), 4.38-4.46(1H, m), 5.87
carboxylic acid (obtained from
|
(2H, s), 6.96-6.99(2H, m), 7.24-7.26(2H, m), 7.49(1H, d), 8.34
hydrolysis of the commercially
|
(1H, s)
available 3-Amino-4-
|
methanesulfonyl-thiophene-2-
|
carboxylic acid methyl ester)
|
63 (IV)
491
127-129
(DMSO-D6) δ 1.42-1.96(8H, m), 2.26(3H, s), 2.32-2.41(2H, m),
Example 2 step c
|
(M + H)
2.53-2.59(2H, m), 2.67-3.11(4H, m), 3.24(3H, s), 4.28-4.35(2H,
|
m), 6.77-6.81(1H, m), 6.95(1H, d), 7.26(1H, dd), 7.50(1H, ddd),
|
7.70(1H, d), 7.76-7.82(1H, m), 7.98(1H, ddd)
|
79 (IV)
497
168-169
(DMSO-D6) δ 1.41-1.49(2H, m), 1.53-1.60(2H, m), 1.80(2H, d),
Example 2 step c
|
(M + H)
1.92(2H, dz), 2.27(3H, s), 2.38(2H, t), 2.54-2.62(2H, m), 2.77(2H,
|
t), 2.93-3.12(2H, m), 3.40(3H, s), 4.33(2H, dt), 6.80(1H, dd), 6.95
|
(1H, d), 7.26(1H, d), 7.49(1H, d), 7.77(1H, d)
|
423 (I)
(M + H)
181-183
(DMSO-D6) δ 1.44-1.63(6H, m), 1.91-1.98(3H, m), 2.36-2.39
Example 2 step c
|
499
(2H, m), 2.53-2.62(4H, m), 2.76-2.90(2H, m), 3.03-3.11(1H, m),
|
3.34-3.42(1H, m), 4.40-4.45(1H, m), 4.56-4.64(1H, m), 6.96-6.99
|
(1H, m), 7.24(1H, s), 7.48-7.51(1H, m), 7.61-7.65(1H, m),
|
8.39-8.47(2H, m), 9.06-9.08(1H, m)
|
578 (I)
(M + H)
145-147
(DMSO-D6) δ 1.33-1.45(2H, m), 1.53-1.64(2H, m), 1.76-1.94
Example 2 step c
|
473
(4H, m), 2.36-2.44(2H, m), 2.55-2.64(1H, m), 2.70-2.80(3H, m),
|
3.03-3.15(1H, m), 4.35-4.44(1H, m), 4.51-4.61(1H, m), 5.08-5.20
|
(1H, m), 6.93-7.00(2H, m), 7.25-7.34(2H, m), 7.45-7.50
|
(1H, m), 7.57-7.63(1H, m), 8.33(1H, s), 8.50-8.62(1H, m)
|
580 (I)
(M + H)
>200
(DMSO-D6) δ 1.43-1.65(4H, m), 1.85-1.96(3H, m), 2.32-2.41
Example 2 step c
|
500
(2H, m), 2.54-2.62(2H, m), 2.73-3.14(4H, m), 3.40-3.47(1H, m),
|
4.37-4.45(1H, m), 4.53-4.62(1H, m), 6.45(1H, d), 6.93-7.00(1H,
|
m), 7.17-7.26(2H, m), 7.33-7.59(4H, m), 11.99(1H, s)
|
419 (I)
(M + H)
>200
(DMSO-D6) δ 1.25-1.68(5H, m), 1.72-1.81(2H, m), 1.88-1.95
Example 2 step c
|
464
(2H, m), 2.22(3H, s), 2.31-2.40(2H, m), 2.60-2.78(3H, m), 2.92-3.00
|
(1H, m), 3.44-3.52(1H, m), 4.36-4.49(2H, m), 5.92-6.11(1H,
|
m), 6.91-7.06(1H, m), 7.25(1H, s), 7.30-7.41(1H, m), 7.44-7.54
|
(1H, m), 11.86(1H, s)
|
550 (I)
(M + H)
80-85
(DMSO-D6) δ 1.40-1.65(5H, m), 1.83-1.96(3H, m), 2.31-2.43
Example 2 step c
|
484
(2H, m), 2.50-2.56(1H, m), 2.69-2.92(4H, m), 3.08-3.17(1H, m),
|
4.36-4.42(1H, m), 4.65-4.73(1H, m), 6.94-7.00(1H, m), 7.19-7.25
|
(1H, m), 7.45-7.50(1H, m), 7.58-7.71(3H, m), 8.00-8.05
|
(1H, m), 8.39-8.46(1H, m), 8.91-8.96(1H, m)
|
426 (I)
(M + H)
158-159
(DMSO-D6) δ 1.36-1.45(2H, m), 1.53-1.61(2H, m), 1.72-1.79
Example 2 step c
|
464
(2H, m), 1.88-1.96(2H, m), 2.35-2.43(2H, m), 2.52-2.57(1H, m),
|
2.72-2.79(2H, m), 2.85-2.94(2H, m), 3.32-3.38(1H, m), 3.49
|
(3H, s), 3.99-4.12(1H, m), 4.34-4.51(1H, m), 6.36(1H, d), 6.90-7.06
|
(1H, m), 7.21-7.29(1H, m), 7.42-7.54(2H, m), 7.91-8.03(1H,
|
m)
|
416 (I)
(M + H)
133-135
(DMSO-D6) δ 1.38-1.45(2H, m), 1.53-1.60(2H, m), 1.66-1.84
Example 2 step c
|
448
(2H, m), 1.88-1.95(2H, m), 2.34-2.41(2H, m), 2.51-2.58(1H, m),
|
2.73-2.78(3H, m), 3.01-3.10(1H, m), 3.29-3.36(3H, m), 3.53-3.63
|
(1H, m), 4.38-4.53(2H, m), 6.94-7.01(1H, m), 7.21-7.28
|
(1H, m), 7.29-7.35(1H, m), 7.47-7.52(1H, m), 7.68-7.75(1H, m),
|
8.42-8.50(1H, m)
|
575 (I)
(M + H)
140-142
Example 2 step c
|
645
|
534 (I)
(M + H)
189-190
Example 2 step c
|
543
|
294 (IV)
(M + H)
foam
(CDCl3) δ 1.32-1.45(1H, m), 1.56-1.71(2H, m), 1.79-2.01(5H,
Example 2 step c
|
529
m), 2.46-2.61(3H, m), 2.79-2.87(3H, m), 2.92-3.16(4H, m), 3.36-3.42
|
(1H, m), 4.28-4.33(1H, m), 4.79(1H, t), 6.90(2H, dd), 7.12
|
(1H, dt), 7.49(1H, dd), 7.89(1H, ddd), 8.01(1H, dd)
|
67 (IV)
(M + H)
132-133
(CDCl3) δ 1.38-1.65(2H, m), 1.73-2.04(6H, m), 2.40-2.67(3H,
Example 2 step c
|
495
m), 2.72-2.89(3H, m), 2.99-3.08(1H, m), 3.23-3.28(3H, m), 3.33-3.53
|
(1H, m), 4.21-4.33(1H, m), 4.61-4.86(1H, m), 6.87-6.92(2H,
|
m), 7.10-7.14(1H, m), 7.31-7.37(1H, m), 7.55-7.70(2H, m), 8.07
|
(1H, td)
|
83 (IV)
(M + H)
foam
(CDCl3) δ 1.50-1.63(2H, m), 1.85-2.00(6H, m), 2.44-2.51(2H,
Example 2 step c
|
501
m), 2.56-2.66(1H, m), 2.80-2.88(2H, m), 3.01(2H, s), 3.20(3H, s),
|
4.27-4.51(3H, m), 6.91(2H, dd), 7.13(1H, dt), 7.23(1H, d), 7.63
|
(1H, d)
|
295 (IV)
(M + H)
(CDCl3) δ 1.75-2.03(10H, m), 2.18-2.19(3H, m), 2.44-2.54(2H,
Example 2 step c
|
491
m), 2.77-2.89(3H, m), 3.00-3.09(1H, m), 3.23-3.28(3H, m), 3.36-3.52
|
(1H, m), 4.63-4.85(1H, m), 6.70-6.75(1H, m), 7.05-7.11(2H,
|
m), 7.31-7.37(1H, m), 7.56-7.68(2H, m), 8.05-8.10(1H, m)
|
568 (I)
(M + H)
(DMSO-D6) δ 1.21-1.95(8H, m), 2.35-2.42(2H, m), 2.57-2.66
Example 2 step c
|
558
(1H, m), 2.72-2.77(2H, m), 3.08-3.17(1H, m), 4.08-4.13(1H, m),
|
4.29(2H, d), 4.40-4.46(3H, m), 6.96-7.00(1H, m), 7.25-7.26(1H,
|
m), 7.48-7.51(1H, m), 7.58-7.62(1H, m), 8.01-8.07(2H, m), 8.40-8.43
|
(1H, m), 8.75-8.78(2H, m)
|
296 (IV)
(M + H)
(CDCl3) δ 1.58-1.68(4H, m), 1.85(2H, s), 2.00(2H, s), 2.19(3H, s),
Example 2 step c
|
525
2.51-2.59(3H, m), 2.80-2.92(3H, m), 2.98-3.16(4H, m), 3.37-3.43
|
(1H, m), 4.33(1H, s), 4.76-4.85(1H, m), 6.72-6.74(1H, m),
|
7.06-7.12(2H, m), 7.45-7.53(1H, m), 7.88-7.91(1H, m), 8.00-8.02
|
(1H, m)
|
471 (I)
472
δ 1.40(m, 2H), 1.57(m, 2H), 1.79(m, 2H), 1.90(m, 2H), 2.40(m, 2H),
Example 2 step c
|
(M + H)
2.58(m, 1H), 2.79(m, 2H), 2.87(m, 2H), 4.30(d, 2H), 4.43(m, 1H),
|
6.97(dd, 1H), 7.13(m, 2H), 7.25(d, 1H), 7.43(d, 1H), 7.49(d, 1H),
|
7.65(m, 2H)
|
475 (I)
526
(DMSO-D6) δ 1.67-1.78(m, 2H), 1.95-2.09(m, 3H), 2.18-2.27
Example 2 step c
|
(M + H)
(m, 2H), 2.44(d 3H), 2.77-2.88(m, 1H), 3.08-3.19(m, 3H), 3.33-3.52
|
(m, 5H), 3.59-3.67(m, 1H), 4.60-4.68(m, 1H), 4.84(s, 1H),
|
7.05(ddd, 1H), 7.14-7.27(m, 1H), 7.37(dd, 1H), 7.55(t, 1H), 7.61
|
(q, 1H), 7.70-7.71(m, 2H), 7.78-7.80(m, 1H), 7.86-7.89(m, 1H),
|
569 (I)
512
(DMSO-D6) δ 1.65-1.80(m, 2H), 1.99-2.09(m, 2H), 2.19-2.30
Example 2 step c
|
(M + H)
(m, 3H), 2.77-2.90(m, 1H), 3.07-3.21(m, 3H), 3.30-3.37(m, 3H),
|
3.47-3.57(m, 2H), 3.59-3.71(m, 1H), 4.59-4.69(m, 1H), 4.82-4.86
|
(m, 1H), 7.05(ddd, 1H), 7.37(dd, 1H), 7.49(s, 2H), 7.55(t, 1H),
|
7.64-7.69(m, 2H), 7.84-7.86(m, 1H), 7.92(td, 1H)
|
477 (I)
507
(DMSO-D6) δ 1.64-1.78(m, 2H), 1.99-2.09(m, 2H), 2.17-2.29
Example 2 step c
|
(M + H)
(m, 3H), 2.70-2.85(m, 1H), 3.04-3.19(m, 3H), 3.28-3.38(m, 3H),
|
3.31(s, 3H), 3.46-3.55(m, 2H), 3.66(t, 2H), 4.12(t, 2H), 4.56-4.68
|
(m, 1H), 4.81-4.86(m, 1H), 6.94-6.97(m, 2H), 7.04(dd, 1H), 7.05
|
(ddd, 1H), 7.34-7.39(m, 2H), 7.55(t, 1H),
|
584 (I)
592
(CDCl3) δ 1.45(s, 9H), 1.48-1.67(m, 4H), 1.75-1.85(m, 2H), 1.90-2.03
Example 2 step c
|
(M + H)
(m, 3H), 2.42-2.51(m, 2H), 2.56(m, 1H), 2.71-2.84(m, 3H),
|
2.91-3.06(m, 1H), 3.54(q, 2H), 3.75-3.88(m, 1H), 4.03(t, 2H),
|
4.27(septet, 1H), 4.68-4.82(m, 1H), 4.93-5.01(m, 1H), 6.75(dd,
|
1H), 6.90-7.00(m, 3H), 7.25-7.32(m, 3H)
|
325 (I)
491
(DMSO-D6) δ 1.69-1.83(2H, m), 1.98-2.11(3H, m), 2.17-2.28
Example 2 step c using acid prepared
|
(M + H)
(3H, m), 2.81-2.92(1H, m), 3.08-3.21(3H, m), 3.47-3.59(2H, m),
according to Journal of Heterocyclic
|
3.61-3.71(1H, m), 4.61-4.73(2H, m), 4.82-4.86(1H, m), 7.05
chemistry, 1972, p1149
|
(1H, ddd), 7.37(1H, dd), 7.56(1H, t), 7.77(1H, ddd), 8.51(1H, s),
|
8.80(1H, d)
|
585 (I)
507
(DMSO-D6) δ 1.70-1.78(m, 2H), 2.00-2.09(m, 2H), 2.18-2.26
Example 2 step c, using 3-tert-
|
(M + H)
(m, 2H), 3.05-3.17(m, 2H), 3.24-3.40(m, 2H), 3.97-4.06(m, 2H),
butoxycarbonylmethoxy-benzoic
|
4.44-4.52(m, 2H), 4.59-4.70(m, 2H), 4.73(s, 2H), 4.81-4.86(m,
acid, followed by the addition of
|
1H), 4.91-4.93(m, 2H), 6.90-6.93(m, 1H), 6.96-7.04(m, 1H),
(1M) HCl in ether to form final
|
7.07-7.11(m, 1H), 7.17-7.20(m, 1H), 7.34-7.43(m, 2H), 7.52-7.55
compound as hydrochloride salt.
|
(m, 1H),
(HCl also cleaved tert-butyl ester to
|
leave acid.)
|
586 (I)
492
(DMSO-D6) δ 1.56-1.87(3H, m), 1.94-2.17(5H, m), 3.06-3.27(7H,
Prepared by deprotection of 584(I)
|
(M + H)
m), 3.50-3.78(3H, m), 4.19(2H, t), 4.57-4.69(1H, m), 4.80-4.85(1H,
using trifluoroacetic acid in
|
m), 6.98-7.10(4H, m), 7.34-7.44(2H, m), 7.57(1H, dd)
dichloromethane
|
588 (I)
551
145
(CDCl3) δ 0.09(2H, dd), 0.44(2H, dd), 0.83-0.89(1H, m), 1.67-1.78
Example 2 step c
|
(M + H)
(2H, m), 1.96-2.09(3H, m), 2.18-2.28(4H, m), 2.78-2.89(1H,
|
m), 3.08-3.20(4H, m), 3.34(2H, s), 3.47-3.65(3H, m), 4.59-4.68
|
(1H, m), 4.84(1H, s), 7.05(1H, ddd), 7.36(1H, dd), 7.55(1H, t), 7.73-7.81
|
(2H, m), 7.90(1H, t), 8.00(1H, d)
|
71 (IV)
497
(CDCl3) δ 1.56(2H, qd), 1.79-1.99(8H, m), 2.19(3H, s), 2.45-2.52
Example 2 step c
|
(M + H)
(2H, m), 2.60(1H, tt), 2.76-2.83(2H, m), 2.91-3.11(2H, m), 3.21
|
(3H, s), 4.28-4.35(1H, m), 6.74(1H, d), 7.05-7.12(2H, m), 7.24
|
(1H, d), 7.63(1H, d)
|
245 (IV)
486
120-126
(CDCl3) δ 1.45-1.61(2H, m), 1.80-2.03(6H, m), 2.19(3H, s), 2.45-2.53
Example 2 step c using 2-Oxo-2,3-
|
(M + H)
(2H, m), 2.54-2.62(1H, m), 2.79-3.09(4H, m), 3.80-3.99(1H,
dihydro-benzothiazole-6-carboxylic
|
m), 4.28-4.34(1H, m), 4.62-4.81(1H, m), 6.73(1H, d), 7.05-7.12
acid prepared according to Chem.
|
(3H, m), 7.30(1H, dd), 7.47(1H, d)
Pharm. Bull. 1988, 36, p2253
|
297 (IV)
526
115-117
(CDCl3) δ 1.42-1.64(2H, m), 1.78-1.87(3H, m), 1.93-2.01(3H,
Example 2 step c
|
(M + H)
m), 2.19(3H, s), 2.44-2.51(2H, m), 2.57(1H, tt), 2.75-2.88(3H,
|
m), 3.01-3.14(1H, m), 3.64-3.73(1H, m), 4.27-4.33(1H, m), 4.65 -4.74
|
(1H, m), 6.73(1H, d), 7.07(1H, dd), 7.11(1H, d), 7.52(1H, dd),
|
7.58(1H, d), 8.11(1H, d)
|
298 (IV)
480
120-126
(CDCl3) δ 1.31-1.66(2H, m), 1.70-2.05(6H, m), 2.19(3H, s), 2.38-2.60
Example 2 step c
|
(M + H)
(3H, m), 2.73-2.83(2H, m), 2.85-3.11(2H, m), 3.71-3.86(1H,
|
m), 4.26-4.35(1H, m), 4.76-4.92(1H, m), 6.73(1H, d), 7.07(1H,
|
dd), 7.11(1H, s), 7.19-7.34(1H, m), 7.57(1H, t), 7.59-7.68(1H, m),
|
7.73(1H, t), 8.46(1H, d)
|
214 (IV)
514
96
(CDCl3) δ 1.42-1.62(2H, m), 1.74-2.02(6H, m), 2.19(3H, s), 2.44-2.61
Example 2 step c
|
(M + H)
(3H, m), 2.75-2.85(3H, m), 2.95-3.11(1H, m), 3.42(2H, s),
|
3.45(3H, s), 3.78-3.93(1H, m), 4.26-4.36(1H, m), 4.64-4.81(1H,
|
m), 6.74(1H, d), 7.02-7.15(3H, m), 7.27(1H, s), 7.38(1H, d)
|
589 (I)
540
(CDCl3) δ 1.52-1.62(2H, m), 1.68(1H, d), 1.84(1H, d), 1.92(2H, d),
Example 2 step c
|
(M + H)
2.35-2.42(2H, m), 2.52-2.55(1H, m), 2.63(6H, s), 2.72-2.83(3H,
|
m), 2.99-3.13(2H, m), 3.46-3.56(2H, m), 4.38-4.45(1H, m), 4.49
|
(1H, d), 6.98(1H, dd), 7.25(1H, d), 7.49(1H, d), 7.73-7.75(2H, m),
|
7.81-7.83(1H, m), 8.31(1H, s)
|
590 (I)
556
(DMSO-D6) δ 1.43-1.62(4H, m), 1.66(1H, d), 1.85(1H, d), 1.89-1.97
Example 2 step c
|
(M + H)
(2H, m), 2.35-2.44(3H, m), 2.73-2.87(3H, m), 3.11(1H, t),
|
3.42(3H, s), 3.52(1H, d), 4.39-4.46(1H, m), 4.50(1H, d), 6.98(1H,
|
dd), 7.25(1H, d), 7.49(1H, d), 8.36(1H, t), 8.54(1H, t), 8.67(1H, t)
|
591 (I)
526
(DMSO-D6) δ 1.29-1.39(2H, m), 1.90(2H, d), 2.11-2.18(1H, m),
Example 2 step c
|
(M + H)
2.39(2H, t), 3.13(2H, t), 3.44-3.52(2H, m), 3.65-3.73(2H, m),
|
3.82-3.91(4H, m), 3.94-4.01(2H, m), 4.47-4.57(1H, m), 6.15
|
(1H, d), 6.88-6.93(1H, m), 6.95(1H, dd), 7.03(1H, d), 7.31(1H, t),
|
7.62-7.65(1H, m), 8.32-8.51(2H, m), 8.95(1H, t)
|
593 (I)
536
(DMSO-D6) δ 1.42-1.63(4H, m), 1.66(1H, d), 1.84(1H, d), 1.89-1.97
Example 2 step c
|
(M + H)
(2H, m), 2.32-2.45(1H, m), 2.50-2.61(2H, m), 2.72-2.87(3H,
|
m), 3.08(1H, t), 3.37(3H, s), 3.48(1H, d), 4.37-4.46(1H, m), 4.46-4.55
|
(1H, m), 6.98(1H, dd), 7.25(1H, d), 7.49(1H, d), 8.21(1H, t),
|
8.30(1H, t), 8.48(1H, t)
|
594 (I)
550
(DMSO-D6) δ 1.38-1.52(2H, m), 1.53-1.64(2H, m), 1.84(2H, d),
Example 2 step c
|
(M + H)
1.88-1.98(2H, m), 2.37-2.45(4H, m), 2.58-2.68(1H, m), 2.74-2.82
|
(3H, m), 3.17(3H, s), 4.37-4.50(2H, m), 6.99(1H, dd), 7.00-7.02
|
(1H, m), 7.26(1H, d), 7.49(1H, d), 7.61(1H, d), 7.70(1H, dd),
|
8.23(1H, d)
|
299 (IV)
525
(DMSO-D6) δ 1.38-1.5(2H, m), 1.60-1.70(2H, m), 1.81-2.00
Example 12
|
(M + H)
(2H, m), 2.40(3H, s), 2.41-3.31(9H, m), 3.35(3H, s), 3.41-3.58
|
(1H, m), 4.4-4.55(2H, m), 7.09(1H, d), 7.34(1H, d), 7.71(2H, m),
|
7.90(1H, s), 8.0(1H, m)
|
300 (IV)
489
(DMSO-D6) δ 1.10(3H, t), 1.35-1.50(2H, m), 1.58-1.70(2H, m),
Example 12
|
(M + H)
1.81-1.97(2H, m), 2.25-3.20(11H, m), 3.32(3H, s), 3.4-3.6(1H,
|
m), 4.25-4.6(2H, m), 6.85-7.00(3H, m), 7.63-7.78(2H, m), 7.90
|
(1H, s), 7.98-8.02(1H, m)
|
143 (IV)
465
(CDCl3) δ 1.63-1.74(2H, m), 1.78-1.88(3H, m), 1.92-2.04(3H,
Example 2 step c
|
(M + H)
m), 2.19(3H, s), 2.43-2.55(2H, m), 2.64(1H, tt), 2.76-2.94(3H,
|
m), 3.13-3.27(1H, m), 4.25-4.35(2H, m), 4.82-4.90(1H, m), 6.74
|
(1H, d), 7.07(1H, dd), 7.11(1H, d), 7.56(1H, dd), 7.85(1H, d), 8.25
|
(1H, dd), 8.32(1H, d), 9.19(1H, dd)
|
301 (IV)
530
(CDCl3) δ 1.57-1.71(2H, m), 1.80-1.91(3H, m), 1.95-2.06(3H,
Example 2 step c
|
(M + H)
m), 2.20(3H, s), 2.47-2.55(2H, m), 2.61-2.72(1H, m), 2.79-2.86
|
(2H, m), 2.91-3.35(2H, m), 3.08(3H, s), 4.28-4.37(1H, m), 4.69-4.80
|
(2H, m), 6.74(1H, d), 6.90(1H, d), 7.07(1H, dd), 7.12(1H, d),
|
7.57(1H, d), 7.79(1H, dd), 8.32(1H, d)
|
572 (I)
500
(CDCl3) δ 1.37-1.66(2H, m), 1.73-1.88(3H, m), 1.93-2.05(3H,
Example 2 step c
|
(M + H)
m), 2.41-2.51(2H, m), 2.52-2.63(1H, m), 2.75-2.86(2H, m), 2.86-3.09
|
(2H, m), 3.71-3.90(1H, m), 4.23-4.32(1H, m), 4.77-4.93(1H,
|
m), 6.75(1H, dd), 6.99(1H, d), 7.27-7.32(3H, m), 7.54-7.67(1H,
|
m), 7.57(1H, t), 7.74(1H, t), 8.46(1H, d)
|
120 (IV)
480
(CDCl3) δ 1.46-1.66(2H, m), 1.79-2.01(6H, m), 2.19(3H, s), 2.45-2.52
Example 2 step c using acid available
|
(M + H)
(2H, m), 2.59(1H, tt), 2.75-2.84(2H, m), 2.92-3.20(2H, m),
from Bionet Research Ltd., Highfield
|
3.74-4.00(1H, m), 4.27-4.35(1H, m), 4.55-4.90(1H, m), 6.49
Industrial Estate, Camelford,
|
(1H, dd), 6.74(1H, d), 7.07(1H, dd), 7.11(1H, d), 7.76(1H, d), 7.88
Cornwall, PL32 9QZ, United
|
(1H, dd), 8.03(1H, d), 8.48(1H, d), 8.57(1H, d)
Kingdom
|
145 (IV)
538
(CDCl3) δ 1.35-1.73(2H, m), 1.77-1.89(3H, m), 1.92-2.06(3H,
Example 2 step c using acid available
|
(M + H)
m), 2.19(3H, s), 2.43-2.64(3H, m), 2.74-2.83(2H, m), 2.83-2.94
from Peakdale Inc.
|
(1H, m), 3.00-3.12(1H, m), 3.38-3.54(1H, m), 4.26-4.35(1H, m),
109 East Scotland Drive
|
4.76-4.92(1H, m), 6.73(1H, d), 7.07(1H, dd), 7.11(1H, d), 7.70
Bear, DE, 19701-1756
|
(1H, d), 7.98(1H, dd), 8.19(1H, d)
USA
|
240 (IV)
465
(CDCl3) δ 1.62-1.74(2H, m), 1.77-1.86(3H, m), 1.93-2.03(3H,
Example 2 step c
|
(M + H)
m), 2.33(3H, s), 2.41-2.54(2H, m), 2.65(1H, tt), 2.78-2.86(1H,
|
m), 2.89(2H, td), 3.21(1H, td), 4.21-4.35(2H, m), 4.81-4.90(1H,
|
m), 6.67(1H, dd), 6.78(1H, d), 7.20(1H, d), 7.57(1H, dd), 7.85(1H,
|
d), 8.25(1H, dd), 8.32(1H, d), 9.19(1H, dd)
|
267 (IV)
453
(CDCl3) δ 1.62(2H, qd), 1.79-2.01(6H, m), 2.19(3H, s), 2.43-2.52
Example 2 step c
|
(M + H)
(2H, m), 2.64(1H, tt), 2.74-2.85(2H, m), 3.12-3.22(1H, m), 4.26-4.32
|
(1H, m), 4.77-4.86(1H, m), 5.24-5.33(1H, m), 6.74(1H, d),
|
6.84(1H, td), 7.07(1H, dd), 7.11(1H, d), 7.21(1H, dd), 7.23(1H, dd),
|
7.60(1H, dd), 8.06(1H, d), 8.13(1H, dt)
|
199 (IV)
470
(CDCl3) δ 1.57-1.67(2H, m), 1.81-1.88(2H, m), 1.93-2.01(4H,
Example 2 step c
|
(M + H)
m), 2.20(3H, s), 2.50(2H, td), 2.65(1H, tt), 2.82(2H, td), 2.96-3.20
|
(2H, m), 4.28-4.35(1H, m), 4.74(2H, d), 6.73-6.75(2H, m), 7.01-7.12
|
(3H, m), 7.28(1H, d), 7.35(1H, dd), 9.35(1H, s)
|
181 (IV)
538
(CDCl3) δ 1.50-1.65(2H, m), 1.70-1.83(3H, m), 1.93-2.04(3H,
Example 2 step c
|
(M + H)
m), 2.32(3H, s), 2.40-2.50(2H, m), 2.52-2.62(1H, m), 2.76-2.92
|
(3H, m), 3.01-3.10(1H, m), 3.38-3.52(1H, m), 4.22-4.30(1H, m),
|
4.77-4.90(1H, m), 6.67(1H, dd), 6.77(1H, d), 7.20(1H, d), 7.70
|
(1H, d), 7.98(1H, dd), 8.19(1H, d)
|
216 (IV)
526
(CDCl3) δ 1.47-1.66(2H, m), 1.79-1.88(3H, m), 1.95-2.04(3H,
Example 2 step c
|
(M + H)
m), 2.32(3H, s), 2.53-2.61(2H, m), 2.70(1H, tt), 2.76-2.89(3H,
|
m), 2.99-3.13(1H, m), 3.63-3.74(1H, m), 4.27-4.33(1H, m), 4.63-4.77
|
(1H, m), 6.67(1H, dd), 6.77(1H, d), 7.20(1H, d), 7.50(1H, dd),
|
7.56(1H, d), 8.09(1H, d)
|
266 (IV)
480
(CDCl3) δ 1.37-1.67(2H, m), 1.76-1.85(3H, m), 1.93-2.01(3H,
Example 2 step c
|
(M + H)
m), 2.32(3H, s), 2.41-2.48(2H, m), 2.50-2.60(1H, m), 2.77-2.85
|
(2H, m), 2.86-3.10(2H, m), 3.73-3.85(1H, m), 4.23-4.29(1H, m),
|
4.77-4.92(1H, m), 6.67(1H, dd), 6.77(1H, d), 7.20(1H, d), 7.21-7.31
|
(1H, m), 7.54-7.68(1H, m), 7.56(2H, t), 7.73(1H, t), 8.46(1H,
|
d)
|
540 (I)
485
(CDCl3) δ 1.69-1.84(4H, m), 1.95-2.02(4H, m), 2.43-2.53(2H,
Example 2 step c
|
(M + H)
m), 2.65(1H, tt), 2.79-2.93(3H, m), 3.18-3.25(1H, m), 4.23-4.35
|
(2H, m), 4.82-4.90(1H, m), 6.75(1H, dd), 7.00(1H, d), 7.31(1H, d),
|
7.57(1H, dd), 7.86(1H, d), 8.25(1H, dd), 8.32(1H, d), 9.19(1H, dd)
|
204 (IV)
470
(CDCl3) δ 1.57-1.67(2H, m), 1.77-1.85(2H, m), 1.94-2.02(4H,
Example 2 step c
|
(M + H)
m), 2.33(3H, s), 2.45-2.52(2H, m), 2.61-2.69(1H, m), 2.81-2.86
|
(2H, m), 2.97-3.18(2H, m), 4.24-4.30(1H, m), 4.74(2H, d), 6.68
|
(1H, dd), 6.73(1H, d), 6.78(1H, d), 7.04(1H, td), 7.20(1H, d), 7.28
|
(1H, d), 7.35(1H, dd), 9.34(1H, s).
|
104 (IV)
480
(CDCl3) δ 1.49-1.63(2H, m), 1.76-2.00(6H, m), 2.33(3H, s), 2.43-2.49
Example 2 step c
|
(M + H)
(2H, m), 2.59(1H, tt), 2.79-2.85(3H, m), 3.00-3.18(1H, m),
|
3.81-3.96(1H, m), 4.24-4.29(1H, m), 4.67-4.83(1H, m), 6.49
|
(1H, dd), 6.67(1H, dd), 6.78(1H, d), 7.20(1H, d), 7.76(1H, d), 7.88
|
(1H, dd), 8.03(1H, d), 8.48(1H, d), 8.57(1H, d)
|
243 (IV)
486
(DMSO-D6/CDCl3) δ 1.43-1.59(2H, m), 1.73-1.98(6H, m), 2.32
Example 2 step c
|
(M + H)
(3H, s), 2.43-2.48(2H, m), 2.79-2.87(2H, m), 2.91-3.40(5H, m),
|
4.23-4.30(1H, m), 6.68(1H, dd), 6.78(1H, d), 7.14(1H, d), 7.19
|
(1H, d), 7.26(1H, dd), 7.43(1H, d), 7.51(1H, s).
|
191 (IV)
514
(CDCl3) δ 1.46-1.59(2H, m), 1.76-2.00(6H, m), 2.32(3H, s), 2.44-2.48
Example 2 step c
|
(M + H)
(2H, m), 2.54-2.59(1H, m), 2.78-2.85(3H, m), 3.42(3H, s),
|
3.45(3H, s), 3.79-3.92(1H, m), 4.23-4.30(1H, m), 4.67-4.79(1H,
|
m), 6.67(1H, dd), 6.77(1H, d), 7.02(1H, d), 7.15(1H, s), 7.20(1H, d),
|
7.37(1H, d)
|
519 (I)
490
(CDCl3) δ 1.61(2H, qd), 1.77-1.85(2H, m), 1.94-2.02(4H, m), 2.38-2.51
Example 2 step c
|
(M + H)
(2H, m), 2.65(1H, tt), 2.80-2.85(2H, m), 2.95-3.14(2H, m),
|
4.25-4.30(1H, m), 4.73-4.77(2H, m), 6.73(1H, d), 6.75(1H, dd),
|
7.00(1H, d), 7.03(1H, td), 7.27(1H, dd), 7.31(1H, d), 7.35(1H, dd),
|
9.49(1H, s)
|
494 (I)
558
(CDCl3) δ 1.48-1.71(2H, m), 1.74-1.83(3H, m), 1.93-2.03(3H,
Example 2 step c
|
(M + H)
m), 2.42-2.50(2H, m), 2.55-2.62(1H, m), 2.76-2.93(3H, m), 3.01-3.10
|
(1H, m), 3.40-3.50(1H, m), 4.22-4.31(1H, m), 4.77-4.90(1H,
|
m), 6.75(1H, dd), 6.98(1H, d), 7.30(1H, d), 7.67(1H, d), 7.98(1H,
|
dd), 8.19(1H, d)
|
238 (IV)
511
172-173
(CDCl3) δ 1.53-1.63(2H, m), 1.82-1.89(3H, m), 2.00-2.05(3H,
Example 21
|
(M + H)
m), 2.05-2.61(3H, m), 2.80-2.84(3H, m), 2.98-3.09(1H, m), 3.03
|
(3H, s), 3.77(1H, br s), 4.41-4.45(1H, m), 4.70(1H, br s), 6.99(2H,
|
d), 7.21-7.26(1H, m), 7.44-7.54(2H, m), 7.86(2H, d)
|
496 (I)
500
(DMSO-D6) δ 1.46(2H, qd), 1.54-1.61(2H, m), 1.65-1.88(3H, m),
Example 2 step c
|
(M + H)
1.89-1.97(2H, m), 2.37-2.42(2H, m), 2.54-2.61(1H, m), 2.73-2.83
|
(2H, m), 3.04-3.17(1H, m), 3.61-3.72(1H, m), 4.39-4.56(2H,
|
m), 6.62(1H, dd), 6.98(1H, dd), 7.25(1H, d), 7.49(1H, d), 7.87(1H,
|
dd), 7.97(1H, dd), 8.04(1H, dd), 8.52(1H, dd), 8.65(1H, dd)
|
483 (I)
506
(DMSO-D6) δ 1.41(2H, qd), 1.53-1.62(2H, m), 1.68-1.82(2H, m),
Example 2 step c
|
(M + H)
1.89-1.96(2H, m), 2.36-2.43(3H, m), 2.53-2.59(3H, m), 2.74-2.80
|
(3H, m), 4.39-4.45(1H, m), 6.97(1H, dd), 7.13(1H, d), 7.25
|
(1H, d), 7.30(1H, dd), 7.49(1H, d), 7.66(1H, d)
|
302 (IV)
498
(CDCl3) δ 1.40-1.74(2H, m), 1.79-2.02(6H, m), 2.20(3H, s), 2.42-2.61
Example 2 step c
|
(M + H)
(3H, m), 2.67(1H, td), 2.74-2.84(2H, m), 3.16(1H, t), 3.91-4.00
|
(1H, m), 4.26-4.36(1H, m), 4.58-4.78(5H, m), 6.74(1H, d),
|
6.76-6.79(1H, m), 6.98-7.02(3H, m), 7.07(1H, dd), 7.12(1H, d)
|
303 (IV)
498
(CDCl3) δ 1.42-1.61(2H, m), 1.77-1.90(3H, m), 1.93-2.03(3H,
Example 2 step c
|
(M + H)
m), 2.33(3H, s), 2.41-2.49(2H, m), 2.57(1H, tt), 2.67(1H, t), 2.77-2.84
|
(2H, m), 3.16(1H, t), 3.95(1H, d), 4.24-4.29(1H, m), 4.59-4.77
|
(5H, m), 6.68(1H, dd), 6.75-6.79(2H, m), 6.97-7.00(3H, m),
|
7.21(1H, d)
|
596 (I)
518
(CDCl3) δ 1.43-1.64(2H, m), 1.77-1.89(3H, m), 1.94-2.01(3H,
Example 2 step c
|
(M + H)
m), 2.41-2.50(2H, m), 2.57(1H, tt), 2.68(1H, t), 2.76-2.83(2H, m),
|
3.16(1H, t), 3.94-3.97(1H, m), 4.24-4.30(1H, m), 4.58-4.63(1H,
|
m), 4.68(2H, s), 4.76(2H, d), 6.76-6.78(2H, m), 6.98-7.00(3H, m),
|
7.26(1H, s), 7.31(1H, d)
|
467 (I)
534
(DMSO-D6) δ 1.35-1.50(2H, m), 1.52-1.65(3H, m), 1.68-1.84
Example 2 step c
|
(M + H)
(2H, m), 1.88-1.98(2H, m), 2.35-2.44(2H, m), 2.54-2.61(1H, m),
|
2.73-2.82(3H, m), 3.37(3H, s), 3.57(2H, s), 3.60-3.71(1H, m),
|
4.38-4.56(2H, m), 6.98(1H, dd), 7.07(1H, dd), 7.24(1H, d), 7.26
|
(1H, d), 7.47(1H, d), 7.50(1H, d)
|
269 (IV)
453
(CDCl3) δ 1.55-1.68(4H, m), 1.75-2.01(4H, m), 2.33(3H, s), 2.41-2.51
Example 2 step c
|
(M + H)
(2H, m), 2.64(1H, tt), 2.78-2.87(3H, m), 3.12-3.24(1H, m),
|
4.21-4.29(1H, m), 4.76-4.88(1H, m), 5.23-5.34(1H, m), 6.67
|
(1H, dd), 6.78(1H, d), 6.84(1H, t), 7.19-7.26(2H, m), 7.60(1H, d),
|
8.06(1H, s), 8.13(1H, dd)
|
597 (I)
546
(CDCl3) δ 1.39-1.66(2H, m), 1.73-1.86(4H, m), 1.92-2.03(2H,
Example 2 step c
|
(M + H)
m), 2.41-2.50(2H, m), 2.53-2.63(1H, m), 2.76-2.88(2H, m), 2.98-3.12
|
(1H, m), 3.62-3.77(1H, m), 4.24-4.29(1H, m), 4.62-4.78(1H,
|
m), 6.75(1H, dd), 6.99(1H, d), 7.31(2H, d), 7.53(1H, dd), 7.57(1H,
|
t), 8.12(1H, d)
|
598 (I)
474
CDCl3) δ 1.58-1.75(2H, m), 1.80-1.88(2H, m), 1.91-2.05(4H,
Example 2 step c
|
(M + H)
m), 2.53-2.61(2H, m), 2.71-2.90(4H, m), 3.18-3.22(1H, m), 4.27-4.33
|
(1H, m), 4.84(1H, d), 5.55(1H, d), 6.75(1H, dd), 6.95(1H, dd),
|
7.00(1H, d), 7.31(1H, d), 8.09(1H, s), 8.46(1H, dd), 8.62(1H, dd)
|
579 (I)
491
(CDCl3) δ 1.61(1H, qd), 1.75-2.02(7H, m), 2.42-2.51(2H, m), 2.59-2.67
Example 2 step c
|
(M + H)
(1H, m), 2.75-2.86(3H, m), 3.12-3.21(1H, m), 4.23-4.29
|
(1H, m), 4.76-4.85(1H, m), 5.23-5.32(1H, m), 6.75(1H, dd), 6.99
|
(1H, d), 7.16(1H, ddd), 7.30(1H, d), 7.58(1H, dd), 8.07(2H, s)
|
599 (I)
487
(CDCl3) δ 1.58-1.67(1H, m), 1.75-2.02(7H, m), 2.43-2.51(3H,
Example 2 step c
|
(M + H)
m), 2.59-2.68(1H, m), 2.61(3H, s), 2.76-2.85(3H, m), 3.12-3.23
|
(1H, m), 4.23-4.28(1H, m), 4.78-4.87(1H, m), 5.30-5.38(1H, m),
|
6.67(1H, d), 6.75(1H, dd), 7.20(1H, dd), 7.30(1H, d), 7.51(1H, d),
|
8.01(1H, s)
|
600 (I)
507
(CDCl3) δ 1.61(1H, qd), 1.70-2.04(7H, m), 2.41-2.53(2H, m), 2.63
Example 2 step c
|
(M + H)
(1H, t), 2.73-2.88(3H, m), 3.09-3.23(1H, m), 4.21-4.31(1H, m),
|
4.74-4.86(1H, m), 5.20-5.30(1H, m), 6.75(1H, dd), 6.99(1H, d),
|
7.19(1H, d), 7.30(1H, d), 7.55(1H, d), 8.04(1H, s), 8.19(1H, s)
|
304 (IV)
505
CDCl3) δ 1.57-1.68(2H, m), 1.82-2.01(6H, m), 2.46-2.54(2H,
Example 2 step c
|
(M + H)
m), 2.46(3H, s), 2.59-2.69(1H, m), 2.73-2.90(3H, m), 3.10-3.23
|
(1H, m), 4.32-4.39(1H, m), 4.76-4.85(1H, m), 5.22-5.32(1H, m),
|
6.75(1H, d), 7.14-7.27(2H, m), 7.58(1H, dd), 8.07(2H, s)
|
601 (I)
487
(CDCl3) δ 1.55-1.65(1H, m), 1.75-2.01(7H, m), 2.40(3H, s), 2.44 -2.50
Example 2 step c
|
(M + H)
(2H, m), 2.63(1H, qt), 2.73-2.86(3H, m), 3.10-3.22(1H, m),
|
4.22-4.28(1H, m), 4.75-4.86(1H, m), 5.22-5.34(1H, m), 6.66
|
(1H, dd), 6.75(1H, dd), 6.99(1H, d), 7.30(1H, d), 7.34(1H, s), 7.97
|
(1H, s), 7.99(1H, d)
|
343 (I)
566
(CDCl3) δ 1.39-1.65(1H, m), 1.77-1.89(4H, m), 1.94-2.03(3H,
Example 2 step c
|
(M + H)
m), 2.43-2.50(2H, m), 2.54-2.62(1H, m), 2.77-2.90(3H, m), 3.03-3.13
|
(1H, m), 3.53(3H, s), 3.65-3.74(1H, m), 4.26-4.31(1H, m),
|
4.26(2H, s), 4.69-4.79(1H, m), 6.75(1H, dd), 6.99(1H, d), 7.26-7.35
|
(3H, m), 8.00(1H, d)
|
603 (I)
526
(CDCl3) δ 1.49-1.58(2H, m), 1.76-1.84(3H, m), 1.90-2.01(4H,
Example 2 step c
|
(M + H)
m), 2.44-2.48(2H, m), 2.53-2.59(1H, m), 2.78-2.82(2H, m), 2.78-3.00
|
(5H, m), 3.15-3.19(1H, m), 4.24-4.29(1H, m), 4.96(2H, s),
|
6.74-6.80(2H, m), 6.99(1H, d), 7.31(1H, d), 7.66-7.70(2H, m)
|
534 (I)
543
(CDCl3) δ 1.49(3H, t), 1.57-2.00(6H, m), 2.43-2.52(2H, m), 2.56-2.62
Example 2 step c
|
(M + H)
(3H, m), 2.67(3H, s), 2.78-2.84(3H, m), 3.10-3.19(1H, m),
|
3.74(1H, d), 4.25(1H, dquintet), 4.42-4.49(2H, m), 4.76(1H, d),
|
6.75(1H, dd), 6.99(1H, d), 7.23(1H, d), 7.30(1H, d), 8.09(1H, s),
|
8.60(1H, d)
|
5 (II)
474
Example 2 step c
|
(M + H)
|
6 (II)
468
(DMSO-D6) δ 1.39-1.45(1H, m), 1.54-1.93(6H, m), 2.32-2.39
Example 2 step c
|
(2H, m), 2.49-2.53(2H, m), 2.72-3.02(4H, m), 3.29-3.32(2H, m),
|
4.31-4.34(1H, m), 6.75-6.79(1H, m), 7.08(1H, ddd), 7.30(2H, dt),
|
7.49-7.56(2H, m), 7.76(1H, t), 8.24(1H, dd)
|
7 (II)
453
(DMSO-D6) δ 1.45-1.69(5H, m), 1.84-1.99(3H, m), 2.40(2H, t),
Example 2 step c
|
(M + H)
2.59-2.66(1H, m), 2.73-2.92(3H, m), 3.03-3.14(1H, m), 3.69-3.76
|
(1H, m), 4.31-4.37(1H, m), 4.55-4.61(1H, m), 6.78(1H, dd),
|
7.09(1H, ddd), 7.31(1H, dt), 7.69-7.78(2H, m), 8.49-8.65(2H, m),
|
9.15(1H, dd)
|
8 (II)
441
(DMSO-D6) δ 1.34-1.45(2H, m), 1.52-1.61(2H, m), 1.76-1.86
Example 2 step c
|
(M + H)
(2H, m), 1.87-1.96(2H, m), 2.33-2.44(2H, m), 2.56-2.63(1H, m),
|
2.72-2.81(3H, m), 3.05-3.14(1H, m), 4.29-4.38(1H, m), 4.51-4.61
|
(1H, m), 5.09-5.19(1H, m), 6.73-6.79(1H, m), 6.94-6.99
|
(1H, m), 7.04-7.12(1H, m), 7.28-7.34(2H, m), 7.61(1H, dd), 8.30
|
(1H, s), 8.56(1H, dt)
|
305 (IV)
514
DMSO-D6) δ 1.42-1.51(2H, m), 1.60-1.93(6H, m), 2.41-2.47
Example 2 step c
|
(M + H)
(2H, m), 2.41(3H, s), 2.54-2.60(1H, m), 2.72-2.80(2H, m), 3.05-3.15
|
(1H, m), 3.29-3.35(1H, m), 3.60-3.71(1H, m), 4.44-4.54(2H,
|
m), 6.59-6.64(1H, m), 7.07-7.13(1H, m), 7.31-7.38(1H, m), 7.86-7.89
|
(1H, m), 7.95-7.99(1H, m), 8.01-8.07(1H, m), 8.50-8.54(1H,
|
m), 8.63-8.67(1H, m)
|
306 (IV)
531
(DMSO-D6) δ 1.39-1.95(8H, m), 2.40(3H, s), 2.42-2.47(2H, m),
Example 2 step c
|
(M + H)
2.55-2.63(2H, m), 2.72-2.81(2H, m), 2.94-3.09(2H, m), 3.42(3H,
|
s), 4.14-4.32(1H, m), 4.46-4.54(1H, m), 7.10(1H, d), 7.36(1H, d),
|
7.49(1H, d), 7.78(1H, d)
|
307 (IV)
525
(DMSO-D6) δ 1.39-1.95(9H, m), 2.42(3H, s), 2.44-2.48(1H, m),
Example 2 step c
|
(M + H)
2.55-2.61(1H, m), 2.70-2.83(2H, m), 2.99-3.10(1H, m), 3.29
|
(3H, s), 3.41-3.52(2H, m), 4.46-4.58(2H, m), 7.11(1H, d), 7.36
|
(1H, d), 7.66(2H, dd), 7.99(2H, dd)
|
308 (IV)
512
(DMSO-D6) δ 1.60-4.25(18H, m), 4.55-4.80(1H, m), 5.22-5.45(1H,
Prepared in a similar manner to
|
(M + H)
m), 7.05(1H, t), 7.75-7.82(2H, m), 7.85(1H, s), 8.00-8.18(2H, m),
Example 15 and isolated as the
|
8.60(1H, s), 9.63(1H, br s)
trifluoroacetate salt
|
1 (V)
509
87-88
(DMSO-D6) δ 1.11-1.18(2H, m), 1.36-1.53(4H, m), 1.63-1.78
Example 2 step c
|
(M + H)
(2H, m), 2.07(2H, t), 2.48-2.52(2H, m), 2.81-2.84(4H, m), 3.01-3.04
|
(2H, m), 3.27-3.27(3H, m), 3.49-3.50(1H, m), 4.44-4.53(1H,
|
m), 7.15-7.18(1H, m), 7.44-7.45(1H, m), 7.50-7.53(1H, m), 7.69-7.76
|
(2H, m), 7.90(1H, t), 7.98-8.02(1H, m)
|
2 (V)
510
(CDCl3) δ 1.38-1.48(3H, m), 1.59(1H, br s), 1.81-2.07(4H, m),
Example 12
|
(M + H)
2.34(2H, t), 2.55-2.60(1H, m), 2.84-2.92(3H, m), 3.07(4H, s), 3.21
|
(1H, br s), 3.60(1H, d), 3.68(1H, br s), 4.74(1H, br s), 6.41(1H, dd),
|
6.64(1H, d), 7.16(1H, d), 7.62-7.70(2H, m), 7.97-8.02(2H, m)
|
3 (V)
523
(DMSO-D6) δ 1.42-1.56(4H, m), 1.64-1.86(4H, m), 2.33(2H, t),
Prepared in a similar maner to
|
(M + H)
2.54-2.61(1H, m), 2.76-2.85(1H, m), 2.87-2.93(2H, m), 3.04-3.12
Example 12 using (3, 4-Dichloro-
|
(1H, m), 3.28(3H, s), 3.36-3.44(1H, m), 3.48-3.57(1H, m),
phenyl)-piperidin-4-yl-methanone
|
4.47-4.55(1H, m), 7.70-7.77(2H, m), 7.80(1H, d), 7.91-7.95(2H,
hydrochloride (free base was made
|
m), 8.00(1H, dt), 8.14-8.16(1H, m)
insitu using triethylamine
|
310 (IV)
478
169-170
(DMSO-D6) δ 1.29-1.40(2H, m), 1.53-1.62(2H, m), 1.71-1.77
Example 26 using 4-
|
(M + H)
(2H, m), 1.89-1.96(2H, m), 2.35-2.42(2H, m), 2.45-2.49(1H, m),
Methoxyphenylisocyanate
|
2.68-2.79(4H, m), 3.70(3H, s), 4.10-4.17(2H, m), 4.38-4.45(1H,
|
m), 6.78-6.82(2H, m), 6.98(1H, dd), 7.25(1H, d), 7.30-7.34(2H,
|
m), 7.49(1H, d), 8.30(1H, s)
|
311 (IV)
466
217
(DMSO-D6) δ 1.29-1.40(2H, m), 1.53-1.62(2H, m), 1.72-1.78
Example 26 using 4-
|
(M + H)
(2H, m), 1.89-1.96(2H, m), 2.36-2.42(2H, m), 2.44-2.49(1H, m),
Fluorophenylisocyanate
|
2.71-2.79(4H, m), 4.11-4.17(2H, m), 4.38-4.45(1H, m), 6.98
|
(1H, dd), 7.05(2H, t), 7.25(1H, d), 7.45(2H, tt), 7.49(1H, d), 8.50(1H,s)
|
312 (IV)
494
170-172
DMSO-D6) δ 1.29-1.40(2H, m), 1.52-1.62(2H, m), 1.72-1.78
Example 26 using 3-
|
(M + H)
(2H, m), 1.89-1.96(2H, m), 2.36-2.42(2H, m), 2.43(3H, s), 2.44-2.48
(Methylthio)phenylisocyanate
|
(1H, m), 2.71-2.79(4H, m), 4.15(2H, d), 4.38-4.45(1H, m),
|
6.81(1H, d), 6.98(1H, dd), 7.15(1H, t), 7.24-7.27(2H, m), 7.43(1H,
|
t), 7.49(1H, d), 8.48(1H, s)
|
313 (IV)
462
178-179
(DMSO-D6) δ 1.22-1.34(2H, m), 1.52-1.61(2H, m), 1.65-1.72
Example 26 using Benzylisocyanate
|
(M + H)
(2H, m), 1.88-1.95(2H, m), 2.33-2.46(3H, m), 2.61-2.76(4H, m),
|
3.99-4.05(2H, m), 4.22(2H, d), 4.37-4.44(1H, m), 6.97(1H, dd),
|
7.04(1H, t), 7.18-7.31(6H, m), 7.49(1H, d)
|
314 (IV)
492
166-167
(DMSO-D6) δ 1.21-1.32(2H, m), 1.51-1.61(2H, m), 1.64-1.71
Example 26 using 4-
|
(M + H)
(2H, m), 1.88-1.95(2H, m), 2.32-2.46(3H, m), 2.59-2.67(2H, m),
Methoxybenzylisocyanate
|
2.69-2.76(2H, m), 3.71(3H, s), 4.01(2H, d), 4.14(2H, d), 4.37-4.44
|
(1H, m), 6.83-6.87(2H, m), 6.94-6.99(2H, m), 7.14-7.18(2H, m),
|
7.25(1H, d), 7.49(1H, d)
|
315 (IV)
480
209-210
(DMSO-D6) δ 1.21-1.32(2H, m), 1.52-1.61(2H, m), 1.65-1.71
Example 26 using 4-
|
(M + H)
(2H, m), 1.88-1.95(2H, m), 2.32-2.46(3H, m), 2.60-2.68(2H, m),
Fluorobenzylisocyanate
|
2.70-2.76(2H, m), 4.01(2H, d), 4.19(2H, d), 4.38-4.44(1H, m),
|
6.97(1H, dd), 7.05(1H, t), 7.11(2H, t), 7.24-7.29(3H, m), 7.49(1H, d)
|
|
MS = Mass Spectrum has been obtained using either APCI+ or ES+ or ES−
|
[0417] The preparations of certain intermediates are now presented.
Method A
[0418] 1-(3-Methoxy-4-nitro-benzoyl)-piperidin-4-one
[0419] CDI (9 g) added to a solution of 3-methoxy-4-nitrobenzoic acid (10 g) stirring in THF (200 ml) at RT. After 1 hour, 4-piperidone hydrochloride (6.9 g) and triethylamine (7.8 ml) were added and the mixture stirred overnight. The mixture was diluted with ethyl acetate, washed with 2N HCl (100 ml) then saturated NaHCO3 solution (200 ml) then saturated brine (200 ml). The organic layer was dried (MgSO4) and evaporated to leave a residue which was purified by column chromatography (silica, mixtures of MeOH in dichloromethane) to give the product as a yellow solid (8.5 g; MS: APCI+(M+H) 279).
Method B
[0420] 1-(3-Methanesulfonyl-benzoyl)-piperidin-4-one
[0421] PyBrOP™ (17.3 g) was added to a stirred mixture of 3-methanesulphonyl benzoic acid (7.35 g), 4-piperidone hydrochloride (5 g) and Hunig's base (25 ml) in dichloromethane (250 ml) with stirring at RT. The mixture was stirred overnight then washed with saturated NaHCO3 solution (200 ml) and then with saturated brine (200 ml). The organic layer was evaporated and the resulting residue purified by column chromatography (silica, 1:1 ethyl acetate: dichloromethane) to give the product as a thick oil (9.6 g; MS: APCI+(M+H) 282).
Method C
[0422] 1-(Benzo[1,2,3]thiadiazole-5-carbonyl)-piperidin-4-one
[0423] CDI (4.5 g) added to a solution of the benzo[1,2,3]thiadiazole-5-carboxylic acid (5 g) stirring in THF (100 ml) at RT. After 1 hour 4-piperidone hydrochloride (3.7 g) and triethylamine (4.3 ml) were added and the mixture stirred overnight. The resulting mixture was diluted with ethyl acetate, washed with 2M HCl (100 ml), saturated NaHCO3 solution (200 ml) and then with saturated brine (200 ml). The organic layer was dried (MgSO4) and evaporated to leave a residue which was purified by column chromatography (silica, eluting with mixtures of ethyl acetate in dichloromethane) to give the product as a yellow oil (2.1 g; MS: APCI+(M+H)262).
Method D
[0424] [1,4′]Bipiperidinyl-4-ol
[0425] 4-Oxo-piperidine-1-carboxylic acid tert-butyl ester (20 g) and 4-hydroxypiperidine (6.7 g) were stirred together in dichloroethane (200 ml) with acetic acid (4 ml) at RT for 30 minutes. Sodium triacetoxyborohydride (23 g) was then added and the mixture stirred at RT overnight. The mixture was evaporated to dryness and the residue taken into water, extracted with diethyl ether (3×200 ml), the aqueous was basified to pH 9-10 and extracted with dichloromethane (3×200 ml). The dichloromethane extracts were combined, dried (MgSO4) and evaporated to leave an oil (19 g; same compound as Example 9 step 1). The oil was dissolved in methanol (300 ml) and treated with concentrated hydrochloric acid (5 ml). The mixture was stirred overnight and then evaporated to dryness to leave the title compound as the hydrochloride salt (15 g).
[0426]
1
H NMR (400 MHz, DMSO-D6) δ1.6-2.4 (m, 9H), 2.8-3.5 (m, 8H), 3.62 (m, 1H), 3.95 (s, 1H), 9.29 and 9.059 (bs, 2H), 10.9 and 11.09 (bs, 1H).
Method E
[0427] (4-Hydroxy-[1,4′]bipiperidinyl-1′-yl)-(3-methanesulfonyl-phenyl)-methanone
[0428] PyBrOP™ (25.3 g) was added to a stirred solution of 3-methanesulphonyl benzoic acid (10 g), [1,4′]bipiperidinyl-4-ol dihydrochloride (13 g, see Method D) and Hunig's base (34 ml) in dichloromethane (500 ml). The resulting mixture was stirred at RT overnight, then washed with saturated NaHCO3 solution (300 ml) followed by saturated brine (300 ml). The organic layer was dried (MgSO4) and evaporated to leave an oily residue. Column chromatography (silica, 20% methanol in DCM) gave the product as a white solid (16 g; MS: APCI+(M+H) 367).
Method F
[0429] 4-(3-Chloro-4-fluoro-phenoxy)-piperidine
[0430] DEAD (0.43 ml) was added to a solution of triphenylphosphine (0.72 g), 3-chloro-4-fluorophenol (0.403 g) and 4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (0.5 g) in THF at RT. The resulting mixture was stirred overnight, HCl in dioxan (2 ml of 4M) was added and the mixture stirred at RT overnight. The mixture was then evaporated to dryness and triethylamine (5 ml) was added. The mixture was evaporated and the residue was dissolved in methanol (10 ml), placed onto a SCX cartridge (Varian, 10 g, SCX cartridge available from International Sorbent Technology Isolute® Flash SCX-2) and eluted: first with methanol then with 10% NH3 in methanol. The basic fractions were combined and evaporated to give the product as an oil (0.6 g).
[0431]
1
H NMR (299.946 MHz, DMSO-D6) δ1.34-1.46 (2H, m), 1.83-1.91 (2H, m), 2.53-2.59 (2H, m), 2.87-2.96 (2H, m), 3.22-3.39 (1H, m), 4.39 (1H, septet), 6.92-6.98 (1H, m), 7.17-7.20 (1H, m), 7.30 (1H, t).
[0432] The following intermediates were prepared in similar manner to Method F:
14|
|
MS: (M + H)
|
|
4-(4-chloro-2-methyl-phenoxy)-piperidine226
4-(4-chloro-3-fluoro-phenoxy)-piperidine230
4-(4-chloro-2-methoxy-phenoxy)-piperidine242
4-(4-fluoro-2-methoxy-phenoxy)-piperidine226
4-(4-methoxy-phenoxy)-piperidine208
4-p-tolyloxy-piperidine192
4-(4-chloro-3-methyl-phenoxy)-piperidine226
4-(4-chloro-phenoxy)-piperidine212
4-(4-fluoro-phenoxy)-piperidine196
4-(2,4-dichloro-phenoxy)-piperidine246
4-(2-chloro-4-fluoro-phenoxy)-piperidine230
4-(2,4-difluoro-phenoxy)-piperidine214
4-(4-chloro-2-fluoro-phenoxy)-piperdine230
4-(4-fluoro-2-methyl-phenoxy)-piperidine210
4-(4-chloro-2,6-dimethyl-phenoxy)-piperdine240
4-(2,3-dichloro-phenoxy)-piperidine246
4-(2,5-dichloro-phenoxy)-piperidine246
4-(2-chloro-4-methyl-phenoxy)-piperdine226
4-(2-chloro-5-methyl-phenoxy)-piperidine226
1-[3-methyl-4-(piperidin-4-yloxy)-phenyl]-ethanone234
4-(2-chloro-6-methyl-phenoxy)-piperidine226
4-[2-(piperidin-4-yloxy)-phenyl]-morpholine263
4-(4-chloro-2-ethyl-phenoxy)-piperidine240
7-(piperidin-4-yloxy)-quinoline229
4-(2-tert-butyl-phenoxy)-piperidine234
4-(indan-5-yloxy)-piperidine218
4-(4-chloro-2-cyclohexyl-phenoxy)-piperdine294
5-chloro-2-(piperidin-4-yloxy)-benzamide255
4-(4-chloro-2-isoxazol-5-yl-phenoxy)-piperidine279
4-(5-chloro-2-methyl-phenoxy)-piperdine226
4-phenoxy-piperidine178
4-(2,4-dichloro-6-methyl-phenoxy)-piperidine260
4-(3-chloro-4-methyl-phenoxy)-piperidine226
5-chloro-2-(piperidin-4-yloxy)-benzonitrile237
4-(2,4-dichloro-3-methyl-phenoxy)-piperidine260
4-(2-ethyl-4-fluoro-phenoxy)-piperidine224
4-(4-methanesulfonyl-phenoxy)-piperidine297
|
Method G
[0433] 4-Amino-3-ethoxy-benzoic acid
[0434] Potassium hydroxide (0.278 g) was added to a solution of 3-fluoro-4-nitrobenzoic acid (0.4 g) in ethanol (7 ml) and the reaction treated with microwaves (300W, 100° C.) for 5 minutes. The reaction mixture was acidified using 2N HCl and extracted with ethyl acetate. The extracts were combined, washed with water, dried (MgSO4) and evaporated to give 3-ethoxy-4-nitro-benzoic acid (0.325 g).
[0435] 3-Ethoxy-4-nitrobenzoic acid (0.31 g) was treated with 5% palladium on charcoal under an atmosphere of hydrogen (1 bar) for 3 hours. The reaction mixture was filtered and the filtrate was evaporated to leave the product as a beige solid (0.245 g; MS: ES−(M-H) 180).
Method H
[0436] 3,4-bis-Methanesulfonyl-benzoic acid
[0437] To 3-fluoro-4-nitro-benzoic acid tert-butyl ester (0.5 g) in DMSO was added NaSO2Me. The reaction mixture was heated to 100° C. for 24 hours. A mixture of water, diethyl ether and ethyl acetate (1:1:1) was added and the resulting mixture was extracted with diethyl ether/ethyl acetate (1:1). The organic extracts were combined, dried with MgSO4 and concentrated to leave a residue which was purified by chromatography (using 80% ethyl acetate/20% hexane) to give 3,4-bis-methanesulfonyl-benzoic acid tert-butyl ester (366 mg). 1H NMR (399.98 MHz, DMSO-D6) 1.59 (9H, s), 3.50 (3H, s) 3.52 (3H, s), 8.37-8.65 (3H, m).
[0438] To 3,4-bis-methanesulfonyl-benzoic acid tert-butyl ester (0.366 g) in dichloromethane was added trifluoroacetic acid and the reaction mixture was stirred for 3 hours. The mixture was evaporated and trituration of the residue with diethyl ether gave the title compound (0.29 g; MS: APCI+(M+H) 279).
Method I
[0439] 4-Carbamoyl-5-methanesulfonyl-thiophene-2-carboxylic acid
[0440] To 4-cyano-5-methanesulfonyl-thiophene-2-carboxylic acid methyl ester (0.5 g) in THF/H20 (3:1; 16 ml) was added LiOH (0.102 g). Hydrochloric acid (2M) was added and the resulting mixture was extracted with ethyl acetate. The extracts were combined and the solvent evaporated to leave a mixture of 4-cyano-5-methanesulfonyl-thiophene-2-carboxylic acid and the title compound. This mixture was used without further purification. 1H NMR (299.944 MHz, DMSO-D6) δ3.62 (3H, s), 7.99 (1H, s).
Method J
[0441] 3-(2-Methyl-propane-1-sulfonyl)-benzoic acid
[0442] To a suspension of 3-sulfo-benzoic acid (1 g) and potassium carbonate (1.2 g) in dimethylacetamide (10 ml) was added iso-butyl iodide (0.65 ml). The mixture was heated by microwaves (600W) at 150° C. for 15 minutes. The reaction mixture was partitioned between water (100 ml) and ethyl acetate (100 ml), the aqueous layer was separated, acidified to pH 1 with HCl (2N) and extracted with ethyl acetate (100 ml). The extract was evaporated to leave a residue which was purified by flash chromatography (Biotage 12S eluting with ethyl acetate:hexane:acetic acid, 29:70:1) to give the title product as a white solid (0.34 g).
[0443]
1
H NMR: (399.98 MHz, DMSO-D6) δ0.98 (6H, d), 2.03 (1H, septet), 3.29 (2H, d), 7.81 (1H, t), 8.16 (1H, ddd), 8.27 (1H, dt), 8.38 (1H, t).
[0444] 3-Cyclopropylmethanesulfonyl-benzoic acid was prepared in a similar manner to that described in Method J. MS: (M-H) 239; 1H NMR: (DMSO-d6) 6 0.06-0.10 (2H, m), 0.40-0.45 (2H, m), 0.82-0.89 (1H, m), 3.34 (2H, d), 7.80 (1H, t), 8.14 (1H, d), 8.28 (1H, d), 8.39 (1H, s).
Method K
[0445] 3-(2-Methoxy-ethoxy)-benzoic acid methyl ester
[0446] To a solution of methyl 3-hydroxybenzoate (5.7 g) and 2-bromoethylmethyl ether (5.2 g) in dimethylformamide (100 ml) was added caesium carbonate (24.3 g). The reaction mixture was stirred for 12 hours. The mixture was then patitioned between ethyl acetate (400 ml) and water (400 ml). The organic layer was separated, dried (MgSO4) and the solvent removed under reduced pressure. The residue was purified by flash chromatography (Biotage 12M, eluting iso-hexane then MeOH:dichloromethane 2:98) to give the product as a colourless oil (5.3 g).
[0447]
1
H NMR: (CDCl3) δ3.44 (3H, s), 3.75 (2H, t), 3.89 (3H, s), 4.15 (2H, t), 7.13 (1H, ddd), 7.32 (1H, t), 7.57 (1H, dd), 7.62 (1H, dt).
[0448] 3-tert-Butoxycarbonylmethoxy-benzoic acid methyl ester can be prepared in a similar manner to that described in Method K: 1H NMR: (299.944 MHz CDCl3) 1.49 (9H, s), 3.91 (3H, s), 4.56 (2H, s), 7.13-7.68 (4H, m).
Method L
[0449] 3-(2-Methoxy-ethoxy)-benzoic acid
[0450] To a suspention of 3-(2-methoxy-ethoxy)-benzoic acid methyl ester (5.3 g) in tetrahydrofuran (200 ml) was added lithium hydroxide monohydrate (5.3 g) followed by water until an homogeneous solution was obtained. The reaction mixture was stirred for 12 hours, acidified and partitioned between ethyl acetate (200 ml) and water (200 ml). The organic layer was separated, dried (MgSO4) and the solvent removed under reduced pressure to yield a colourless solid (3.6 g).
[0451]
1
H NMR: (DMSO-D6) δ3.31 (3H, s), 3.67 (2H, t), 4.14 (2H, t), 7.20 (1H, ddd), 7.41 (1H, t), 7.44 (1H, dd), 7.53 (1H, dt)
[0452] 3-(2-tert-Butoxycarbonylamino-ethoxy)-benzoic acid can be prepared in a similar manner to that described in Method L.
[0453] 3-tert-Butoxycarbonylmethoxy-benzoic acid can be prepared in a similar manner to that described in Method L: 1H NMR (299.944 MHz, DMSO-D6) δ2.51 (9H, s), 4.74 (2H, s), 7.18 (1H, dq), 7.38 (1H, m), 7.41 (1H, m), 7.55 (1H, dt), 13.03 (1H, s).
Method M
[0454] 4-(2-Carboxy-2-phenyl-ethyl)-piperazine-1-carboxylic acid tert-butyl ester
[0455] Piperazine-1-carboxylic acid tert-butyl ester (17.43 g) and 2-phenylacrylic acid (18 g) in iso-propanol (500 ml) was heated at reflux for four days. The resulting precipitate was filtered, washed with diethyl ether and dried under vacuum to give the title compound as a white solid (17 g; MS: APCI+(M+H) 335).
Method N
[0456] 5-Methanesulfonyl-1H-indole-2-carboxylic acid
[0457] To a solution of the 5-methanesulfonyl-1H-indole-2-carboxylic acid methyl ester (0.49 g) in THF (12 mL) and water (4 ml) was added LiOH (0.098 g). The reaction mixture was left to stir for 2 hours. Acetic acid was added and the product extracted with dichloromethane. The organic extracts were combined, dried with magnesium sulfate, filtered and the filtrate evaporated to give the title compound as a solid (0.110 g).
[0458]
1
H NMR (299.946 MHz, DMSO-D6) δ3.18 (3H, s), 7.32-7.33 (1H, m), 7.61-7.64 (1H, m), 7.73-7.77 (1H, m), 8.30-8.31 (1H, m).
Method O
[0459] 5-Methyl-imidazo[1,2-a]pyridine-2-carboxylic acid was prepared in a similar manner to 6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid (see Example 25) using the commercially available 5-methyl-1,8a-dihydro-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester. 6-Methyl-imidazo[1,2-a]pyridine-2-carboxylic acid and 6-methyl-imidazo[1,2-a]pyridine-2-carboxylic acid ethyl ester were prepared in a similar manner to 6-fluoro-imidazo[1,2-a]pyridine-2-carboxylic acid and its ester above.
Method P
[0460] Preparation of 4-Methyl-1,1,3-trioxo-1,2,3,4-tetrahydro-1l6-benzo[1,4]thiazine-6-carboxylic acid
[0461] Step 1:4-Methyl-1,1,3-trioxo-1,2,3,4-tetrahydro-1l6-benzo[l ,4]thiazine-6-carboxylic acid methyl ester
95
[0462] To a solution of 4-methyl-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazine-6-carboxylic acid methyl ester (1 g) in dichloromethane (25 ml) was added 32% peracetic acid dropwise over 10 minutes. The reaction mixture was stirred at room temperature for 48 hours and then diluted with dichloromethane. The organic phase was washed once with water, twice with aqueous sodium sulfite solution, and once with saturated aqueous sodium bicarbonate. The organic phase was dried over magnesium sulfate, filtered, and the solvent evaporated to give the sub-title compound as a solid (1.012 g).
[0463]
1
H NMR (399.978 MHz, CDCl3) δ3.58 (3H, s), 4.00 (3H, s), 4.27 (2H, s), 7.96-7.99 (2H, m), 8.04-8.06 (1H, m).
[0464] Step 2: 4-Methyl-1,1,3-trioxo-1,2,3,4-tetrahydro-1 16-benzo[1 ,4]thiazine-6-carboxylic acid
[0465] To a solution of 4-methyl-1,1,3-trioxo-1,2,3,4-tetrahydro-11 6-benzo[1,4]thiazine-6-carboxylic acid methyl ester (1 g, from step 1) in MeOH (7 ml) was added dropwise a solution of sodium hydroxide (0.6 g) in water (5 ml). The reaction mixture was stirred at room temperature for 1 hour, diluted with water, cooled in an ice/water bath. Slow acidification with HCl (1N) to pH 2 yielded a precipitate which was isolated by filtration to give the title compound (0.595 g) as a solid.
[0466]
1
H NMR (399.978 MHz, DMSO-D6) δ3.49 (3H,s), 4.91 (2H,s), 7.90-8.03 (3H,m).
Method Q
[0467] Preparation of 4-(4-methanesulfonyl-phenoxy)-[1,4′]bipiperidinyl
[0468] Step a: 4-(4-methanesulfonyl-phenoxy)-[1,4′]bipiperidinyl-1′-carboxylic acid tert-butyl ester
[0469] To a solution of 4-(4-methanesulfonyl-phenoxy)-piperidine (0.7 g) dissolved in THF (5 ml) and 1,2-dichloroethane (10 ml) with 1-Boc-4-piperidone (0.71 g) was added NaBH(OAc)3 (0.926 g) and acetic acid (0.18 g). After 16 hours at RT aqueous NaOH (1M) solution and dichloromethane were added and the mixture was extracted with dichloromethane. The combined organic extracts were washed with water, dried with magnesium sulfate and concentrated to leave a residue which was purified by chromatography (dichloromethane:methanol 90:10) to give the sub-title product (1.1 g; MS: APCI+(M+H) 439).
[0470] Step b: 4-(4-methanesulfonyl-phenoxy)-[1,4′]bipiperidinyl
[0471] The product of step a was dissolved in dichloromethane (20 ml) and trifluoroacetic acid (5 ml) was added. After 16 hours at room temperature the solution was evaporated to leave the title compound as a TFA salt. The free base (0.7 g; oil; MS: APCI+(M+H) 339) was liberated by addition of aqueous NaOH (1M) and extraction with dichloromethane followed by evaporation of the solvent.
[0472] 3-Methanesulfonyl-5-nitro-benzoic acid and 3-cyano-5-methanesulfonyl-benzoic acid can be prepared according to a method described in EP-A1-556674.
[0473]
2
-amino-5-MeSO2-benzoic acid can be prepared according to a method described in J. Org. Chem. (1953) 18 1380.
[0474]
3
-Ethanesulfonyl-benzoic acid can be prepared according to a method described in J. Chem. Soc. 1946, 763.
[0475]
3
-Methylsulfamoyl-benzoic acid and 3-dimethylsulfamoyl-benzoic acid can be prepared according to a method described in DE2133038. 3-Methylsulfamoyl-benzoic acid 1H NMR: (399.98 MHz, DMSO-D6) δ7.42 (3H, d), 7.63 (1H, q), 7.76 (1H, t), 8.01 (1H, m), 8.18 (1H, dt), 8.31 (1H, t), 13.48 (1H, s).
[0476] Other intermediates can be prepared by literature methods, by adaptation of literature methods or are available commercially. For example:
[0477] (2-methyl-4-nitro-2H-pyrazol-3-yl)methanecarboxylic acid, 2-{1-[sulfonyl chloride]-ethyl}-isoindole-1,3-dione and (1,3-dimethyl-3,7-dihydro-purine-2,6-dion-8-yl)methanecarboxylic acid are available from Salor (Aldrich Chemical Company Inc 1001 West Saint Paul Avenue Milwaukee, Wis. 53233 USA);
[0478] [4-amino-5-(iso-propyl-sulfonyl)-thiophen-3-yl]carboxylic acid, [3-methyl-5-(4-methyl-[1,2,3]thiadiazol-5-yl)-isoxazol-4-yl]carboxylic acid, 3-cyano-4-(pyrrol-1-yl)-thiophen-5-yl)carboxylic acid, 4-isopropylsulfanyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid and 1-cyclopropyl-5-methoxy-2-methyl-2,3-dihydro-1H-indole-3-carboxylic acid, (5-(isoxazol-3-yl)-thiophen-2-yl)sulfonyl chloride, 4-bromo-1-methyl-1H-pyrazol-3-ylmethanal, 4-chloro-1H-pyrazol-3-ylmethanal and 1-(4-chloro-benzyl)-1H-pyrazol-3-ylmethanal are available from Maybridge Chemical Company Ltd.; Trevillett, Tintagel, Cornwall PL34 0HW, UK;
[0479] (5-methanesulfonyl-1H-indol-2-yl)carboxylic acid is available by hydrolysis of an ester available from Maybridge Chemical Company Ltd., details above;
[0480] (4-chloro-5-methyl-3-nitro-pyrazol-1-yl)methanecarboxylic acid, (5-methyl-3,4-dinitro-pyrazol-1-yl)methanecarboxylic acid and (2,4-dinitro-imidazol-1-yl)methanecarboxylic acid are available from ASINEX Ltd., 6 Schukinskaya ulitsa, Moscow 123182, Russia;
[0481] (6-(imidazol-1-yl)-pyridin-3-yl)carboxylic acid and 2-methyl-2-([1,2,4]triazol-1-yl)-propanoic acid are available from Bionet Research Ltd, 3 Highfield Industrial Estate, Camelford, Cornwall PL32 9QZ, UK; and,
[0482] (2-methyl-[1,8]naphthyridin-3-yl)carboxylic acid, (2-methyl-[1,6]naphthyridin-3-yl)carboxylic acid and (5-trifluoromethyl-thieno[3,2-b]pyridin-6-yl)-methanecarboxylic acid are available from Peakdale Fine Chemicals Ltd., 7 Brookfield Industrial Estate, Glossop, Derbyshire, SK13 6LQ, UK.
Pharmacological Analysis: Calcium Flux [Ca2+]i Assay
[0483] Human Eosinophils
[0484] Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., J. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended (5×106 ml−1) and loaded with 5 μM FLUO-3/AM+Pluronic F127 2.2 μl/ml (Molecular Probes) in low potassium solution (LKS; NaCl 118 mM, MgSO4 0.8 mM, glucose 5.5 m M, Na2CO3 8.5 mM, KCl 5 mM, HEPES 20 mM, CaCl2 1.8 mM, BSA 0.1%, pH 7.4) for one hour at room temperature. After loading, cells were centrifuged at 200 g for 5 min and resuspended in LKS at 2.5×106 ml−1. The cells were then transferred to 96 well FLIPr plates (Poly-D-Lysine plates from Becton Dickinson pre-incubated with 5 μM fibronectin for two hours) at 25 μl/well. The plate was centrifuged at 200 g for 5 min and the cells were washed twice with LKS (200 μl; room temperature).
[0485] A compound of the Examples was pre-dissolved in DMSO and added to a final concentration of 0.1% (v/v) DMSO. Assays were initiated by the addition of an A50 concentration of eotaxin and the transient increase in fluo-3 fluorescence (IEx=490 nm and IEm=520 nm) monitored using a FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices, Sunnyvale, U.S.A.).
[0486] Human Eosinophil Chemotaxis
[0487] Human eosinophils were isolated from EDTA anticoagulated peripheral blood as previously described (Hansel et al., J. Immunol. Methods, 1991, 145, 105-110). The cells were resuspended at 10×106 ml−1 in RPMI containing 200 IU/ml penicillin, 200 μg/ml streptomycin sulphate and supplemented with 10% HIFCS, at room temperature.
[0488] Eosinophils (700 μl) were pre-incubated for 15 mins at 37° C. with 7 μl of either vehicle or compound (100×required final concentration in 10% DMSO). The chemotaxis plate (ChemoTx, 3 μm pore, Neuroprobe) was loaded by adding 28 μl of a concentration of eotaxin (0.1 to 100 nM) containing a concentration of a compound according to the Examples or solvent to the lower wells of the chemotaxis plate. The filter was then placed over the wells and 25 μl of eosinophil suspension were added to the top of the filter. The plate was incubated for 1 hr at 37° C. in a humidified incubator with a 95% air/5% CO2 atmosphere to allow chemotaxis.
[0489] The medium, containing cells that had not migrated, was carefully aspirated from above the filter and discarded. The filter was washed once with phosphate buffered saline (PBS) containing 5 mM EDTA to remove any adherent cells. Cells that had migrated through the filter were pelleted by centrifugation (300×g for 5 mins at room temperature) and the filter removed and the supernatant transferred to each well of a 96-well plate (Costar). The pelleted cells were lysed by the addition of 28 μl of PBS containing 0.5% Triton×100 followed by two cycles of freeze/thawing. The cell lysate was then added to the supernatant. The number of eosinophils migrating was quantified according to the method of Strath et al., J. Immunol. Methods, 1985, 83, 209 by measuring eosinophil peroxidase activity in the supernatant.
[0490] Compounds of the Examples were found to be antagonists of the eotaxin mediated human eosinophil chemotaxis.
EXAMPLE 29
[0491] Guinea-Pig Isolated Trachea
[0492] (See for example, Harrison, R. W. S., Carswell, H. & Young, J. M. (1984) European J. Pharmacol., 106, 405-409.)
[0493] Male albino Dunkin-Hartley guinea-pigs (250 g) were killed by cervical dislocation and the whole trachea removed. After clearing the adherent connective tissue, the trachea was cut into six ring segments each three cartilage bands wide and then suspended in 20 ml organ baths containing Krebs-Henseleit solution of the following composition (mM): NaCl 117.6, NaH2PO4 0.9, NaHCO3 25.0, MgSO4 1.2, KCl 5.4, CaCl2 2.6 and glucose 11.1. The buffer was maintained at 37° C. and gassed with 5% CO2 in oxygen. Indomethacin (2.8 μM) was added to the Krebs solution to prevent development of smooth muscle tone due to the synthesis of cyclo-oxygenase products. The tracheal rings were suspended between two parallel tungsten wire hooks, one attached to an Ormed beam isometric force transducer and the other to a stationary support in the organ bath. Changes in isometric force were recorded on 2-channel Sekonic flat bed chart recorders.
[0494] Experimental Protocols
[0495] At the beginning of each experiment a force of 1 g was applied to the tissues and this was reinstated over a 60 minute equilibration period until a steady resting tone was achieved. Subsequently, a cumulative histamine concentration effect (E/[A]) curve was constructed at 0.5 log10 unit increments, in each tissue. The tissues were then washed and approximately 30 minutes later, test compound or vehicle (20% DMSO) was added. Following an incubation period of 60 minutes a second E/[A] curve was performed to histamine.
[0496] Contraction responses were recorded as a percentage of the first curve maximum.
[0497] Data Analysis
[0498] Experimental E/[A] curve data were analysed for the purposes of estimating the potencies (p[A50] values) of histamine in the absence and presence of the test compound. Affinity (pA2) values of test compounds were subsequently calculated using the following equation:
log(r−1)=log[B]+pA2
[0499] where r=[A]50 in presence of test compound/[A]50 in absence of antagonist and [B] is the concentration of test compound. Compounds of the Examples were found to be H1 antagonists.
Claims
- 1. A compound of formula (I):
- 2. A compound as claimed in claim 1 wherein aryl is phenyl or naphthyl.
- 3. A compound as claimed in claim 1 or 2 wherein heterocyclyl is furyl, thienyl, pyrrolyl, 2,5-dihydropyrrolyl, thiazolyl, pyrazolyl, oxazolyl, isoxazolyl, imidazolyl, piperidinyl, morpholinyl, pyridinyl, pyrimidinyl, indolyl, 2,3-dihydroindolyl, benzo[b]furyl, benz[b]thienyl, 2,3-dihydrobenz[b]thienyl, indazolyl, benzimidazolyl, benztriazolyl, benzoxazolyl, benzthiazolyl, 2,3-dihydrobenzthiazolyl, 1,2,3-benzothiadiazolyl, imidazo[1,2a]pyridinyl, thieno[3,2-b]pyridin-6-yl 1,2,3-benzoxadiazolyl, 2,1,3-benzothiadiazolyl, benzofurazan, quinoxalinyl, dihydro-1-benzopyryliumyl, 3,4-dihydro-1H-2, 1-benzothiazinyl, a pyrazolopyridine, a purine, quinolinyl, isoquinolinyl, a naphthyridinyl, a benzothiazinyl, benzo[d]imidazo[2,1-b]thiazol-2-yl or dibenzothiophenyl; or an N-oxide thereof, or an S-oxide or S-dioxide thereof.
- 4. A compound as claimed in claim 1, 2 or 3 wherein the variables m and p are such that m+p is 0, 1 or 2.
- 5. A compound as claimed in any one of the preceding claims wherein n is 0 or 1.
- 6. A compound as claimed in any one of the preceding claims wherein q and r are both 0.
- 7. A compound as claimed in any one of the preceding claims wherein m, p and t are all 1.
- 8. A compound as claimed in any one of the preceding claims wherein s is 0.
- 9. A compound as claimed in any one of the preceding claims wherein X is O.
- 10. A compound as claimed in any one of the preceding claims wherein R1 is phenyl substituted with one or more of fluorine, chlorine, C1-4 alkyl or C1-4 alkoxy.
- 11. A compound of formula (Ia″):
- 12. A compound as claimed in any one of the preceding claims wherein T is C(O), S(O)2 or CH2.
- 13. A compound of formula (If):
- 14. A compound as claimed in any one of the preceding claims wherein R3 is aryl or heteroaryl either of which is optionally substituted as described in claim 1.
- 15. A compound as claimed in any one of the preceding claims wherein R3 is phenyl or heterocyclyl, either of which is optionally substituted by: halo, hydroxy, nitro, cyano, amino, C1-4 alkyl (itself optionally substituted by S(O)2(C1-4 alkyl), S(O)2phenyl), C1-4 alkoxy, S(O)kR46 (wherein k is 0, 1 or 2; and R46 is C1-4 alkyl, C1-4 hydroxyalkyl, C3-7 cycloalkyl(C1-4 alkyl) or phenyl), C1-4 haloalkylthio, C(O)NH2, NHS(O)2(C1-4 alkyl), S(O)2NH2, S(O)2NH(C1-4 alkyl) or S(O)2N(C1-4 alkyl)2.
- 16. A compound as claimed in claim 11 wherein m and p are both 1.
- 17. A compound as claimed in claim 11 or claim 13 wherein n is 0 or 1.
- 18. A compound as claimed in claim 13 wherein R1 is phenyl substituted with one or more of fluorine, chlorine, C1-4 alkyl or C1-4 alkoxy.
- 19. A compound as claimed in claim 13 wherein s is 0 and t is 1.
- 20. A process for preparing a compound of formula (I) as claimed in claim 1, which comprises:
a) when R47 is not hydrogen, coupling a compound of formula (II): 99with a compound of formula (III): 100wherein L is a suitable leaving group, and the variables Y and T are optionally protected during the course of the reaction; b) when s is 1, R47 is hydrogen and T is CO, reacting a compound of formula (II): 101with an isocyanate O═C═N—(CH2)n-(CH2)r,-R3; c) reductively aminating of a compound of formula (XX): 102with an amine of formula (XXI): 103d) performing a fluoride displacement reaction on F—R1 in the presence of compound of formula (XVIII): 104provided that R47 is not hydrogen.
- 21. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof or a solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
- 22. A compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, for use as a medicament.
- 23. The use of a compound of the formula (I) as claimed in claim 1, or a pharmaceutically acceptable salt thereof or a solvate thereof, in the manufacture of a medicament for use in therapy.
- 24. The use of a compound of a formula (I):
- 25. A compound of a formula (I), as defined in claim 24, which is both a modulator of chemokine receptor activity and an H1 antagonist.
- 26. Method of treating a CCR3 mediated disease state comprising administering to a patient an effective amount of a compound of formula (I) as defined in claim 24.
Priority Claims (3)
Number |
Date |
Country |
Kind |
0008626.4 |
Apr 2000 |
GB |
|
0019111.4 |
Aug 2000 |
GB |
|
0003664-0 |
Oct 2000 |
SE |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
09827488 |
Apr 2001 |
US |
Child |
10341027 |
Jan 2003 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10341027 |
Jan 2003 |
US |
Child |
10436582 |
May 2003 |
US |